{"title": "Lajos Pusztai", "author": "Lajos Pusztai", "url": "https://www.yalemedicine.org/specialists/lajos-pusztai", "hostname": "yalemedicine.org", "description": "Lajos Pusztai, MD, DPhil, is a medical oncologist who specializes in breast cancer. He is the co-director of the Genomics, Genetics, and Epigenetics Program at the Yale Cancer Center.He says he enjoys the delicate work of helping patients overcome the fear and shock of a breast cancer diagnosis. \"I ensure that they maximize their chance of cure through the best available treatments,\" he says. \"I also love the research component of my job, to push the boundaries of existing knowledge and developing new therapies.\"Dr. Pusztai says he gravitated to medical oncology at the beginning of his career because of an inspiring mentor, and that the best part of his job is seeing patients remain disease-free for years and continuing with their life.He is chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG), a global cancer research community that designs and conducts publicly funded clinical trials. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical, and epidemiological characteristics.He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai is also the principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer.", "sitename": "Yale Medicine", "date": "2021-11-09", "cleaned_text": "- Center for Breast CancerSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, MD, DPhil, is a medical oncologist who specializes in breast cancer. He is the co-director of the Genomics, Genetics, and Epigenetics Program at the Yale Cancer Center. He says he enjoys the delicate work of helping patients overcome the fear and shock of a breast cancer diagnosis. \"I ensure that they maximize their chance of cure through the best available treatments,\" he says. \"I also love the research component of my job, to push the boundaries of existing knowledge and developing new therapies.\" Dr. Pusztai says he gravitated to medical oncology at the beginning of his career because of an inspiring mentor, and that the best part of his job is seeing patients remain disease-free for years and continuing with their life. He is chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG), a global cancer research community that designs and conducts publicly funded clinical trials. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical, and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai is also the principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer. Titles - Professor of Medicine (Medical Oncology) - Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center Education & Training - FellowUniversity of Texas MD Anderson Cancer Center (1999) - ResidencyUniversity of Rochester St. Mary's Hospital (1996) - InternUniversity of Rochester St. Mary's Hospital (1994) - DPhilUniversity of Oxford (1993) - MDSemmelweis University School of Medicine (1987) Languages Spoken - English - Magyar (Hungarian) Additional Information - Clinical Science Research Prize: Yale Cancer Center (2022) - Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.](http://www.ncbi.nlm.nih.gov/pubmed/37433103)Litton J, Regan M, Pusztai Rugo H, Tolaney Garrett-Mayer E, Amiri-Kordestani L, Basho R, Best A, Boileau J, Denkert C, Foster J, Harbeck N, Jacene H, King T, Mason G, O'Sullivan C, Prowell T, Richardson A, Sepulveda K, Smith M, Tjoe J, Turashvili G, Woodward W, Butler L, Schwartz E, Korde L. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. [Radiotherapy Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial](http://www.ncbi.nlm.nih.gov/pubmed/37410451)Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein S, Zeidan P, Pusztai L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the with the Rest](http://www.ncbi.nlm.nih.gov/pubmed/37400619)Kim L, Coman M, Pusztai L, Park T. ASO Visual Abstract: Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancers\u2014Catching up with 2023, [PMID: 37400619](https://pubmed.ncbi.nlm.nih.gov/37400619), [DOI: 10.1245/s10434-023-13842-4](https://doi.org/10.1245/s10434-023-13842-4). [Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37391697)Foldi J, Tsagianni A, M, C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer early-stage cancer](http://www.ncbi.nlm.nih.gov/pubmed/37378695)Kahn R, M, spatial in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer Breast Cancer Research Treatment 2023, 1-10. [PMID: 37378695](https://pubmed.ncbi.nlm.nih.gov/37378695), [DOI: 10.1007/s10549-023-06977-1](https://doi.org/10.1007/s10549-023-06977-1). [Incorporating clinicopathological and molecular risk tools to improve outcomes in early HR+/HER2- breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37380659)Curigliano G, Dent R, Llombart-Cussac A, Pegram M, Pusztai L, Turner N, Viale G. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer Npj Breast T. Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest Annals Of Oncology 2023, 1-9. [PMID: 37349612](https://pubmed.ncbi.nlm.nih.gov/37349612), [DOI: 10.1245/s10434-023-13714-x](https://doi.org/10.1245/s10434-023-13714-x). - Pusztai L. Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look? Journal [Oncotype recommendations for early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37291235)Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Bianchini G. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer Npj Kumar Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic Clinical 2023, I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. [DOI: 10.1200/jco.2023.41.16_suppl.e18855](https://doi.org/10.1200/jco.2023.41.16_suppl.e18855). [Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history.](https://doi.org/10.1200/jco.2023.41.16_suppl.576)Rozenblit M, Suwalska A, Hofstatter E, Reisenbichler E, M, Pusztai L. Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history. Journal Of Clinical Oncology 2023, 41: 576-576. [DOI: 10.1200/jco.2023.41.16_suppl.576](https://doi.org/10.1200/jco.2023.41.16_suppl.576). [Biomarkers the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).](https://doi.org/10.1200/jco.2023.41.16_suppl.102)Wolf D, Yau C, Campbell M, Glas A, Mittempergher L, Kuilman M, Barcaru A, Brown Swigart Nanda Chien Pusztai Stringer-Reasor E, Shatsky R, Isaacs C, Perlmutter J, DeMichele A, Yee D, Esserman L, van 't Veer L. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS). Journal Of 2023, 41: 102-102. thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.](https://doi.org/10.1200/jco.2023.41.16_suppl.1076)Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in 1076-1076. Rugo Pohlmann P, Pusztai L, Symmans W, Borowsky A, Finestone S, Yee D, Hylton N, van 't Veer L, Esserman L, DeMichele A. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. Journal Of Clinical Oncology 2023, 41: 514-514. [DOI: 10.1200/jco.2023.41.16_suppl.514](https://doi.org/10.1200/jco.2023.41.16_suppl.514). [MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.](https://doi.org/10.1200/jco.2023.41.16_suppl.521)Beitsch P, Pellicane J, Pusztai L, Baron P, Cobain E, Murray M, Ashikari A, Kelemen P, Mislowsky A, Barone J, Cowan K, Layeequr Rahman R, Dooley W, Menicucci A, Finn C, Audeh M, Whitworth P. MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Journal Of Clinical signature and landscape tumors from 896 patients with early-stage breast cancer (BC).](https://doi.org/10.1200/jco.2023.41.16_suppl.539)Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology [DOI: 10.1200/jco.2023.41.16_suppl.539](https://doi.org/10.1200/jco.2023.41.16_suppl.539). complete response in SWOG S0800 neoadjuvant chemotherapy trial](http://www.ncbi.nlm.nih.gov/pubmed/37179362)Fanucci Y, Pelekanou Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy](https://doi.org/10.1016/s0960-9776(23)00137-6)Bardia A, Pusztai L, Albain K, Kalinsky W, Tokunaga E, Ciruelos E, Loirat D, Isaacs C, Testa L, Dry H, Kozarski R, (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant s23. [DOI: 10.1016/s0960-9776(23)00137-6](https://doi.org/10.1016/s0960-9776(23)00137-6). [P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study](https://doi.org/10.1016/s0960-9776(23)00242-4)K\u00fcmmel S, Schmid P, Harbeck N, Takahashi M, Untch Boileau J, Cortes J, McArthur H, Dent R, O'Shaughnessy J, Pusztai L, Foukakis T, Park Y, Hui R, Cardoso F, Denkert C, Zhu Y, Pan W, Karantza V, Fasching P. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study The Breast 2023, 68: s63-s64. [DOI: 10.1016/s0960-9776(23)00242-4](https://doi.org/10.1016/s0960-9776(23)00242-4). [Response to Neoadjuvant Therapy and in Patients With Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/36989609)Liedtke C, Mazouni C, Hess K, Andr\u00e9 F, Tordai A, Mejia J, Symmans W, Gonzalez-Angulo A, Hennessy B, Green M, Cristofanilli M, Hortobagyi G, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal Of early-stage breast cancer (DESTINY-Breast11)](https://doi.org/10.1016/s0960-9776(23)00228-x)Harbeck N, Boileau J, Modi S, Kelly C, Ohno S, Wu J, Konpa A, Herbolsheimer P, Safdar S, Zhang Y, Pusztai L. 10.1016/s0960-9776(23)00228-x](https://doi.org/10.1016/s0960-9776(23)00228-x). [BPI23-012: Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 Therapy Related Cardiac Events in HER2+ Breast Cancer Patients](https://doi.org/10.6004/jnccn.2022.7224)Hood A, Mukallari B, Majeski J, Pusztai L, Adelson K, Amin K. BPI23-012: Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 Therapy Related Cardiac Events in HER2+ Breast Cancer Patients Journal Of The National Comprehensive Cancer Network 2023, 21: bpi23-012. [DOI: 10.6004/jnccn.2022.7224](https://doi.org/10.6004/jnccn.2022.7224). [Variable Landscape of PD-L1 Expression as Detected by the DAKO 22C3 Immunohistochemistry Assay](http://www.ncbi.nlm.nih.gov/pubmed/36866462)Danziger N, Sokol E, Graf Maule J, Parimi V, Palmieri C, Pusztai L, Ross J, Huang R. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the (MBC)](https://doi.org/10.1158/1538-7445.sabcs22-p2-23-09)Fanucci K, lustberg M, Fischbach M, Sivapiragasam M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Research 2023, 83: p2-23-09-p2-23-09. from placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: S1207](https://doi.org/10.1158/1538-7445.sabcs22-gs1-07)Chavez J, Wendt A, Carney J, Sharma P, Gralow J, Lew D, Barlow W, Hortobagyi G. Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative immune response Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-12)Blenman K, Marczyk M, Foldi J, Gunasekharan V, Silber A, Pusztai L. Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC Cancer Research 2023, 83: p1-04-12-p1-04-12. [DOI: 10.1158/1538-7445.sabcs22-p1-04-12](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-12). Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K. Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial RxPONDER trial (SWOG S1007) by menopausal status](https://doi.org/10.1158/1538-7445.sabcs22-gs1-04)Kang I, Forschmiedt J, Loch M, Barlow W, Lew D, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Rastogi P, Schott A, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K, Henry N. Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal [Abstract HER2-19: HER2-19 Impact of status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized +/- G, Kalinsky K. Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score 25 randomized to endocrine therapy +/- chemotherapy: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study](https://doi.org/10.1158/1538-7445.sabcs22-p2-11-11)Shao D, Barlow W, Li H, Lu C, Albain K, Rae J, Hayes D, Godwin A, Thompson A, Madabhushi A, Pusztai L. Abstract P2-11-11: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814](https://doi.org/10.1158/1538-7445.sabcs22-p2-11-16)Chen Y, Barlow W, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain K, Pusztai L, Rae J, Hayes D, Godwin A, Thompson A, Madabhushi A. Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from characterization carcinoma by quantitative RT-PCR using Oncotype DX\u00ae](https://doi.org/10.1158/1538-7445.sabcs22-p2-23-14)Rozenblit M, Lin H, Can N, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner F, Pusztai L. Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using in the ALTTO and NeoALTTO clinical trials](https://doi.org/10.1158/1538-7445.sabcs22-p4-09-05)Rediti M, Venet D, Garcia A, Agbor-Tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Ueno T, Cosimo S, Piccart S, R, Viale G, Roth\u00e9 F, C. Abstract P4-09-05: Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO 10.1158/1538-7445.sabcs22-p4-09-05](https://doi.org/10.1158/1538-7445.sabcs22-p4-09-05). [Abstract P6-05-06: Patient-reported anxiety in the RxPONDER trial (SWOG S1007) by menopausal status](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-06)Loch M, Forschmiedt J, Kang I, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Rastogi P, Schott A, Shak S, Sharma P, Lew D, Miao J, Barlow W, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K, Henry N. Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal [Abstract PD3-01: Neoadjuvant pembrolizumab placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study](https://doi.org/10.1158/1538-7445.sabcs22-pd3-01)McArthur H, Cort\u00e9s J, Dent R, O'Shaughnessy J, Pusztai L, K\u00fcemmel S, Foukakis T, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Denkert C, Zhu Y, Ding Y, Pan W, Schmid P. Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study Cancer predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents](https://doi.org/10.1158/1538-7445.sabcs22-pd5-04)Wolf D, Yau C, Wulfkuhle J, Gallagher R, Swigart L, Hirst G, Coppe J, Magbanua M, Sayaman R, Investigators I, Sit L, Hylton N, DeMichele A, Berry D, Pusztai L, Yee D, Esserman L, Petricoin E, Van 't Veer L. Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents Cancer Research 2023, 83: pd5-04-pd5-04. [DOI: 10.1158/1538-7445.sabcs22-pd5-04](https://doi.org/10.1158/1538-7445.sabcs22-pd5-04). [Abstract receptor positive/human epidermal growth factor receptor-2 negative Karn Rozenblit M, Foldi Marczyk K, U, Kalinsky K, Meric-Bernstam F, Pusztai L. Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative onapristone in patients with estrogen receptor-positive, receptor-positive, K, N. OT2-01-04: ELONA: An open-label, phase 1b-2 study of elacestrant, in onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced Research 2023, 83: ot2-01-04-ot2-01-04. [DOI: 10.1158/1538-7445.sabcs22-ot2-01-04](https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-04). - Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)](http://www.ncbi.nlm.nih.gov/pubmed/36647745)Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain E, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of of breast cancer for whole transcriptome and targeted messenger RNA sequencing](http://www.ncbi.nlm.nih.gov/pubmed/36650408)Marczyk M, Fu C, Lau R, Du L, Trevarton A, Sinn B, Gould R, Pusztai L, Hatzis C, Symmans W. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial](http://www.ncbi.nlm.nih.gov/pubmed/36649570)Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial Cancer risk and aging are linked to replication-driven changes to the epigenome](https://doi.org/10.1158/1538-7445.agca22-pr009)Minteer C, Thrush K, Niimi P, Rozowsky J, Liu J, Frank M, McCabe T, Hofstatter E, Rozenblit M, Pusztai L, Beckman K, Gerstein M, Levine M. Abstract PR009: Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome Circulating Tumor Cells in Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/36634296)Nanou A, Miao J, Coumans F, Dolce E, Darga E, Barlow W, Smerage J, Paoletti C, Godwin A, Pusztai L, Sharma P, Thompson A, Hortobagyi G, Terstappen L, Hayes D. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast double-blind, Barlow Gralow J, Puhalla S, Anders C, Goldstein L, Tripathy D, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Pusztai L, Hayes D, Hortobagyi G. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer (S1416): randomised, double-blind, and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/36634607)Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn M, L, B, K, Saura Untch M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. Journal Of The National Comprehensive Cancer Network 2023, 21: 33-41.e16. [PMID: 36634607](https://pubmed.ncbi.nlm.nih.gov/36634607), Marczyk M, Shan K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer](https://doi.org/10.1016/j.ijrobp.2022.07.410)Jagsi R, Barlow W, Woodward W, Connolly E, Shumway D, Speers C, Stecklein S, Zhang H, Sharma P, L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer International Journal Of 114: s43. [DOI: 10.1016/j.ijrobp.2022.07.410](https://doi.org/10.1016/j.ijrobp.2022.07.410). and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021](http://www.ncbi.nlm.nih.gov/pubmed/36445704)Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021 JAMA L. Intratumour heterogeneity, from hypothesis to the clinic of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy](http://www.ncbi.nlm.nih.gov/pubmed/36206298)Ibrahim EY, Munshani Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during in the neoadjuvant and post-neoadjuvant breast cancer settings.](http://www.ncbi.nlm.nih.gov/pubmed/36125946)Pusztai L. The effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer settings. Clinical vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522](https://doi.org/10.1016/j.annonc.2022.07.170)Dent H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Haiderali A, Jia L, Nguyen A, Pan W, O'Shaughnessy J, Schmid P. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial](https://doi.org/10.1016/j.annonc.2022.07.174)Rediti M, Venet D, Garcia A, Agbor-tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Liu M, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, F, Sotiriou C. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer Breast Cancer Research And 196: 221-227. den Heuvel R. Analysis by residual cancer burden further clarifies effect of pembrolizumab 2022 [DOI: 10.55788/70fdb2dd](https://doi.org/10.55788/70fdb2dd). [Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.](http://www.ncbi.nlm.nih.gov/pubmed/35903931)Foldi J, Kahn A, Silber A, Qing T, Reisenbichler Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy and non-African American triple negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35869114)Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer in early TNBC: Asian subgroup](https://doi.org/10.1016/j.annonc.2022.05.066)Takahashi M, Cort\u00e9s J, Dent R, Pusztai L, Mcarthur H, K\u00fcmmel S, Denkert C, Park Y, Im S, Ahn J, Mukai H, Huang C, Chen S, Kim M, Jia L, Li X, Tryfonidis K, Karantza V, Iwata H, Schmid P. PS2-3 Neoadjuvant + chemo, followed by adjuvant pembrolizumab/placebo in subgroup Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. [DOI: 10.1200/jco.2022.40.16_suppl.e18834](https://doi.org/10.1200/jco.2022.40.16_suppl.e18834). [Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.](https://doi.org/10.1200/jco.2022.40.16_suppl.516)Foldi J, Kahn A, Silber A, Qing T, Reisenbichler Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.](https://doi.org/10.1200/jco.2022.40.16_suppl.594)Blenman Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Pusztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating peripheral neuropathy risk factor in white and black patients in SWOG 0221.](https://doi.org/10.1200/jco.2022.40.16_suppl.12023)Chen C, Zirpoli G, McCann S, Barlow W, Budd G, Pusztai L, Hortobagyi G, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.](https://doi.org/10.1200/jco.2022.40.16_suppl.12084)Lambertini M, Ceppi M, Anderson R, Cameron D, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, L, Mastro L, Partridge A, Saura C, Untch Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the 40: 12084-12084. burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.](https://doi.org/10.1200/jco.2022.40.16_suppl.503)Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kuemmel S, Bergh J, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. by molecular subtype in the I-SPY2 Trial.](https://doi.org/10.1200/jco.2022.40.16_suppl.504)Huppert L, Rugo H, Pusztai L, Mukhtar R, Chien A, Yau C, Wolf D, Berry D, van 't Veer L, Yee D, DeMichele A, Esserman L. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 and maximize response: Predictive biomarkers across 10 cancer therapies](http://www.ncbi.nlm.nih.gov/pubmed/35623341)Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu R, O'Grady N, Basu A, Delson A, JP, Lu R, Braun J, Investigators I, Asare SM, Sit L, Matthews JB, GL, cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 Delaloge S, Harbeck N, Hayes D, Kalinsky K, Pusztai L, Regan M, Sestak I, Spanic T, Sparano J, S, modulation through de-intensification to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials](http://www.ncbi.nlm.nih.gov/pubmed/35513244)Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y, Balassanian R, Nanda R, Parker B, Krings G, Sattar H, Zeck J, Albain K, Boughey J, Liu M, Elias A, Clark A, Venters S, Shad S, Basu A, Asare A, Rugo H, Perlmutter J, DeMichele A, Yee D, Berry D, Veer L, Symmans W, Esserman L, Pusztai L, Consortium I. Treatment Efficacy Score\u2014continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer HER2-positive breast cancer S, Ciniselli C, de Azambuja E, Venet D, De Cecco L, Pong N, Cappelletti V, Tagliabue E, Wang Y, Manich C, Nuciforo P, Kuemmel S, Pusztai P. 2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast A, Mayer Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: Rozenblit M, Foldi J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert Sinn M, Foldi J, Rimm DL, Loibl S, Pusztai Predictive Markers Response with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide O, Hanley MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression L, Hern\u00e1ndez-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Pe\u00f1a R, Monta\u00f1\u00e9s DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celi\u00e0-Terrassa T. LCOR mediates tumor immunogenicity and responsiveness to immune-checkpoint blockade 10.1038/s43018-022-00339-4](https://doi.org/10.1038/s43018-022-00339-4). [Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors](http://www.ncbi.nlm.nih.gov/pubmed/35263168)Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Rodriguez A, Billings PR, Grothey A, Taieb J, Cunningham D, Yoshino T, Kopetz S. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors Npj Breast Chakraborty R, Lustberg M, Pusztai L, Campbell S, Zhao H, Halene S, Hwa J. MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTS Journal Of The American College Of 2022, 1912. [DOI: 10.1016/s0735-1097(22)02903-5](https://doi.org/10.1016/s0735-1097(22)02903-5). Pusztai L. Comprehensive Analysis of aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes](http://www.ncbi.nlm.nih.gov/pubmed/35209953)Rozenblit M, Hofstatter E, Liu Z, O'Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes](https://doi.org/10.1158/1538-7445.sabcs21-p3-07-01)Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes Cancer Research 2022, 82: p3-07-01-p3-07-01. [DOI: 10.1158/1538-7445.sabcs21-p3-07-01](https://doi.org/10.1158/1538-7445.sabcs21-p3-07-01). - Fernandez Fadare O, Hanley K, Harigopal J, Kuba M, Ly A, Podoll M, Rabe K, Sanders M, Singh K, Snir O, Soong R, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm D. Abstract P1-02-02: Examination of low Her2 expression in breast tumors](https://doi.org/10.1158/1538-7445.sabcs21-p1-05-02)Foldi J, Reisenbichler E, Pan L, Sorg K, Church S, Pusztai L. Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low [Abstract P2-08-03: PD-L1 protein expression relation to Recurrence Score values in early stage ER+HER2- breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-08-03)Blenman K, Harigopal M, Huang R, Reisenbichler E, Qing T, Ibrahim E, Singh K, Ramkissoon S, Mustimbo R, Ross J, Pusztai L. Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer for metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs21-p5-08-16)Pusztai L, Danziger N, Sokol E, Pavlick D, Graf R, Ramkissoon S, Huang R, Decker B, Ross J. Abstract P5-08-16: MTAP deletion and synthetic lethality-based drug development for Sehgal R, Shan N, Muthusamy V, Umlau S, Surovtseva P5-17-01: Targeting Acetyl-CoA signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies](https://doi.org/10.1158/1538-7445.sabcs21-pd10-07)Soliman H, Wolf D, Chien J, Yau C, Campbell M, Magbanua M, Lu R, O'Grady N, Brown-Swigart L, Hirst G, Parker B, Sit L, Asare S, Yee D, DeMichele A, Nanda R, Pusztai L, Berry D, Esserman Veer L. Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score\u00ae assay in node-positive postmenopausal breast in the SWOG S8814 trial](https://doi.org/10.1158/1538-7445.sabcs21-pd9-06)Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner F, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score\u00ae assay in node-positive postmenopausal breast cancer: Results from an chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses](https://doi.org/10.1158/1538-7445.sabcs21-gs1-01)Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M, Im S, Ahn J, Gion M, Baron-Hay S, Boileau J, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J. Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity gs1-01-gs1-01. [DOI: 10.1158/1538-7445.sabcs21-gs1-01](https://doi.org/10.1158/1538-7445.sabcs21-gs1-01). [Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) 25 randomized to endocrine therapy (ET) +/- chemotherapy W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly C, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas C, Brain E, Lee E, Pierga J, Bermejo B, Ramos-Vasquez M, Jung K, Ferrero J, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G. Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) 25 randomized to endocrine therapy (ET) of clinical and expression-based immune signatures by race in the I-SPY 2 trial](https://doi.org/10.1158/1538-7445.sabcs21-gs4-02)Kyalwazi B, Yau C, Olopade O, Chien A, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van 't Veer L, Berry D, Esserman L. Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 Research 2022, in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)](https://doi.org/10.1158/1538-7445.sabcs21-ot1-12-04)Harbeck N, Boileau J, Modi S, Kelly C, Ohno S, Wu J, Brekenridge M, Herbolsheimer P, Yu T, Pusztai L. Abstract OT1-12-04: in patients with high-risk HER2-positive alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial](https://doi.org/10.1158/1538-7445.sabcs21-pd5-05)Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn S, Azambuja E, Demeestere I. Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of pd5-05-pd5-05. [DOI: 10.1158/1538-7445.sabcs21-pd5-05](https://doi.org/10.1158/1538-7445.sabcs21-pd5-05). L, McArthur H, K\u00fcmmel S, Bergh J, Denkert N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay J. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer New K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. and macrophage-mediated immune suppression](http://www.ncbi.nlm.nih.gov/pubmed/35108062)Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-B signaling and as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study](https://doi.org/10.1016/j.ejso.2021.12.430)K\u00fcmmel S, Cort\u00e9s Dent R, Pusztai L, McArthur H, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso G, Karantza V, O'Shaughnessy J, Schmid P. Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study 10.1016/j.ejso.2021.12.430](https://doi.org/10.1016/j.ejso.2021.12.430). [Quantitative assessment of African American Triple Negative Breast Cancer: a case-control study](http://www.ncbi.nlm.nih.gov/pubmed/34906209)Yaghoobi V, Moutafi M, Aung E, Vathiotis Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study Breast and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients](http://www.ncbi.nlm.nih.gov/pubmed/34902335)Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze L\u00f3pez-Tarruella Consortium Adamson K, Albain K, Asare A, Asare S, Balassanian R, Beckwith H, Berry S, Berry D, Boughey J, Buxton M, Chen Y, Chen B, Chien A, Chui S, Clark A, Clennell J, Datnow B, DeMichele A, Duan X, Edmiston K, Elias A, Ellis E, Esserman L, Euhus D, Fadare O, Fan F, Feldman M, Forero-Torres A, Haley B, Han H, Harada S, Haugen T, Hirst G, Hylton N, Isaacs C, Kemmer K, Khan Q, Khazai L, Klein M, Krings G, Lang J, LeBeau L, Leyland-Jones B, Liu M, Lo S, Lu J, Magliocco A, Matthews J, Melisko M, Mhawech-Fauceglia P, Moulder I, Olopade O, Pambuccian S, Paoloni M, Park J, Parker B, Perlmutter J, Peterson G, Pusztai L, Rendi M, Rugo H, Sahoo S, Sams E, Symmans W, Tawfik M, Veer L, Venters S, Vinh T, Viscusi R, Wallace A, Wei S, Wilson A, Yau C, Yee D, Zeck J, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut S, Thomas J, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, van 't Veer L, Esserman L, Symmans W. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of KS, SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer New England Journal the Front-line Treatment of Patients Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222SWOG L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, Survival in Neoadjuvant Treatment for High-risk Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34529000)Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace A, Clark AS, Kemmer K, Isaacs JE, Han Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for Type of Neoadjuvant Chemotherapy Regimen](http://www.ncbi.nlm.nih.gov/pubmed/34644277)Olawoyin OM, Mehta S, Chouairi F, Gabrick T, Pusztai L, Alperovich M. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen waterfall plots to increase value of response data generated by small single arm Phase II trials](http://www.ncbi.nlm.nih.gov/pubmed/34634476)Han G, Pusztai L, Hatzis C. Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials Contemporary Clinical Trials 2021, 110: 106589. [PMID: 34634476](https://pubmed.ncbi.nlm.nih.gov/34634476), Surovtseva Y, Negahban Z, Pusztai L, Gerstein MB. Network propagation-based prioritization of long tail genes in 17 cancer DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, KK, Petricoin L, DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer for Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34638323)Iwase X, Reisenbichler E, R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial](http://www.ncbi.nlm.nih.gov/pubmed/34521624)Paoletti C, Barlow L, DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Wang X, Jun T, Ding L, Pusztai L, Huang K. Genomic Determinants of Homologous Recombination Deficiency Profiling for Breast Cancer Research with the GeoMx\u00ae Digital Spatial Profiler](http://www.ncbi.nlm.nih.gov/pubmed/34503266)Bergholtz H, Carter JM, Cesano Church J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin \u00d6, SM, Warren SE, Consortium O. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx\u00ae Digital neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC](https://doi.org/10.1016/j.annonc.2021.06.014)Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso G, Karantza V, J. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for Tkaczuk K, Assad H, Pusztai L, Hurvitz J, Krop I, Medgyesy D, Abraham J, Modi S, Li H, Wu S, Garfin P, Weekly ladiratuzumab to trastuzumab in with early-stage cancer](http://www.ncbi.nlm.nih.gov/pubmed/34465600)Vathiotis IA, Moutafi Divakar Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, DL. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical Rediti M, Maetens L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Roth\u00e9 F, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34315723)Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman K, Balko JM, Institute A, Leyland-Jones B, Agency C, Chia S, Serpanchy R, Yu C, University E, McMillan S, Mosley R, Nguyen K, Wood E, Zelnak A, University G, Dillis C, Donnelly R, Harrington T, Isaacs C, Kallakury B, Liu M, Lynce F, Oppong B, Pohlmann P, Tousimis E, Warren R, Willey S, Wong J, Zeck J, Center L, Albain K, Bartolotta M, Bova D, Brooks C, Busby B, Czaplicki K, Duan X, Gamez R, Ganesh K, Gaynor E, Godellas C, Grace-Louthen C, Kuritza T, Lo S, Nagamine A, Perez C, Robinson P, Rosi D, Vaince F, Ward K, Hospital I, Choquette K, Edmiston K, Gallimore H, McGovern J, Mokarem K, Pajaniappan M, Rassulova S, Scott K, Sherwood K, Wright J, Clinic A, Anderson K, Gray R, Myers S, Northfelt D, Pockaj B, Roedig J, Wasif N, Clinic R, Arens A, Boughey J, Brandt K, Carroll J, Chen B, Connors A, Degnim A, Farley D, Greenlee S, Haddad T, Hieken T, Hobday T, Jakub J, Liberte L, Liu M, Loprinzi C, Menard L, Moe M, Moynihan T, O'Sullivan C, Olson E, Peethambaram P, Ruddy K, Russell B, Rynearson A, Smith D, Visscher D, Windish A, Institute H, Cox K, Dawson K, Newton O, Ramirez W, University O, Bengtson H, Bucher J, Chui S, Gilbert-Ghormley B, Hampton R, Kemmer K, Kurdyla D, Nauman D, Spear J, Wilson A, Institute S, Beatty D, Dawson P, Ellis E, Fer M, Hanson J, Goetz M, Haddad T, Iriarte D, Kaplan H, Porter B, Rinn K, Thomas H, Thornton S, Tickman R, Varghis N, Birmingham U, Caterinichia V, Santos J, Falkson C, Forero A, Krontiras H, Vaklavas C, Wei S, University of Arizona, Bauland A, Inclan L, Lewallen D, Powell A, Roney C, Schmidt K, Viscusi R, Wright H, San Diego University of California, Blair S, Boles S, Bykowski J, Datnow B, Densley P, Ojeda-Fournier H, Onyeacholem I, Parker B, Podsada K, Schwab R, Wallace A, Yashar C, San Francisco University of California, Alvarado M, Au A, Balassanian R, Benz C, Buxton M, Chen Y, Chien J, D'Andrea C, Davis S, Esserman L, Ewing C, Goga A, Hirst G, Hwang M, Hylton N, Joe B, Lyandres J, Kadafour M, Krings G, Melisko M, Moasser M, Munter P, Ngo Z, Park J, Price E, Rugo H, Veer L, Wong J, Yau C, University of Chicago, Abe H, Jaskowiak N, Nanda R, Olopade F, Schacht D, University of Colorado D, Borges V, Colvin T, Diamond J, Elias A, Finlayson C, Fisher C, Hardesty L, Kabos P, Kounalakis N, Mayordomo J, McSpadden T, Murphy C, Rabinovitch R, Sams S, Shagisultanova E, University of Kansas, Baccaray S, Khan Q, University of Minnesota, Beckwith H, Blaes A, Emory T, Haddad T, Hui J, Klein M, Kuehn-Hajder J, Nelson M, Potter D, Tuttle T, Yee D, Zera R, University of Pennsylvania, Bayne L, Bradbury A, Clark A, DeMichele A, Domchek S, Fisher C, Fox K, Frazee D, Lackaye M, Matro J, McDonald E, Rosen M, Shah P, Tchou J, Volpe M, Center U, Alvarez R, Barcenas C, Berry D, Booser D, Brewster A, Brown P, Gonzalez-Angulo A, Ibrahim N, Karuturi M, Koenig K, Moulder S, Murray J, Murthy R, Pusztai L, Saigal B, Symmans W, Tripathy D, Theriault R, Ueno N, Valero V, California U, Brown M, Carranza M, Flores Y, Lang J, Luna A, Perez N, Tripathy D, Watkins K, Center U, Armstrong S, Boyd C, Chen L, Clark V, Frankel A, Euhus D, Froehlich T, Goudreau S, Haley B, Harker-Murray A, Klemow D, Leitch A, Leon R, Li H, Morgan T, Qureshi N, Rao R, Reeves M, Rivers A, Sadeghi N, Seiler S, Staves B, Tagoe V, Thomas G, Tripathy D, Unni N, Weyandt S, Wooldridge R, Zuckerman J, Universty of Washington, Korde L, Griffin M, Butler B, Cundy A, Rubinstein L, Hixson C. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy Current Treatment Options alpha-smooth muscle actin expression in the stroma of patients with HER2+ breast cancer](https://doi.org/10.1158/1538-7445.am2021-339)Vathiotis I, Moutafi M, Divakar P, Aung T, Fernandez A, Yaghoobi V, Shafi S, Syrigos K, Fountzilas G, Pusztai L, Warren S, Rimm D. Abstract 339: Resistance to trastuzumab is associated with alpha-smooth muscle actin expression in the stroma of patients with 339-339. [DOI: 10.1158/1538-7445.am2021-339](https://doi.org/10.1158/1538-7445.am2021-339). [Abstract 423: Pooled analysis patient outcome in I-PREDICT and WINTHER studies](https://doi.org/10.1158/1538-7445.am2021-423)Casadevall D, Marczyk M, Monzonis X, Pusztai L, Albanell J. Abstract 423: Pooled analysis of matching score and patient outcome in I-PREDICT and WINTHER studies Cancer - Huang RSP, Decker B, Hiemenz MC, Lechpammer M, Danziger N, Schiavone GJ, Razis ED, Bartsch R, Giannoudis JS, Palmieri C, Ramkissoon SH. Clinicopathologic and from the adaptively randomized I-SPY2 trial](http://www.ncbi.nlm.nih.gov/pubmed/34143979)Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Sanil AL, Matthews Melisko for cancer: Lou B, T, Pusztai L. The Way of the Future: Personalizing Treatment Plans Through Technology. American Society Of scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations](http://www.ncbi.nlm.nih.gov/pubmed/34040000)Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations Npj Breast Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? 2021, triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).](https://doi.org/10.1200/jco.2021.39.15_suppl.564)Blenman K, Marczyk M, Qing T, O'Meara T, Yaghoobi V, Pelekanou V, Bai Y, Reisenbichler E, Li X, Gunasekharan V, Ibrahim E, Rimm D, Pusztai L, Cole K. Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African Efficacy Score continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.](https://doi.org/10.1200/jco.2021.39.15_suppl.587)Marczyk M, Mrukwa A, Yau C, Wolf D, van 't Veer L, Esserman L, Symmans W, Pusztai L. Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial. Journal Of Clinical Oncology 2021, 39: 587-587. 10.1200/jco.2021.39.15_suppl.587](https://doi.org/10.1200/jco.2021.39.15_suppl.587). Lujambio A, Marczyk M, Pusztai L, Huang KL. Diverse immune response of DNA damage repair-deficient tumors Cell similar genomic alterations to non-inflammatory breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/33902690)Li X, Kumar S, Harmanci A, Li S, Kitchen RR, Zhang Y, Wali VB, Reddy SM, Woodward WA, Reuben JM, Rozowsky Gerstein M. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast protein expression between primary and metastatic lesions in patients with lung cancer](http://www.ncbi.nlm.nih.gov/pubmed/33833050)Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer Journal For Cancer: Systematic Review and Meta-Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33810205)Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, Rimawi MF, Schiff R, Arpino G, De Placido S, Prat A, Generali D. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic Breast Cancer Research And Between Primary and Metastatic Lesions in Lung Cancer Patients](https://doi.org/10.1016/j.jtho.2021.01.671)Moutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, Wei W, Pusztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients and HER2-negative (HR+/HER2) breast cancer before chemo-endocrine therapy](http://www.ncbi.nlm.nih.gov/pubmed/33617937)Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst G, Bedrosian I, Layman R, Carter J, Klein M, Venters S, Shad S, van der Noordaa M, Chien A, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu M, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Veer L, Valero V, Esserman L, Symmans W. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2) perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-ss2-05)Park K, Gregory M, Lustberg M, Bazan J, Shen C, Rosenberg S, Blinder V, Sharma P, Pusztai L, Partridge A, Thompson A. Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer Cancer Research 2021, 81: ss2-05-ss2-05. [DOI: 10.1158/1538-7445.sabcs20-ss2-05](https://doi.org/10.1158/1538-7445.sabcs20-ss2-05). [Abstract GS3-00: First results from phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)](https://doi.org/10.1158/1538-7445.sabcs20-gs3-00)Kalinsky K, Barlow W, Meric-Bernstam F, Gralow J, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Mart\u00edn M, Gil M, Arce-Salinas C, Brain E, Park I, Pierga J, Lluch A, Vasquez M, Borrego M, Jung K, Ferrero J, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Hortobagyi G, Pusztai L. Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence of triple breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial](https://doi.org/10.1158/1538-7445.sabcs20-gs3-05)Stecklein S, Barlow Pusztai L, Timms K, Kennedy R, Badve S, G\u00f6kmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore](https://doi.org/10.1158/1538-7445.sabcs20-gs4-07)van der Noordaa M, Yau C, Shad S, Osdoit M, Steenbruggen T, de Croze D, Hamy A, Lae M, Reyal F, Del Monte-Mill\u00e1n M, Martin M, Tarruella S, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-03)Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk L, Modi S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo Z, Garfin P, Burris H. Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer Cancer Research 2021, 81: ot-03-03-ot-03-03. [DOI: 10.1158/1538-7445.sabcs20-ot-03-03](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-03). - M, de Croze D, Hamy A, Lae M, Reyal F, Martin M, Del Monte-Mill\u00e1n M, L\u00f3pez-Tarruella S, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin A, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, Van't Veer L, Symmans F, Esserman L, Yau C. Abstract PD13-02: Site of recurrence after neoadjuvant therapy: A olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-pd14-02)Wolf D, Yau C, Brown-Swigart L, O'Grady N, Hirst G, Sit L, Asare S, Berry D, Esserman L, Han H, Pusztai L, van 't Veer L. Abstract PD14-02: Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer Cancer Research 2021, 81: pd14-02-pd14-02. [DOI: 10.1158/1538-7445.sabcs20-pd14-02](https://doi.org/10.1158/1538-7445.sabcs20-pd14-02). - Qing M, Foldi J, Blenman K, Gunasekharan V, Pusztai L. Abstract PS19-05: Functional importance of long-tail mutations in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial](https://doi.org/10.1158/1538-7445.sabcs20-ps2-04)Paoletti C, Barlow W, Bergqvist M, Mehta J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG expression between primary tumors and metastatic lesions in triple negative breast cancers](https://doi.org/10.1158/1538-7445.sabcs20-ps5-08)Rozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Cancer Research 2021, 81: ps5-08-ps5-08. [DOI: 10.1158/1538-7445.sabcs20-ps5-08](https://doi.org/10.1158/1538-7445.sabcs20-ps5-08). - Pusztai L. Abstract K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples](http://www.ncbi.nlm.nih.gov/pubmed/33541297)Fu C, Marczyk M, Samuels M, Trevarton AJ, Qu J, Lau R, Du L, Pappas T, Sinn BV, Gould RE, Pusztai L, Hatzis WF. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples BMC M, Cristofanilli M, Pusztai G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy](http://www.ncbi.nlm.nih.gov/pubmed/33514405)Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy Breast Cancer Research 2021, 23: 14. Dynamic clustering of cancer genomics datasets beyond pre-defined human 29: pr12-pr12. [DOI: 10.1158/1538-7755.disp20-pr12](https://doi.org/10.1158/1538-7755.disp20-pr12). [Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/33239417)Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Journal For ImmunoTherapy vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients](https://doi.org/10.1136/jitc-2020-sitc2020.0323)Pusztai L, Lu H, Hale C, Grosse-Wilde A, Specht J, Modi S, Han H, Cortes J, Oliveira M, Garfin P, Wang Z, Onsum M. 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients 2020, a198-a199. [DOI: 10.1136/jitc-2020-sitc2020.0323](https://doi.org/10.1136/jitc-2020-sitc2020.0323). of Treatment Strategies (HER2)-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33226431)Kunst N, Wang SY, Hood MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)](https://doi.org/10.1016/j.annonc.2020.10.021)Dent R, Cortes J, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Jensen E, V, G, O'Shaughnessy J, Schmid P. of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast 31: s1241-s1242. [DOI: 10.1016/j.annonc.2020.10.021](https://doi.org/10.1016/j.annonc.2020.10.021). [PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32709714)Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer Wildiers H, Curigliano T, Ciruelos E, Rottey S, Rugo H. Expected medium and long term impact of the COVID-19 outbreak in oncology Annals Comprehensive Genomic Profiling and PDL1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32869930)Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Williams E, Elvin J, Vergilio J, Killian J, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen M, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom J, Alexander B, Brown C, Pusztai L, Ross J, Ramkissoon S. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PDL1 Immunohistochemistry Biomarkers in 312 Patients Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32701140)Consortium I, Yee D, DeMichele A, Yau C, Isaacs C, Symmans W, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman I, Tawfik S, Vinh T, Chien A, Forero-Torres A, Stringer-Reasor E, Wallace A, Pusztai L, Boughey J, Ellis E, Elias A, Lu J, Lang J, Han H, Clark A, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Park J, Liu M, Olopade O, Leyland-Jones B, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton N, Veer L, Perlmutter J, Melisko M, Wilson A, Peterson G, Asare A, Buxton M, Paoloni M, Clennell J, Hirst R, Steeg K, Matthews J, Asare S, Sanil A, Berry S, Esserman L, Berry D. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast R, Mougalian SS. Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer Cancer Cell 32931742](https://pubmed.ncbi.nlm.nih.gov/32931742), [DOI: 10.1016/j.ccell.2020.08.006](https://doi.org/10.1016/j.ccell.2020.08.006). [Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer](https://doi.org/10.1016/j.annonc.2020.08.309)Licata L, Viale G, Criscitiello C, Giordano A, Chavez-MacGregor M, Curigliano G, Foldi J, Oke O, Giuliano M, Collins R, Del Mastro L, Puglisi F, Montemurro Vernieri L, Pusztai L, Bianchini G. Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer Annals Of Oncology 2020, 31: s317-s318. [DOI: 10.1016/j.annonc.2020.08.309](https://doi.org/10.1016/j.annonc.2020.08.309). [Abstract 4973: Comparison immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients](https://doi.org/10.1158/1538-7445.am2020-4973)Yaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D, Blenman K. Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients Cancer 2020, cells after Navitoclax treatment](https://doi.org/10.1158/1538-7445.am2020-6333)Marczyk M, Gunasekharan V, Zhao J, Qu R, Li X, Patwardhan G, Wali V, Gupta A, Pillai M, transcriptomic, epigenetic profiling of triple-negative breast cancer Navitoclax treatment Cancer Research 2020, 6333-6333. [DOI: 10.1158/1538-7445.am2020-6333](https://doi.org/10.1158/1538-7445.am2020-6333). L, Tripathy D, G, Bartholomeusz C. Abstract 1897: Mechanism of MEK inhibitor resistance in triple negative breast Cancer Research 80: 1897-1897. [DOI: 10.1158/1538-7445.am2020-1897](https://doi.org/10.1158/1538-7445.am2020-1897). [Abstract 1998: Predictive and and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial](https://doi.org/10.1158/1538-7445.am2020-1998)Rediti M, Venet D, Roth\u00e9 F, Qing M, Harbeck N, Untch M, Rimm D, Chia S, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical Qing T, Samstein R, Cordon-Cardo C, L, Huang K. Abstract 2226: Precise stratification of immunotherapy outcomes using paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL](https://doi.org/10.1158/1538-7445.am2020-ct011)Pusztai L, Han H, Yau C, Wolf D, Wallace A, Shatsky R, Helsten T, Boughey J, Haddad T, Stringer-Reasor E, Falkson C, Chien A, Mukhtar R, Elias A, Virginia B, Nanda R, Yee D, Kalinsky K, Albain K, Muller A, Kemmer K, Clark A, Isaacs C, Thomas A, Hylton N, Symmans W, Perlmutter J, Melisko M, Rugo H, Schwab R, Wilson A, Wilson A, Singhrao R, Asare S, van't Veer L, DeMichele A, Sanil A, Berry D, Esserman L. Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY TRIAL Cancer Yaghoobi Blenman K, Cole K, Pelekanou V, endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.](https://doi.org/10.1200/jco.2020.38.15_suppl.527)Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. [DOI: 10.1200/jco.2020.38.15_suppl.527](https://doi.org/10.1200/jco.2020.38.15_suppl.527). Gralow J, Huggins-Puhalla Anders C, Goldstein L, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Pusztai L, Hayes D, Hortobagyi G. Results of a phase II randomized trial of cisplatin +/- of to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.3117)Iwase T, Pusztai L, Blenman K, Li X, Seitz R, Nielsen T, Schweitzer B, Hout D, Bailey D, Zhang X, Shen Y, Ueno N. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Clinical Oncology 2020, 38: 10.1200/jco.2020.38.15_suppl.3117](https://doi.org/10.1200/jco.2020.38.15_suppl.3117). molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.](https://doi.org/10.1200/jco.2020.38.15_suppl.511)Rediti M, Venet D, Rothe F, Qing T, M, I, M, Cosimo S, Hilbers Bajji Harbeck Untch M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. Of Clinical Oncology 2020, 38: 511-511. [DOI: 10.1200/jco.2020.38.15_suppl.511](https://doi.org/10.1200/jco.2020.38.15_suppl.511). [SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps1104)Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk L, Modi S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo H, Mitri Z, Garfin P, Burris III H. SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. Journal Of Clinical Oncology 2020, 38: tps1104-tps1104. [DOI: 10.1200/jco.2020.38.15_suppl.tps1104](https://doi.org/10.1200/jco.2020.38.15_suppl.tps1104). [EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3647)Bruce J, Pusztai L, Braiteh F, Gorla S, Wu C, Baranda J. EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3647-tps3647. 10.1200/jco.2020.38.15_suppl.tps3647](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3647). [A phase neoadjuvant chemotherapy and adjuvant endocrine therapy in Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast 10.1200/jco.2020.38.15_suppl.tps604](https://doi.org/10.1200/jco.2020.38.15_suppl.tps604). [Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden](http://www.ncbi.nlm.nih.gov/pubmed/32415133)Qing T, Mohsen H, Marczyk M, Ye Y, O'Meara T, Zhao H, Townsend JP, Gerstein M, Hatzis C, Kluger Y, Pusztai L. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden Nature Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.](http://www.ncbi.nlm.nih.gov/pubmed/32407488)Schettini F, Giudici F, M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal Of The Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale TO, Badve SS, Symmans Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi L, Beck Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert F, Swanton C, Braybrooke JP, Hanna MG, Soler-Mons\u00f3 MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma S, Thagaard P, Brogi Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale TO, Badve SS, Symmans Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi L, Beck Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert F, Swanton C, Braybrooke JP, Hanna MG, Soler-Mons\u00f3 MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma S, Thagaard P, Brogi Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Complete Response in Women With Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32053137)Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Singhrao Asare A, S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with neoadjuvant chemotherapy and adjuvant endocrine therapy in Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Loi S. 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2 Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer](https://doi.org/10.1201/9780429137723-6)Liedtke C, Pusztai L. Gene Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer 2020, 77-96. [DOI: 10.1201/9780429137723-6](https://doi.org/10.1201/9780429137723-6). [Prospective multi-institutional evaluation of pathologist assessment of assays for patient selection in triple negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/32300181)Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome](http://www.ncbi.nlm.nih.gov/pubmed/31919134)Powles RL, Wali VB, Li X, Barlow WE, Nahleh Z, Thompson AM, Godwin AK, Hatzis C, Pusztai L. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome Clinical K\u00fcmmel S, Bergh J, Denkert M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J. Pembrolizumab for Early Triple-Negative Breast Cancer New England with J, M, la L, FS, Azambuja Untch Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy International Journal Of cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd1-01)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello A. Abstract dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative Research 2020, 80: pd1-01-pd1-01. [DOI: 10.1158/1538-7445.sabcs19-pd1-01](https://doi.org/10.1158/1538-7445.sabcs19-pd1-01). [Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer](https://doi.org/10.1158/1538-7445.sabcs19-p2-09-02)Hofstatter E, Levine M, Liu Z, O'Meara T, Dalela D, Pusztai L. Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer Cancer Research 2020, 80: p2-09-02-p2-09-02. [DOI: 10.1158/1538-7445.sabcs19-p2-09-02](https://doi.org/10.1158/1538-7445.sabcs19-p2-09-02). [Abstract PD10-05: Cost-effectiveness of different neoadjuvant by adjuvant treatment combination strategies for women with HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-pd10-05)Kunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, Pusztai L. Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer Cancer Research 2020, 80: pd10-05-pd10-05. [DOI: 10.1158/1538-7445.sabcs19-pd10-05](https://doi.org/10.1158/1538-7445.sabcs19-pd10-05). [Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis](https://doi.org/10.1158/1538-7445.sabcs19-gs5-01)Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, Lae M, Martin M, del Monte M, Boughey J, Gould R, Wesseling J, Steenbruggen T, van Seijen M, Sonke G, Edge S, Sammut S, Provenzano E, Abraham J, Hall P, Graham A, Mackintosh L, Cameron D, Wang A, Sharma P, Cole K, Pusztai L, Kim M, van 't Veer L, Esserman L, Symmans W. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy therapy in of exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy](https://doi.org/10.1158/1538-7445.sabcs19-p1-19-12)Rozenblit M, Pusztai L, Adelson K, Mougalian S. Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy Cancer Research 2020, 80: p1-19-12-p1-19-12. [DOI: 10.1158/1538-7445.sabcs19-p1-19-12](https://doi.org/10.1158/1538-7445.sabcs19-p1-19-12). [Abstract P2-20-02: Site of recurrence Clues to biology and impact on endpoints](https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02)Yau C, DeMichele A, Symmans W, Pusztai L, Yee D, Clark A, Hatzis C, Matthews J, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albain K, Chien A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Hylton N, Boughey J, Melisko M, Perlmutter J, Rugo H, Schwab R, van' t Veer L, Berry D, Esserman L. Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on 2020, 80: p2-20-02-p2-20-02. [DOI: 10.1158/1538-7445.sabcs19-p2-20-02](https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02). [Abstract markers of nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-05)Blenman K, Li X, Marczyk M, O'Meara T, Yaghoobi V, Gunasekharan V, Park T, Rimm D, Pusztai L. Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative 2020, 80: p3-09-05-p3-09-05. [DOI: 10.1158/1538-7445.sabcs19-p3-09-05](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-05). assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-14)Ahmed F, McGuire J, Gaule P, Blenman K, Pusztai L, Rimm D. Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer 2020, 80: PD-L1 assays in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-pd5-01)Reisenbichler E, Han G, Pelekanou V, Yaghoobi V, Ahmed F, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison B, Kuba M, Ly A, Miller D, Podoll M, Roden A, Sanders M, Singh K, Wei S, Wen H, Pusztai L, Rimm D. Abstract PD5-01: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer Cancer Research 2020, 80: pd5-01-pd5-01. [DOI: 10.1158/1538-7445.sabcs19-pd5-01](https://doi.org/10.1158/1538-7445.sabcs19-pd5-01). [The impact of RNA accurate RNA sequencing from formalin-fixed paraffin-embedded tissues](http://www.ncbi.nlm.nih.gov/pubmed/31805884)Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed Promotes Resistance to HER2-Targeted Therapies](http://www.ncbi.nlm.nih.gov/pubmed/31825825)Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, del Genio C, Canfield K, DiRenzo J, Wells Kurokawa M. CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.](http://www.ncbi.nlm.nih.gov/pubmed/31657982)Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, P, AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure](http://www.ncbi.nlm.nih.gov/pubmed/31653660)Criscione J, Ji Jeffries L, McGrath JM, Soloway S, Pusztai L, Lakhani S. Identification of a novel MYOC variant in a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure Molecular Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer Scientific (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)](https://doi.org/10.1093/annonc/mdz394.003)Schmid P, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, V, Zhao J, Aktan G, O'Shaughnessy J. LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast Of Oncology treatment sequencing of triple-negative and NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/31196152)Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer AC, Hirsch Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer Breast Cancer level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial\"](http://www.ncbi.nlm.nih.gov/pubmed/30624555)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann DL, Baselga J, Pusztai L. Corrections to \"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.e14180)O'Meara T, Yaghoobi Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). [DOI: MHC II protein expression levels epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.](https://doi.org/10.1200/jco.2019.37.15_suppl.2631)Wulfkuhle J, Yau C, Wolf D, Gallagher R, Brown Swigart L, Hirst G, Campbell M, Nanda R, Liu M, Pusztai L, Esserman L, Berry D, van 't Veer L, Petricoin E. Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 (NAT) and clinical outcome.](https://doi.org/10.1200/jco.2019.37.15_suppl.574)Luen S, Griguolo G, Nuciforo P, Campbell C, Fasani R, Cortes J, Untch M, Lin S, Savas P, Fox S, Di Cosimo S, Llombart Cussac A, Azambuja C, Salgado A, changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical Of Clinical Oncology 2019, 37: 574-574. [DOI: 10.1200/jco.2019.37.15_suppl.574](https://doi.org/10.1200/jco.2019.37.15_suppl.574). [Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade](http://www.ncbi.nlm.nih.gov/pubmed/32914041)Casadevall D, Li F, Hatzis C, Pusztai L. Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Cancer 2019, 297-324. [DOI: 10.1201/9780429066504-14](https://doi.org/10.1201/9780429066504-14). - Karn T, Denkert of metagene KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction Breast Cancer Research And Treatment 2019, 176: 349-356. [PMID: function assessment among breast cancer patients undergoing anthracycline-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/31020471)Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy Breast Cancer Research And Treatment 2019, 176: 261-270. 31020471](https://pubmed.ncbi.nlm.nih.gov/31020471), [DOI: 10.1007/s10549-019-05178-z](https://doi.org/10.1007/s10549-019-05178-z). [Immune profiling tissues from the SWOG S0800 neoadjuvant trial](http://www.ncbi.nlm.nih.gov/pubmed/30967156)Li X, Warren S, Pelekanou V, Wali A, Liu M, DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial Journal For Cancer: Clinical Versus Marczyk M, Sanft T, Silber A, Pusztai L. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Index into extended endocrine therapy decision-making](https://doi.org/10.2217/bmt-2019-0001)Sanft T, Berkowitz A, Schroeder B, Hatzis C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making Breast Cancer Management 2019, 8: bmt22. FJ, Hubbard-Lucey VM, Tang Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast evaluating the use of adjuvant endocrine therapy\u00b1everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)](https://doi.org/10.1016/s0960-9776(19)30460-6)Chavez-Macgregor Mamounas E, Bandos H, Miao J, Gralow J, Hortobagyi G, investigators S. P359 Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy\u00b1everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): L. Abstract P3-05-01: Age-related methylation signals of breast cancer risk in Research 2019, 79: p3-05-01-p3-05-01. [DOI: 10.1158/1538-7445.sabcs18-p3-05-01](https://doi.org/10.1158/1538-7445.sabcs18-p3-05-01). [Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p2-06-06)Marczyk M, Gunasekharan V, Wali V, Shi W, Patwardhan G, Qing T, Pusztai L, Hatzis C. Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer Cancer Research 2019, 79: p2-06-06-p2-06-06. [DOI: 10.1158/1538-7445.sabcs18-p2-06-06](https://doi.org/10.1158/1538-7445.sabcs18-p2-06-06). [Abstract P3-10-01: Single-cell of an immunosuppressive VEGFA metagene](https://doi.org/10.1158/1538-7445.sabcs18-p3-10-01)Karn T, Denkert C, Sinn B, Weber V, Rody A, Meissner T, Hatzis C, El-Balat A, S, C, M, A, von Minckwitz Holtrich U. Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of VEGFA metagene Cancer Research 2019, Patwardhan G, Pusztai P4-03-01: Pathway level complementarity of germline and somatic events in 2019, 79: p4-03-01-p4-03-01. [DOI: 10.1158/1538-7445.sabcs18-p4-03-01](https://doi.org/10.1158/1538-7445.sabcs18-p4-03-01). [Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort](https://doi.org/10.1158/1538-7445.sabcs18-pd5-10)Szekely B, Bareche Y, Van den Eynden G, Salgado C, Pusztai L, Desmedt C. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort Cancer Research 79: pd5-10-pd5-10. [DOI: 10.1158/1538-7445.sabcs18-pd5-10](https://doi.org/10.1158/1538-7445.sabcs18-pd5-10). distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden](https://doi.org/10.1158/1538-7445.sabcs18-p2-07-03)Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, H, J, I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien A, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey J, Ellis E, Elias A, Lang J, Lu J, Han H, Clark A, Korde L, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Wood W, Park J, Liu M, Olopade O, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, van't Veer L, Perlmutter J, Melisko M, Wilson A, Peterson G, Asare A, Buxton M, Paoloni M, Clennell J, Hirst G, Singhrao R, Steeg K, Matthews J, Sanil A, Berry S, Abe H, Wolverton D, Crane E, Ward K, Nelson M, Niell B, Oh K, Brandt K, Bang D, Ojeda-Fournier H, Eghtedari M, Sheth P, Bernreuter W, Umphrey H, Rosen M, Dogan B, Yang W, Joe B, Yee D, Pusztai L, DeMichele A, Asare S, Berry D, Esserman L. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research 2019, 79: p2-07-03-p2-07-03. [DOI: 10.1158/1538-7445.sabcs18-p2-07-03](https://doi.org/10.1158/1538-7445.sabcs18-p2-07-03). [Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL](https://doi.org/10.1158/1538-7445.sabcs18-p2-14-01)Silverstein J, Suleiman L, Yau C, Price E, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain K, Chien A, Forero-Torres A, Wallace A, Pusztai L, Ellis E, Elias A, Lang J, Lu J, Han H, Clark A, Korde L, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Wood W, Park J, Liu M, Olopade O, Leyland-Jones B, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Berry D, Asare S, Esserman L, Boughey J, Mukhtar R. Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL Cancer Research 2019, 79: Piccart J, M, la L, F, Azambuja E, Untch M, Pusztai Pritchard K, Nuciforo P, A, F, Apolone G, de Braud F, Verderio P, Daidone 10.1158/1538-7445.sabcs18-p4-01-03](https://doi.org/10.1158/1538-7445.sabcs18-p4-01-03). [Abstract Impact of long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313](https://doi.org/10.1158/1538-7445.sabcs18-p4-08-06)Sharma P, Barlow W, Hout D, Seitz R, Bailey D, Godwin A, Pathak H, Timms K, Solimeno C, Linden H, Porter P, Tripathy D, Hortobagyi G, Thompson A, Pusztai L, Hayes D. Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG L, G, C. Abstract P5-03-06: Overcoming MEK inhibitor resistance leukemia-1 ( A, B, Hatzis C, Pusztai L. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women Breast Cancer Research And microenvironment predicts survival in and -negative cancers](http://www.ncbi.nlm.nih.gov/pubmed/30558648)Pelekanou 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers Breast Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options](http://www.ncbi.nlm.nih.gov/pubmed/30652574)Gershkovich P, Platt J, Knopf J, Tasoulis MK, Shi W, Pusztai L, Hatzis C. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options JCO Clinical [Association Receptor Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/29902299)Powles RL, Redmond D, Sotiriou C, D, Nuciforo P, Harbeck N, de Azambuja E, Piccart-Gebhart Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Immunological differences between primary and metastatic level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial](http://www.ncbi.nlm.nih.gov/pubmed/29701764)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann DL, Baselga J, Pusztai L. correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients](https://doi.org/10.1093/annonc/mdy272.278)Specht J, Pusztai Mita M, Weise A, Krop I, Grosse-Wilde A, Wang Z, Li M, Hengel S, Garfin P, Means G, Onsum M, Modi S. 286PD Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients Annals Of Oncology [DOI: 10.1093/annonc/mdy272.278](https://doi.org/10.1093/annonc/mdy272.278). with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/29793946)Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)](http://www.ncbi.nlm.nih.gov/pubmed/30137196)Mateo J, Chakravarty D, Dienstmann CKY, Bedard PL, Tortora G, Douillard J, Van Allen EM, Schultz N, Swanton C, Andr\u00e9 F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular VB, AM, Butler Epstein Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Increased epigenetic age in normal breast tissue from luminal breast cancer patients Clinical Epigenetics Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2Targeted Therapy](http://www.ncbi.nlm.nih.gov/pubmed/30139836)Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega Horowitz N, Barcenas CH, V, Tripathy D, Pusztai L, Murthy RK. LongTerm Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study](http://www.ncbi.nlm.nih.gov/pubmed/30062572)Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu A, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study Breast Cancer Research And Treatment 2018, 172: and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial](http://www.ncbi.nlm.nih.gov/pubmed/29588392)Pelekanou V, Barlow Z, Wasserman Szekely Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.](https://doi.org/10.1200/jco.2018.36.15_suppl.578)Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh Z, Hayes D, Hortobagyi G, Barlow W, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.586)Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick T, Harigopal M. dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast Of Clinical Oncology 2018, 36: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps602)Schmid P, Cortes J, Bergh J, Pusztai L, Denkert C, Verma S, McArthur H, Kummel S, Ding Y, Karantza V, Dang T, Dent R. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). Journal Of Clinical Veitch Z, Bedard PL. Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer American Society Of Clinical Oncology Educational Book 2018, vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies](http://www.ncbi.nlm.nih.gov/pubmed/29372234)Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies JAMA non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes](http://www.ncbi.nlm.nih.gov/pubmed/29559730)Gyrffy B, Pongor L, Bottai G, Li X, Budczies J, C, Pusztai L, Santarpia L. integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes British Journal Of T, Cheng CJ, Pusztai L, Irwin ML. Exercise and weight loss interventions and miRNA expression in women with breast cancer Breast Cancer Research And Treatment 2018, C, L. Abstract PD6-02: Immunological differences between primary and metastatic 2018, 78: pd6-02-pd6-02. [DOI: 10.1158/1538-7445.sabcs17-pd6-02](https://doi.org/10.1158/1538-7445.sabcs17-pd6-02). [Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-04-02)Hofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, V, Storniolo A, C, G, Wahlde M, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer Cancer Research 2018, 78: p2-04-02-p2-04-02. [DOI: 10.1158/1538-7445.sabcs17-p2-04-02](https://doi.org/10.1158/1538-7445.sabcs17-p2-04-02). [Abstract P2-09-01: T-cell receptor beta chain region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-01)Powles R, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, C, Pusztai L. Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial Cancer [DOI: 10.1158/1538-7445.sabcs17-p2-09-01](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-01). [Abstract to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial](https://doi.org/10.1158/1538-7445.sabcs17-gs1-04)Sotiriou Roth\u00e9 F, Maetens M, Fumagalli Brown I, Pusztai L, Harbeck N, Ignatiadis M, S, la L, Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Venet D. Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy](https://doi.org/10.1158/1538-7445.sabcs17-ot1-02-04)Pusztai L, Barlow W, Ganz P, Henry N, White J, Jagsi R, Mammen J, Lew D, Mejia J, Karantza V, Aktan G, Sharon E, Korde OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy Cancer [Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot1-03-06)Shagisultanova E, Diamond J, Stopeck P, Borges V. Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer Cancer Research [Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial](https://doi.org/10.1158/1538-7445.sabcs17-p2-05-04)Venet D, Roth\u00e9 F, Dupont F, Maetens R, Bradbury I, Pusztai N, M, la L, M, Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Sotiriou C. Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial Cancer Research 2018, 78: p2-05-04-p2-05-04. [DOI: 10.1158/1538-7445.sabcs17-p2-05-04](https://doi.org/10.1158/1538-7445.sabcs17-p2-05-04). [Abstract P2-09-03: Identifying clinically relevant subgroups women with HER2-positive breast cancer: An analysis of Neo-ALTTO using E, Fumagalli D, Pusztai Harbeck Izquierdo L, Huober J, Baselga J, Piccart M, Verderio P, Tagliabue E. Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the [DOI: P2-09-06: Quantitative spatial profiling of associated macrophages and the PD-1/PD-L1 interaction in breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-06)Pelekanou V, Neumeister V, Pusztai L, Rimm D. Abstract P2-09-06: Quantitative spatial profiling of tumor associated macrophages and the PD-1/PD-L1 interaction in breast cancer Cancer Research 2018, 78: 10.1158/1538-7445.sabcs17-p2-09-06](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-06). [Abstract P2-09-07: compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-07)Rimm D, Carvajal-Hausdorf J, J, Piccart M, Holmes E, Pusztai L. Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast Cancer Research 2018, 78: p2-09-07-p2-09-07. [DOI: with Pusztai K, Weise A, Krop I, Burris H, Kalinsky K, Tsai M, Liu M, Hurvitz S, Wilks S, Ademuyiwa F, Diab S, Han H, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated neoadjuvant, phase II administered concomitantly with weekly paclitaxel followed A, Lannin Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft C, DiGiovanna neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast 333-340. [PMID: 29396664](https://pubmed.ncbi.nlm.nih.gov/29396664), [DOI: 10.1007/s10549-017-4653-2](https://doi.org/10.1007/s10549-017-4653-2). therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR](http://www.ncbi.nlm.nih.gov/pubmed/29344722)Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR Journal Of Cancer Research And lapatinib-induced cardiotoxicity in patients C, H, D, Cosimo Baselga MR, DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients a El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L. Association Between Genomic Metrics and Immune Infiltration in C. germline variants Patient-Reported Outcomes in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30657377)Mougalian SS, Epstein LN, Jhaveri ALM, Adelson K, L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer Testing on Adjuvant Therapy Decision Making](http://www.ncbi.nlm.nih.gov/pubmed/29048991)Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin O, L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference](http://www.ncbi.nlm.nih.gov/pubmed/29667990)Woodward WA, Cristofanilli M, Merajver SD, Van Laere Polyak GR, X, van Golen KL, El-Zein R, Rahal Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference Journal Of AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?\"](http://www.ncbi.nlm.nih.gov/pubmed/28987415)Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter Chung G, Pusztai L, Lannin DR. Discussion of: \"Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?\" The American Journal lymphocytes and PD-L1 expression in breast cancer and its clinical significance](http://www.ncbi.nlm.nih.gov/pubmed/28946899)Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf L, chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance Breast Cancer Research status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?](http://www.ncbi.nlm.nih.gov/pubmed/28939252)Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR. Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? The American Journal pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)](https://doi.org/10.1093/annonc/mdx364.015)Schmid P, Castan J, Bergh J, Pusztai Denkert C, Verma S, McArthur H, Zhao J, Aktan G, Dang T, Dent R. 233TiP KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/28945887)Chung Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park LT, Leyland-Jones B, Mughal TI, L, VA, Ross JS, Ali SM. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic PD-L1 expression in breast cancer and its clinical significance](http://www.ncbi.nlm.nih.gov/pubmed/28784153)Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf H, Brown J, Lannin D, Pusztai L, Rimm DL. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance Breast Cancer Research Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28766195)Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer Annals mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) Study](https://doi.org/10.1158/1538-7445.am2017-5321)Ferrucci L, Cartmel B, Harrigan M, Sanft T, Playdon M, Jia W, Yu H, Johnson C, Pusztai L, Chagpar A, Irwin M. Abstract 5321: Metabolomics and body mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) Study Cancer Research 2017, 77: 5321-5321. L. Abstract 1141: Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer Cancer Research 2017, 77: 1141-1141. [DOI: 10.1158/1538-7445.am2017-1141](https://doi.org/10.1158/1538-7445.am2017-1141). [Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells](https://doi.org/10.1158/1538-7445.am2017-2073)Patwardhan G, Wali V, Pusztai L, Hatzis C. Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells Cancer Research 2017, 77: 2073-2073. [DOI: 10.1158/1538-7445.am2017-2073](https://doi.org/10.1158/1538-7445.am2017-2073). B, Karn T, Hatzis C, Pusztai L. Immune Gene Expression Is Associated with Genomic Aberrations in Breast using somatic mutations and copy number aberrations](http://www.ncbi.nlm.nih.gov/pubmed/28585536)Brown D, Dank M, Szentm\u00e1rtoni G, Udvarhelyi C. Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.](https://doi.org/10.1200/jco.2017.35.15_suppl.572)Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage S, Silber A, Lannin Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach D, E, DiGiovanna (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III genomic characteristics of TNBC in African American women compared to other races.](https://doi.org/10.1200/jco.2017.35.15_suppl.e13028)Szekely B, Safonov A, Karn T, Bhagwagar S, Killelea B, Silber A, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. Journal Of Clinical Oncology 2017, 35: e13028-e13028. [DOI: 10.1200/jco.2017.35.15_suppl.e13028](https://doi.org/10.1200/jco.2017.35.15_suppl.e13028). [Long-term survival of de stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.1021)Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas C, Chavez-Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy R. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. Journal A, G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. [DOI: 10.1200/jco.2017.35.15_suppl.1522](https://doi.org/10.1200/jco.2017.35.15_suppl.1522). [Genomic profiling (ctDNA) from patients (pts) with metastatic breast cancer (mBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1016)Pusztai L, Chung J, Young L, Schrock A, Hartmaier R, Frampton G, Gay L, Stephens P, Miller V, Ali S, Ross J, Vahdat L, O'Shaughnessy J. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer gene signatures characterized by varying levels of chromosomal instability.](https://doi.org/10.1200/jco.2017.35.15_suppl.1096)Gyorffy B, Bottai G, Nagy A, Pusztai L, Santarpia L. Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability. Of lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.](https://doi.org/10.1200/jco.2017.35.15_suppl.519)Pelekanou V, Barlow W, von Wahlde M, Wasserman B, Lo Y, Hayes D, Hortobagyi G, Gralow J, Tripathy D, Livingston R, Porter P, Nahleh Z, Rimm D, Pusztai L. Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer Journal 2017, 35: e12129-e12129. El-Balat A, Rody A, Holtrich U, Becker S, G, L. 40P Immune using somatic mutations and copy number aberrations](http://www.ncbi.nlm.nih.gov/pubmed/28429735)Brown D, Dank M, Szentm\u00e1rtoni G, Udvarhelyi C, Desmedt C. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and C, Gu P, Wu J, Chen X, Niu S, Sun H, Wu L, Li N, Peng J, Shi S, Fan C, Huang M, Wong CC, Gong Q, Kumar-Sinha C, Zhang R, Pusztai L, Rai R, Chang S, Lei M. Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in NT. pathways in breast cancers stratified by estrogen receptor of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).](https://doi.org/10.1200/jco.2017.35.8_suppl.25)Sanft T, Berkowitz A, Schroeder B, Hatzis C, B, Brufsky A, Pusztai L, Gustavsen G, Van Londen G. Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET). Early-Stage Breast Cancer Treated With Aromatase Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/28267392)Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Hofstatter E, Pusztai L. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer Cancer Research 2017, of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy](https://doi.org/10.1158/1538-7445.sabcs16-p2-09-15)Sanft T, Berkowitz A, Schroeder B, Hatzis B, A, Pusztai L, vanLonden G. Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p6-09-49)Gy\u00f6rffy B, Ocana A, Herman Pandiella A, Pusztai L. Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer Cancer Research 2017, El-Balat A, Holtrich U, Becker S, Bianchini G, Pusztai L. Abstract S1-07: Immune sculpting of the triple negative breast cancer breast cancer eligible for targeted checkpoint inhibition](https://doi.org/10.1158/1538-7445.sabcs16-p2-04-16)Bottai G, Loi S, Sotiriou C, Roncalli M, T-cells identify a subset of triple-negative breast cancer of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)](https://doi.org/10.1158/1538-7445.sabcs16-p4-21-09)de Azambuja E, Bradbury I, Ewer M, Campbell R, Sutter T. Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-10-03)Nanda R, Specht J, Dees C, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Ray A, Karantza V, Buisseret L. Abstract P6-10-03: KEYNOTE-012: Long-lasting responses phase study of patients (pts) with FGF aberrant metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-11-03)Mayer I, Arteaga Jhaveri K, Morganstern D, Vogel C, Connolly R, Gradishar W, Patel R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF SGN-LIV1A in patients with heavily pretreated metastatic cancer](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-04)Forero-Torres A, Modi S, Specht J, Miller Weise A, Burris H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily cancer whole-genome sequences](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-01)Li X, Krishnamurthy S, Kumar S, Reddy S, Woodward W, Reuben J, Hatzis C, Ueno N, Gerstein M, Pusztai L. Abstract P1-05-01: Landscape of somatic mutations in inflammatory prognosis in triple-negative breast cancer subtypes](https://doi.org/10.1158/1538-7445.sabcs16-p1-07-06)Bottai G, Balazs G, Nagy A, Pusztai L, Szallasi Z, Reis-Filho J, Santarpia L. Abstract P1-07-06: Immune signatures define and affect prognosis in triple-negative breast Analysis of the Venet R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pe\u00f1a L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary of KEYNOTE-012 study](https://doi.org/10.1016/s0959-8049(17)30206-x)Nanda R, Specht J, Dees E, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Ray A, Karantza V, Pembrolizumab for metastatic triple-negative (mTNBC): long-lasting responses in the phase [Long-Term Prognostic Risk After Neoadjuvant With Residual Cancer Burden and Breast Cancer Subtype](http://www.ncbi.nlm.nih.gov/pubmed/28135148)Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, S, Pusztai C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype Journal ER-Negative/HER2-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28106823)Bottai Diao GA, Santarpia L. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer International Journal Of in Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27872098)Wali VB, Langdon Held B, Pusztai L, Stern DF, Hatzis C. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial](http://www.ncbi.nlm.nih.gov/pubmed/28177460)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients](http://www.ncbi.nlm.nih.gov/pubmed/27192352)Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients Annals Of Wali VB, Pongor L, Li C, Lau R, Gyrffy WF, Pusztai L, Negative Breast Cancer: precision medicine ready for use in breast cancer? Clinical Advances In Hematology And Pusztai L. Clinical Utility of Biomarker Tests in Decisions on Extended Endocrine Therapy Journal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab](http://www.ncbi.nlm.nih.gov/pubmed/27298406)Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab Journal D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27658825)Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer BMC Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss Trial](https://doi.org/10.1016/j.jand.2016.06.326)Harrigan M, Playdon M, Cartmel B, Loftfield E, Sanft T, Chagpar A, Zhou Y, Anderson C, Pusztai L, Irwin M. Predictors of Weight Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss Trial Journal Of The Academy Of Nutrition And Dietetics 2016, 116: a90. [DOI: M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer Breast cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27393622)Nahleh ZA, WE, cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer Breast Cancer Research And Treatment 2016, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer New England Journal 375: 23-34. [PMID: Yau C, van 't Veer MB, AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, GL, LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer New England Journal Sz\u00e9kely B, Pusztai L. Deciphering and Targeting Oncogenic Mutations and Li F, Loftfield E, Playdon M, Zhou Y, Gross C, Ligibel J, SCHMITZ K, Hershman D, Pusztai L, Irwin M. Impact of weight loss and exercise on VEGF levels in breast cancer survivors. Journal Of Clinical Oncology 2016, 34: 10103-10103. [DOI: 10.1200/jco.2016.34.15_suppl.10103](https://doi.org/10.1200/jco.2016.34.15_suppl.10103). [Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.](https://doi.org/10.1200/jco.2016.34.15_suppl.e18136)Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. [DOI: 10.1200/jco.2016.34.15_suppl.e18136](https://doi.org/10.1200/jco.2016.34.15_suppl.e18136). - Safonov A, Jiang Bianchini Platt J, Shi W, Rimm D, Pusztai L, Hatzis C. Association between DNA level aberrations and immune cell infiltration in breast cancer. Journal Of Clinical Oncology 2016, 34: 3078-3078. [DOI: 10.1200/jco.2016.34.15_suppl.3078](https://doi.org/10.1200/jco.2016.34.15_suppl.3078). - Fujii Dong Litton J, Moulder S, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Lim B, Shen Y, Ueno N. New threshold of ER positivity in early stage HER2- breast cancer. Journal Of Clinical 2016, 34: 1067-1067. [DOI: 10.1200/jco.2016.34.15_suppl.1067](https://doi.org/10.1200/jco.2016.34.15_suppl.1067). [Effect of DNA hypermethylation on immune escape through downregulation of antigen presentation genes in breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.11547)Gyorffy B, Nagy A, Pongor L, Locatelli A, Vigano' L, Safonov A, Pusztai L, Gianni L, Bianchini G. Effect of DNA hypermethylation on immune escape through downregulation of antigen presentation genes in breast cancer. Journal Of Clinical Oncology 2016, 34: 11547-11547. [DOI: taselisib (GDC-0032) combined with fulvestrant HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).](https://doi.org/10.1200/jco.2016.34.15_suppl.520)Dickler M, Saura C, Richards D, Krop I, Cervantes A, Bedard P, Patel M, Pusztai L, Oliveira M, Ware J, Jin H, Wilson T, Stout T, Wei M, Hsu J, Baselga J. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer 520-520. [DOI: 10.1200/jco.2016.34.15_suppl.520](https://doi.org/10.1200/jco.2016.34.15_suppl.520). [T-DM1 activity in that received prior therapy with trastuzumab and pertuzumab.](https://doi.org/10.1200/jco.2016.34.15_suppl.585)Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra A, Tripathy D, Valero V, Pusztai L, Murthy R. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. Journal Of Clinical Oncology density breast cancer on aromatase inhibitors.](https://doi.org/10.1200/jco.2016.34.15_suppl.6599)Stratton J, Hu X, Soulos P, Davidoff A, Pusztai L, Gross C, Mougalian S. Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors. Journal Clinical Oncology - Nanda Gupta S, Geva R, Pusztai Pathiraja K, Aktan G, Cheng JD, V, L. With Advanced Triple-Negative Breast Cancer: Phase Ib Bianchini G. New Strategies in Breast L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling Cancer 2016, 122: 1588-1597. [PMID: 26970385](https://pubmed.ncbi.nlm.nih.gov/26970385), [DOI: sequencing data: a comparison of web tools](http://www.ncbi.nlm.nih.gov/pubmed/26980737)Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein Chung A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation sequencing data: a comparison of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) study](https://doi.org/10.1158/1538-7445.sabcs15-p3-08-01)Sanft T, Lu L, Harrigan M, Cartmel B, Zhou Y, Chagpar A, Pusztai L, Irwin M. Abstract P3-08-01: Randomized controlled trial of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) study Cancer Research 2016, 76: p3-08-01-p3-08-01. [DOI: 10.1158/1538-7445.sabcs15-p3-08-01](https://doi.org/10.1158/1538-7445.sabcs15-p3-08-01). [Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial](https://doi.org/10.1158/1538-7445.sabcs15-p3-13-01)Chagpar A, Longley P, Horowitz N, Killelea B, Tsangaris T, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin D, Pusztai L, Loftus M, Davidoff A, Gross C. Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial Cancer Research 2016, 76: p3-13-01-p3-13-01. [DOI: 10.1158/1538-7445.sabcs15-p3-13-01](https://doi.org/10.1158/1538-7445.sabcs15-p3-13-01). [Abstract P6-13-06: Novel combination therapies for negative breast cancer identified by high-throughput screening](https://doi.org/10.1158/1538-7445.sabcs15-p6-13-06)Wali V, Langdon C, Held M, Platt J, Safonov A, Aktas B, Stern D, Pusztai L, Hatzis C. Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening Cancer Research 2016, 76: p6-13-06-p6-13-06. [DOI: 10.1158/1538-7445.sabcs15-p6-13-06](https://doi.org/10.1158/1538-7445.sabcs15-p6-13-06). [Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-03)Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot have different immune milieu in primary and metastatic tumors](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-04)Bianchini G, Riba M, Zambelli S, Safonov N, P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors Cancer Research 2016, 76: p4-04-04-p4-04-04. [DOI: 10.1158/1538-7445.sabcs15-p4-04-04](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-04). [Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p4-07-01)Jiang T, Safonov A, Bianchini G, Shi W, Wali V, Pusztai L, Hatzis C. Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancer Cancer Research 2016, 76: p4-07-01-p4-07-01. [DOI: 10.1158/1538-7445.sabcs15-p4-07-01](https://doi.org/10.1158/1538-7445.sabcs15-p4-07-01). [Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker](https://doi.org/10.1158/1538-7445.sabcs15-p5-07-09)Mani N, Schalper K, Hatzis C, Chagpar A, Pusztai D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker Cancer Research 2016, 76: p5-07-09-p5-07-09. [DOI: 10.1158/1538-7445.sabcs15-p5-07-09](https://doi.org/10.1158/1538-7445.sabcs15-p5-07-09). [Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy](https://doi.org/10.1158/1538-7445.sabcs15-p6-11-03)Safonov A, Hatzis C, Stratton J, Gross C, Russell R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy Cancer Research the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies](https://doi.org/10.1158/1538-7445.sabcs15-s5-01)Pusztai L, Shi W, Jiang T, Nuciforo P, Holmes E, Harbeck N, Sotiriou C, Rimm D, Hatzis C, de la L, J. Abstract exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies Cancer Research 2016, 76: s5-01-s5-01. [DOI: 10.1158/1538-7445.sabcs15-s5-01](https://doi.org/10.1158/1538-7445.sabcs15-s5-01). [Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p1-09-01)Killelea B, Chagpar A, Horowitz N, Pusztai L, Wang S, Mougalian S, Lannin D. Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer Cancer Research 2016, 76: p1-09-01-p1-09-01. [DOI: 10.1158/1538-7445.sabcs15-p1-09-01](https://doi.org/10.1158/1538-7445.sabcs15-p1-09-01). [Abstract OT1-03-11: Phase III evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)](https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-11)Chavez-MacGregor P, Mamounas S, H, Gralow J, D, Hortobagyi G. Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): V, intracellular extracellular domain spatial co-localization [DOI: 10.1158/1538-7445.sabcs15-p3-07-06](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-06). [Abstract P3-14-05: Interim analysis 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast III H, Mita M, Specht Weise A, Liu M, Modi S, Pusztai L, Kostic A, Yang J, Li M, Hengel S, Miller K. Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic p3-14-05-p3-14-05. retrovirus elements in breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-20)Safonov A, Bianchini Jiang T, Pusztai L, Hatzis C. Abstract P4-04-20: Subtype specific differential expression and immunogenicity of endogenous retrovirus elements in breast 10.1158/1538-7445.sabcs15-p4-04-20](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-20). [Abstract PD6-06: Somatic cancer molecular subtypes](https://doi.org/10.1158/1538-7445.sabcs15-pd6-06)Gyorffy B, Pongor L, Szabo A, Bottai G, L. Abstract PD6-06: Somatic mutation patterns differentially affect survival in breast cancer molecular subtypes Cancer Research 2016, 76: pd6-06-pd6-06. Silences c-SRC to Attenuate Tumor Growth in Triple-Negative cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen](https://doi.org/10.1158/1557-3125.advbc15-a32)Ross J, Wang K, Johnson A, Watson J, Hatzis C, Pusztai L, Chmielecki J, Yelensky R, Lipson J, Vergilio J, Suh J, Miller V, Dicke K, Stephens P, Ali S. Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen Molecular Cancer Research 2016, 14: a32-a32. [DOI: 10.1158/1557-3125.advbc15-a32](https://doi.org/10.1158/1557-3125.advbc15-a32). Safonov Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach Breast Cancer Research Survival in Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26286912)Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer Clinical Cancer 2016, Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer European Journal Of Cancer Prevention and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base](http://www.ncbi.nlm.nih.gov/pubmed/26598753)Killelea BK, Yang VQ, Wang SY, Hayse NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base Journal Of Oncology 2015, 33: the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/26578401)Sanft T, Aktas B, Schroeder B, Bossuyt DiGiovanna M, Abu-Khalaf M, Chung G, Silber S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer Breast Cancer Research Pusztai L. Tumor profiling and the incidentalome: patient decisions and Future 26562094](https://pubmed.ncbi.nlm.nih.gov/26562094), biomarkers for precision medicine](http://www.ncbi.nlm.nih.gov/pubmed/26502353)Zheng Y, Qing T, Song Y, Zhu J, Yu Y, Shi W, Pusztai L, Shi L. Standardization efforts enabling next-generation sequencing and microarray based biomarkers for to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26474971)Pongor L, Kormos M, Hatzis C, Pusztai L, Szab\u00f3 A, Gyrffy B. A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients Rouzier R. Predictive and Prognostic Value of the TauProtein in Cancer. Anticancer of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer](https://doi.org/10.1093/annonc/mdv336.21)Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A21 A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer Annals Of Oncology 2015, 26: vi9. [DOI: 10.1093/annonc/mdv336.21](https://doi.org/10.1093/annonc/mdv336.21). - Agarwal D, Qi Y, Jiang T, Liu X, Shi W, Wali VB, Turk B, Ross JS, Fraser Symmans W, Pusztai L, Hatzis C. Characterization of DNA variants in the human kinome in breast cancer Scientific C, E, FJ, Ueno NT, NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma British Journal NeoSphere G, A, Galeota Magazz\u00f9 B, JL, P, complete response after neoadjuvant HER2-directed therapies in Commentary: Divide and Conquer\u2014Breast Cancer Subtypes and Response to Therapy [PMID: 26275950](https://pubmed.ncbi.nlm.nih.gov/26275950), [DOI: 10.1158/1078-0432.ccr-14-3121](https://doi.org/10.1158/1078-0432.ccr-14-3121). [Abstract 3879: Patient incidental genetic information discovered through high-throughput sequencing](https://doi.org/10.1158/1538-7445.am2015-3879)Yushak M, Bouberhan S, Han G, Epstein L, Mougalian Abu-Khalaf M, Chung G, DiGiovanna M, Sanft T, Pusztai L, Hofstatter E. Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing triple-negative breast cancer](https://doi.org/10.1158/1538-7445.am2015-lb-300)Adams B, Wali V, Cheng C, Inukai S, Rimm D, Pusztai L, Saltzman M, Slack F. Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancer 2015, lb-300-lb-300. [DOI: 10.1158/1538-7445.am2015-lb-300](https://doi.org/10.1158/1538-7445.am2015-lb-300). - Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner S, Shao Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra M, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3 opposes and reverses cancer metabolic Wang B, Hess KR, Symmans WF, Shi W, Pusztai L. Reproducibility of Variant Calls in Replicate Next Generation Rognoni Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer New England Journal Of Medicine (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).](https://doi.org/10.1200/jco.2015.33.15_suppl.1012)Chagpar A, Killelea B, Tsangaris T, Butler M, Stavris K, Yao X, Li F, Bossuyt V, Pusztai L, Horowitz N. Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM). Journal Of Clinical Oncology 33: 1012-1012. [DOI: 10.1200/jco.2015.33.15_suppl.1012](https://doi.org/10.1200/jco.2015.33.15_suppl.1012). [Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.](https://doi.org/10.1200/jco.2015.33.15_suppl.538)Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna Abu-Khalaf M, Chung G, Silber S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. [Mutation-based treatment recommendations A comparison of web tools.](https://doi.org/10.1200/jco.2015.33.15_suppl.e12564)Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter P, Hatzis C, L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. [DOI: 10.1200/jco.2015.33.15_suppl.e12564](https://doi.org/10.1200/jco.2015.33.15_suppl.e12564). [A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).](https://doi.org/10.1200/jco.2015.33.15_suppl.6621)Safonov A, Shi W, Platt J, Aktas B, Kurita T, Pusztai L, Hatzis C. A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER). Clinical Oncology 2015, 33: 6621-6621. [DOI: 10.1200/jco.2015.33.15_suppl.6621](https://doi.org/10.1200/jco.2015.33.15_suppl.6621). [Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.](https://doi.org/10.1200/jco.2015.33.15_suppl.1091)Timms K, Chagpar A, Wali V, Bossuyt V, Reid Gutin A, Neff C, Hofstatter E, Lanchbury J, Pusztai L. Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. Journal Of Clinical Oncology 2015, 33: 1091-1091. [DOI: 10.1200/jco.2015.33.15_suppl.1091](https://doi.org/10.1200/jco.2015.33.15_suppl.1091). [Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.](https://doi.org/10.1200/jco.2015.33.15_suppl.e17779)Hofstatter E, Yushak M, Bouberhan S, Han G, Epstein L, Pusztai L. Discovery and disclosure of incidental genetic information obtained through high throughput sequencing. Journal Of Clinical Oncology 2015, 33: e17779-e17779. [DOI: 10.1200/jco.2015.33.15_suppl.e17779](https://doi.org/10.1200/jco.2015.33.15_suppl.e17779). Mougalian Hall J, Adelson K, Abu-Khalaf M, Pusztai L, Gross C. Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. Journal Of Clinical Oncology 2015, 33: 1009-1009. [DOI: 10.1200/jco.2015.33.15_suppl.1009](https://doi.org/10.1200/jco.2015.33.15_suppl.1009). [Contribution of immune epirubicin response in triple-negative (TN) M, Karn T, Pusztai L, Gianni L. Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast 2015, 33: [DOI: 10.1200/jco.2015.33.15_suppl.1081](https://doi.org/10.1200/jco.2015.33.15_suppl.1081). [A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.](https://doi.org/10.1200/jco.2015.33.15_suppl.578)Thompson A, Hadad S, Jordan L, Roy P, Purdie C, Iwamoto T, Pusztai L, Moulder S. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. Journal Of Clinical Oncology in Schalper HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer Journal Of The National Cancer Institute 107 [PMID: (pts) with metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdv115.02)Buisseret L, Specht J, Dees E, Berger R, Gupta S, Geva R, L, Gause C, Karantza V, phase pembrolizumab in patients (pts) with metastatic diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd3-2)Jiang T, Shi W, Symmans W, Li C, Platt J, Lau R, Wali V, Lifton R, Pusztai L, Hatzis C. Abstract PD3-2: Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer 2015, pd3-2-pd3-2. [DOI: 10.1158/1538-7445.sabcs14-pd3-2](https://doi.org/10.1158/1538-7445.sabcs14-pd3-2). [Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes](https://doi.org/10.1158/1538-7445.sabcs14-p2-03-05)Bianchini G, Galeota E, Jiang T, Callari T, T, Hatzis C, Pusztai L, Gianni L. Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes 2015, p2-03-05-p2-03-05. [DOI: 10.1158/1538-7445.sabcs14-p2-03-05](https://doi.org/10.1158/1538-7445.sabcs14-p2-03-05). C, Rody A, M\u00fcller V, Schmidt M, Holtrich U, Becker S. Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patients 2015, p2-05-04-p2-05-04. [DOI: 10.1158/1538-7445.sabcs14-p2-05-04](https://doi.org/10.1158/1538-7445.sabcs14-p2-05-04). heterogeneity from breast tumor biopsies](https://doi.org/10.1158/1538-7445.sabcs14-pd3-4)Shi W, Chagpar A, Jiang T, Lannin D, Killelea B, Horowitz N, Lim R, Platt J, Ng C, Wali V, Weigelt B, Reis-Filho J, Hatzis L. of whole exome sequencing for assessing intratumor [DOI: 10.1158/1538-7445.sabcs14-pd3-4](https://doi.org/10.1158/1538-7445.sabcs14-pd3-4). [Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database](https://doi.org/10.1158/1538-7445.sabcs14-p3-07-11)Chagpar A, Mougalian S, Lannin D, Abu-Khalaf M, Killelea T, Pusztai L. Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database 2015, p3-07-11-p3-07-11. [Abstract OT1-1-13: A Phase 2, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway](https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-13)Abu-Khalaf M, Mayer I, Litten J, Raponi M, Allen A, Pusztai L, Arteaga C. Abstract OT1-1-13: A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in FGF pathway 2015, ot1-1-13-ot1-1-13. [DOI: 10.1158/1538-7445.sabcs14-ot1-1-13](https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-13). [Abstract OT2-3-01: 1 novel antibody-drug conjugate in patients with LIV-1-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-ot2-3-01)Forero A, Burris III H, LoRusso P, Specht J, Miller K, Mita M, Liu M, Modi S, Pusztai L, Sussman D, Kostic A. Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast HER2 (ERBB2) expression chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-02)Yang V, Han G, Mougalian S, Killelea B, Horowitz N, Chagpar A, Hayse B, L, Lannin D. Abstract P3-11-02: Predictors of pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011 without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-16)Nahleh Z, Barlow W, Hayes D, Schott A, Gralow J, Perez E, Sikov W, Chennuru S, Mirshahidi H, Vidito S, Lew pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) 2015, p3-11-16-p3-11-16. [DOI: 10.1158/1538-7445.sabcs14-p3-11-16](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-16). [Abstract P4-07-12: Re-introduction of tumor miR-34a therapeutic efficacy in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p4-07-12)Adams B, Pusztai L, Rimm D, Slack F. Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer 2015, p4-07-12-p4-07-12. [DOI: 10.1158/1538-7445.sabcs14-p4-07-12](https://doi.org/10.1158/1538-7445.sabcs14-p4-07-12). [Abstract S1-09: A phase in patients with advanced triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-s1-09)Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez J, Pathiraja K, Karantza V, Iannone R, Gause C, Cheng J, Buisseret L. Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative cancer 10.1158/1538-7445.sabcs14-s1-09](https://doi.org/10.1158/1538-7445.sabcs14-s1-09). CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States Cancer 2015, 121: 2544-2552. Response to Neoadjuvant Chemotherapy in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25527356)Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer Care Plans: A Feasibility Study](http://www.ncbi.nlm.nih.gov/pubmed/25784577)Bulloch KJ, M, Chung GG, Sanft TB. Systematic Approach to Providing Breast Cancer Survivors With Survivorship Care Plans: A Feasibility for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database](http://www.ncbi.nlm.nih.gov/pubmed/25868410)Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database Journal Of The American College Of Surgeons 2015, 220: 1063-1069. 25859546](https://pubmed.ncbi.nlm.nih.gov/25859546), [PMCID: PMC4381696](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381696), [DOI: 10.18632/oncoscience.129](https://doi.org/10.18632/oncoscience.129). [Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive S, Pusztai L, Hatzis C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers Breast Cancer Research And N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Clinical EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph Jhaveri A, Pusztai L. New targets in breast cancer Memo - Magazine Of European Medical Oncology 2015, 8: 86-91. L. Multigene prognostic tests in breast cancer: past, present, future Breast Bi-Objective Function: Method and Application to Prediction in Oncogenomics](http://www.ncbi.nlm.nih.gov/pubmed/25983540)Gardeux V, Chelouah R, Wanderley MF, Siarry F, Rouzier R, Pusztai L, Natowicz R. Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.](http://www.ncbi.nlm.nih.gov/pubmed/26452382)Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Drug Targets T, Hatzis C, Pusztai L. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets Breast Cancer Research And Treatment 2014, 148: 477-488. EE, Rem\u00e9dios C, Fend L, Hannani D, F, Kroemer G, Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Nature Medicine 2014, 20: 1301-1309. Schmidt M, Becker S, Holtrich U, Pusztai L. Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer Data In Brief 2014, 2: 354-356. Valero V, Ueno NT, Esteva FJ, Avritscher R, Y, WF. Gene Signature-Guided Dasatinib [DOI: 10.1158/1078-0432.ccr-14-0800](https://doi.org/10.1158/1078-0432.ccr-14-0800). [Dynamic classification using casespecific cohorts outperforms static gene expression signatures in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/25274406)Gyrffy B, Karn T, Sztupinszki Z, Weltz B, M\u00fcller V, Pusztai L. Dynamic classification using casespecific training cohorts outperforms static gene expression signatures in breast cancer International Journal Of Cancer 2014, 136: 2091-2098. [PMID: 25274406](https://pubmed.ncbi.nlm.nih.gov/25274406), Wali VB, Kluger Y, Pusztai transcriptional activates Akt/mTOR signaling accelerating breast carcinogenesis and tumor growth](https://doi.org/10.1158/1538-7445.am2014-3927)Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou P, Shin J, Choi H, Chen J, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva F, Luo Y, McKeehan W, Ensor J, Hortobagyi G, Pusztai L, Symmans W, Lee M, Yeung S. Abstract 3927: Obesity induces changes in adipokines profile and activates Akt/mTOR signaling accelerating breast frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.am2014-920)Huelsewig C, Bernemann C, Ruckert C, Kiesel L, Goette M, G, C. Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC) 2014, 920-920. [DOI: 10.1158/1538-7445.am2014-920](https://doi.org/10.1158/1538-7445.am2014-920). - Desmedt Szasz M, Adnet P, Roth\u00e9 D, Kulka J, Sotiriou C. Abstract 986: Unraveling breast cancer progression through geographical and temporal sequencing 2014, 986-986. [DOI: 10.1158/1538-7445.am2014-986](https://doi.org/10.1158/1538-7445.am2014-986). [Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential](http://www.ncbi.nlm.nih.gov/pubmed/25209360)Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, Pusztai L, Huang P. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential Breast Cancer 2014, L. Unvalidated antibodies and misleading results Breast Cancer Research Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24957076)Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Symmans W, Lee MH, Yeung SC. Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor-Positive Breast Cancer Journal Of The dju158. [PMID: DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Impact of Financial Burden of Cancer on Survivors' Quality of Life advanced breast and tumors.](https://doi.org/10.1200/jco.2014.32.15_suppl.2561)Jhaveri Abu-Khalaf M, DiGiovanna M, Pusztai N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Of Clinical Oncology 2014, 32: 2561-2561. [DOI: 10.1200/jco.2014.32.15_suppl.2561](https://doi.org/10.1200/jco.2014.32.15_suppl.2561). [Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients.](https://doi.org/10.1200/jco.2014.32.15_suppl.1065)Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Muller V, Pusztai L. Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients. Journal Of Clinical Oncology 2014, 32: 1065-1065. [DOI: 10.1200/jco.2014.32.15_suppl.1065](https://doi.org/10.1200/jco.2014.32.15_suppl.1065). [An immune-related signature for of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.530)Bianchini G, Rossi G, Callari M, Iwamoto T, Galeota E, Karn T, Kelly C, M, Santarpia L, Pusztai L, Gianni L. An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer. Journal Of Clinical 10.1200/jco.2014.32.15_suppl.530](https://doi.org/10.1200/jco.2014.32.15_suppl.530). - Nanda Berger R, Elfiky A, Pusztai L, Buisseret L, Geva R, Pai S, Pathiraja K, Iannone R, Gause C, Brown H, Houp J, Cheng J, Chow L. A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. Journal Of Clinical Oncology 2014, 32: tps3119-tps3119. [DOI: 10.1200/jco.2014.32.15_suppl.tps3119](https://doi.org/10.1200/jco.2014.32.15_suppl.tps3119). [In Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas](http://www.ncbi.nlm.nih.gov/pubmed/24647569)Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas Clinical Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice](http://www.ncbi.nlm.nih.gov/pubmed/24710307)Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted NextGeneration Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications Next generation sequencing: From bench to bedside AACR Education Book 2014, [DOI: D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer ](http://www.ncbi.nlm.nih.gov/pubmed/24669015)Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24619174)Shi W, Balazs B, Gy\u00f6rffy B, Jiang T, Symmans WF, Hatzis C, Pusztai L. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers Breast Cancer Research And Treatment 2014, 144: 561-568. [PMID: 24619174](https://pubmed.ncbi.nlm.nih.gov/24619174), [DOI: 10.1007/s10549-014-2904-z](https://doi.org/10.1007/s10549-014-2904-z). [Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue](http://www.ncbi.nlm.nih.gov/pubmed/24602449)Aktas B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, Jiang T, Ononye SN, Wali VB, Pusztai L, Symmans WF, Hatzis C. Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes](http://www.ncbi.nlm.nih.gov/pubmed/24296856)Chavez-MacGregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes Cancer Epidemiology of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53mutated breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24462521)Gyrffy Bottai L, T, C, G, Th\u00e8 H, Andr\u00e9 F, Sotiriou C, Hortobagyi Pusztai L, Santarpia L. TP53 mutationcorrelated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in receptor-positive and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers Breast Cancer chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype](https://doi.org/10.1158/0008-5472.sabcs13-p4-06-05)Jiang T, Shi W, Ononye S, Han G, Wali V, Pusztai L, Hatzis C. Abstract P4-06-05: Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype Cancer Research 2013, 73: p4-06-05-p4-06-05. [DOI: 10.1158/0008-5472.sabcs13-p4-06-05](https://doi.org/10.1158/0008-5472.sabcs13-p4-06-05). [Abstract P6-06-09: Baseline assessment of left function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-09)Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline Research 2013, 73: p6-06-09-p6-06-09. [DOI: 10.1158/0008-5472.sabcs13-p6-06-09](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-09). [Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-37)Hatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer Cancer Research 2013, 73: p6-06-37-p6-06-37. [DOI: 10.1158/0008-5472.sabcs13-p6-06-37](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-37). [Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-03)Abu-Khalaf M, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James Y, Veronica C. Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience Cancer Research 2013, 73: p6-11-03-p6-11-03. [DOI: 10.1158/0008-5472.sabcs13-p6-11-03](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-03). [Abstract S6-02: Long-term burden (RCB) classification following neoadjuvant chemotherapy](https://doi.org/10.1158/0008-5472.sabcs13-s6-02)Symmans W, Wei C, Gould R, Zhang Y, Hunt K, Buchholz T, Valero V, Hortobagyi G, Pusztai L, Hatzis C. Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy Cancer Research 2013, G, D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States Cancer Research 2013, 73: p3-14-02-p3-14-02. [DOI: use in the United States](https://doi.org/10.1158/0008-5472.sabcs13-p5-13-05)Hofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, M, AbuKhalaf M, Mougalian S, Chagpar P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United 73: p5-13-05-p5-13-05. [DOI: 10.1158/0008-5472.sabcs13-p5-13-05](https://doi.org/10.1158/0008-5472.sabcs13-p5-13-05). [Abstract P1-08-09: EGFR response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-09)Rimm D, Holmes E, Schalper K, Bradbury I, Zarrella Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the [DOI: 10.1158/0008-5472.sabcs13-p1-08-09](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-09). High HER2 expression to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42)Scaltriti C, H, J, Piccart M, Baselga J. Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial Cancer 2013, 73: p1-08-42-p1-08-42. [DOI: 10.1158/0008-5472.sabcs13-p1-08-42](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42). - Wimberly Pusztai L, Rimm D. Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in Research 2013, 73: p2-10-02-p2-10-02. [DOI: 10.1158/0008-5472.sabcs13-p2-10-02](https://doi.org/10.1158/0008-5472.sabcs13-p2-10-02). [Abstract P2-11-04: Expression of immune checkpoint related genes are prognostic in untreated breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-11-04)Bianchini G, Rossi C, Iwamoto T, Karn T, Callari M, Kelly C, Pusztai L, Gianni L. Abstract P2-11-04: Expression of immune checkpoint related genes are prognostic in untreated breast cancer Cancer Research 2013, 73: p2-11-04-p2-11-04. [DOI: 10.1158/0008-5472.sabcs13-p2-11-04](https://doi.org/10.1158/0008-5472.sabcs13-p2-11-04). [Abstract P3-01-04: Obesity of estrogen receptor-positive breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p3-01-04)Fuentes-Mattei E, Phan L, Velazquez-Torres G, Zhang F, Chou P, Shin J, Choi H, Chen J, Chen J, Gully C, Carlock C, Zhao R, Qi Y, Zhang Y, Wu Y, Esteva F, Lou Y, McKeehan W, Ensor J, Hortobagyi G, Pusztai L, Symmans W, Lee M, Yeung S. Abstract P3-01-04: Obesity induces functional transcriptomic changes enhancing the cancer hallmarks of estrogen receptor-positive P3-05-05: Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p3-05-05)Gy\u00f6rffy B, Karn T, Sztupinszki Z, Weltz B, M\u00fcller V, Pusztai L. Abstract P3-05-05: Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer Cancer Research 2013, 73: p3-05-05-p3-05-05. [DOI: 10.1158/0008-5472.sabcs13-p3-05-05](https://doi.org/10.1158/0008-5472.sabcs13-p3-05-05). [Abstract P4-04-06: Systematic analysis of molecular subgroups and age in patients with breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p4-04-06)Liedtke C, Karn T, Gluz O, Becker S, Pusztai L, Holtrich U, Rody A. Abstract P4-04-06: Systematic analysis of molecular subgroups and age in patients with breast cancer Cancer Research 2013, 73: p4-04-06-p4-04-06. [DOI: 10.1158/0008-5472.sabcs13-p4-04-06](https://doi.org/10.1158/0008-5472.sabcs13-p4-04-06). molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by immunohistochemistory](https://doi.org/10.1158/0008-5472.sabcs13-p4-05-09)Iwamoto T, Matsuoka L. P4-05-09: Estrogen receptor (ER) mRNA expression and molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by [DOI: 10.1158/0008-5472.sabcs13-p4-05-09](https://doi.org/10.1158/0008-5472.sabcs13-p4-05-09). PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers](https://doi.org/10.1158/0008-5472.sabcs13-pd4-6)Shi W, Balazs B, Qi Y, Gy\u00f6rffy B, Wang B, Liu C, Shiang C, Valero V, Moulder-Thompson S, Avritscher R, Powis G, Hortobagyi G, Natowicz R, V, Weinstein J, Symmans W, Pusztai L. Abstract PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers Cancer Research 2013, 73: pd4-6-pd4-6. [DOI: 10.1158/0008-5472.sabcs13-pd4-6](https://doi.org/10.1158/0008-5472.sabcs13-pd4-6). [Abstract S3-06: in advanced estrogen receptor positive breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-s3-06)Jeselsohn R, Yelensky R, Buchwalter G, Meric-Bernstam M, Arteaga C, Balko J, Gilmore L, Schnitt S, Come S, Pusztai L, Stephens P, Miller V, Brown M. Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer Cancer Research 2013, 73: s3-06-s3-06. [DOI: 10.1158/0008-5472.sabcs13-s3-06](https://doi.org/10.1158/0008-5472.sabcs13-s3-06). [Comparison of non-inflammatory breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24274653)Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, JM, Laere SJ, subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers Predict Taxane Chemosensitivity in Breast Gohda Assay for by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient Journal Of clinical cancer genomic profiling test based on massively parallel DNA sequencing](http://www.ncbi.nlm.nih.gov/pubmed/24142049)Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase](http://www.ncbi.nlm.nih.gov/pubmed/24014597)Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase F. Reproducibility of research and preclinical validation: problems and solutions Nature [PMID: 24080600](https://pubmed.ncbi.nlm.nih.gov/24080600), [DOI: resistance to anthracyclines in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26484051)Haibe-Kains B, Desmedt C, Di Leo A, Azambuja E, Larsimont Selleslags Delaloge V, Piccart-Gebhart M, Sotiriou C. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients Data In Brief 21-Gene Recurrence Score (RS) in Early-Stage, Hormone Receptor-Positive, HER2-Normal, Lymph Node-Negative Breast Cancers](https://doi.org/10.1016/j.ijrobp.2013.06.260)Thaker N, Pusztai L, Buchholz T, Woodward W. Complementing Ipsilateral Breast Tumor Recurrence (IBTR!) Estimates With the 21-Gene Recurrence Score (RS) in Early-Stage, Hormone Receptor-Positive, HER2-Normal, Lymph Node-Negative Breast Cancers International Journal Radiation Biology Physics 2013, 87: s100-s101. [DOI: 10.1016/j.ijrobp.2013.06.260](https://doi.org/10.1016/j.ijrobp.2013.06.260). - Hayashi N, Bottai GN, L, Bianchini G. DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24060333)Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, M\u00fcller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte Zambetti M, Sotiriou Haibe-Kains B, Symmans WF, Gianni L. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers Breast in combination with capecitabine in a biweekly schedule in advanced breast cancer.](https://doi.org/10.1200/jco.2013.31.26_suppl.154)James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. [DOI: 10.1200/jco.2013.31.26_suppl.154](https://doi.org/10.1200/jco.2013.31.26_suppl.154). Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA Journal Of of genomics on adjuvant treatments for pre-invasive and invasive breast cancer Breast 2013, 22: s83-s87. [PMID: 24074799](https://pubmed.ncbi.nlm.nih.gov/24074799), [DOI: 10.1016/j.breast.2013.07.015](https://doi.org/10.1016/j.breast.2013.07.015). [Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression Data](http://www.ncbi.nlm.nih.gov/pubmed/23874497)Trentini F, Ji Y, Iwamoto T, Qi Y, Pusztai L, M\u00fcller P. Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression in Early Stage Breast Cancer and Evaluation of IIITubulin Expression as a Predictive Marker](http://www.ncbi.nlm.nih.gov/pubmed/23853246)Saura C, Tseng L, Chan S, Chacko RT, Campone A, Horak L. Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of IIITubulin Expression as a Predictive Marker KS, P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials Clinical Cancer in combination with capecitabine in a biweekly schedule in advanced breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.2587)James E, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Sowers N, Clark M, Lilian R, Chmael S, Cappiello M, Abraham G, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 2587-2587. E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. [DOI: 10.1200/jco.2013.31.15_suppl.1565](https://doi.org/10.1200/jco.2013.31.15_suppl.1565). [Correlation of heterogeneity with chemotherapy sensitivity in breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.1013)Natowicz R, Jiang T, Shi W, Qi Y, Delpech Y, Symmans W, Pusztai L. Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer. Journal Of Clinical Oncology 2013, 31: 1013-1013. [DOI: 10.1200/jco.2013.31.15_suppl.1013](https://doi.org/10.1200/jco.2013.31.15_suppl.1013). Y, Kulka J, Pusztai L. Genomic alterations in matching primary tumors and metastasis in breast cancer. Journal Of Clinical Oncology 2013, 31: 1549-1549. [DOI: 10.1200/jco.2013.31.15_suppl.1549](https://doi.org/10.1200/jco.2013.31.15_suppl.1549). [Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.](https://doi.org/10.1200/jco.2013.31.15_suppl.532)Pusztai L, Mattair D, Ueno N, Valero V, Moulder S, Murray J, Alvarez R, Chavez-Mac Gregor M, Santiago L, Avritscher R, Sahin A, Hortobagyi G, Symmans W, Meric-Bernstam F, Burton E, Gonzalez-Angulo A. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. Journal Of Clinical Oncology 2013, 31: 532-532. [DOI: 10.1200/jco.2013.31.15_suppl.532](https://doi.org/10.1200/jco.2013.31.15_suppl.532). [A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.598)Kelly C, Beamish R, McCaffrey J, SMITH M, Crown J, O'Connor M, McGee S, O'Reilly S, Moylan E, Gonzalez-Angulo A, Litton J, Pusztai L, Kelly C. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Journal 10.1200/jco.2013.31.15_suppl.598](https://doi.org/10.1200/jco.2013.31.15_suppl.598). [Abstract 1899: Metabolic vulnerability of breast on shifts in the expression of metabolic enzyme isoforms.](https://doi.org/10.1158/1538-7445.am2013-1899)Shi W, Gong A, Jiang T, Natowicz R, Pusztai L. Abstract 1899: Metabolic vulnerability of breast cancer based on shifts in the expression of metabolic enzyme breast cancer through receptor tyrosine kinase Axl.](https://doi.org/10.1158/1538-7445.am2013-3032)Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward W, Reuben J, Hortobagyi G, Hung M, Ueno N. Abstract 3032: Tazarotene-induced gene 1 promotes tumorigenicity and invasiveness of inflammatory breast cancer through receptor Wnt signaling as chemotherapy marker of triple negative breast cancer (TNBC).](https://doi.org/10.1158/1538-7445.am2013-5580)Huelsewig C, Bernemann C, Ruckert C, Kiesel L, Pusztai L, Liedtke C. Abstract 5580: Wnt signaling as chemotherapy sensitivity marker of triple negative breast cancer (TNBC). Cancer Research 2013, 73: high-risk categories](http://www.ncbi.nlm.nih.gov/pubmed/23504136)Szekely B, Iwamoto T, Szasz can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories Breast Cancer Research And Treatment 2013, LM, Chan S, Welcher R, D. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Gonzalez-Angulo AM. The prognostic impact of age in patients with triple-negative breast cancer Breast Cancer Research And Treatment cancer containing tumorigenic CD49f quiescent cells](http://www.ncbi.nlm.nih.gov/pubmed/23376849)Kai K, Iwamoto Kobayashi mammary cells into triple-negative breast cancer containing in oestrogen receptor-positive invasive ductal and C. Cancer heterogeneity: implications for targeted therapeutics Factor Following Neoadjuvant Therapy in Women With Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/23337751)Bayraktar S, Barrera A, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer The Cancer E, Liedtke C, Ahr A, Heinrich TM, S\u00e4nger N, Becker S, Karn T. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes Breast Cancer survival in early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23242617)Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim Pusztai L, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer Breast Cancer Research response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study.](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-17)Karn T, Hatzis C, Symmans F, Pusztai L, Ruckhaberle Schmidt M, Muller V, Hanker L, Heinrich T, Holtrich U, Kaufmann M, Rody A. Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. Cancer Research 2012, 72: p2-10-17-p2-10-17. [DOI: 10.1158/0008-5472.sabcs12-p2-10-17](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-17). HER2-negative breast cancer](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-10)Bianchini Callari M, Symmans W, Gianni L. Abstract P2-10-10: implications of molecular heterogeneity in highly proliferative, ER-positive, tumour infiltrating immune cell programs in distinct molecular breast cancer subtypes](https://doi.org/10.1158/0008-5472.sabcs12-p5-10-01)Paladini L, Truglia M, Arcangeli A, De Mattos Iwamoto T, Bottai G, Pusztai L, G, Di Leo A, Santarpia L. Abstract P5-10-01: MicroRNAs 181 and 135a modulate tumour infiltrating immune cell programs in distinct molecular breast cancer subtypes Cancer Research 2012, 72: p5-10-01-p5-10-01. [DOI: 10.1158/0008-5472.sabcs12-p5-10-01](https://doi.org/10.1158/0008-5472.sabcs12-p5-10-01). [Abstract S6-7: Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study](https://doi.org/10.1158/0008-5472.sabcs12-s6-7)Gianni L, Bianchini G, Valagussa P, Belousov A, Thomas M, Ross G, Pusztai L. Abstract S6-7: Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere [DOI: 10.1158/0008-5472.sabcs12-s6-7](https://doi.org/10.1158/0008-5472.sabcs12-s6-7). [High stearoyl-CoA desaturase 1 expression is with shorter survival in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/23208590)Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients Breast Cancer Research And Treatment the Pathological Response of Breast Cancer Patients to Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/23185353)Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients Setting: A Model to Safely Tailor Care While Accelerating Drug Development](http://www.ncbi.nlm.nih.gov/pubmed/23169510)Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Veer L, Berry DA, Esserman L. Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development Journal Of Clinical Oncology 2012, to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/23158478)Shen K, Qi Y, Song N, Tian Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy J, Pusztai L. Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Dean-Colomb Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10-10. [DOI: 10.1200/jco.2012.30.30_suppl.10](https://doi.org/10.1200/jco.2012.30.30_suppl.10). - Cheng J, Greshock J, Shi L, Painter J, Lin X, Lee K, Zheng S, Wooster R, Pusztai L, Menius A. An Adaptive Feature Selection Method for Microarray Data Analysis 2012, 1-6. [DOI: 10.1109/bibm.2012.6392686](https://doi.org/10.1109/bibm.2012.6392686). - Dumay Bertheau P, Espi\u00e9 M, Plassa L, Cottu P, M, Andr\u00e9 F, Sotiriou C, Pusztai L, de Th\u00e9 H. Distinct tumor protein p53 mutants in breast cancer subgroups International Journal Of Cancer 2012, 1227-1231. [PMID: 22886769](https://pubmed.ncbi.nlm.nih.gov/22886769), [DOI: 10.1002/ijc.27767](https://doi.org/10.1002/ijc.27767). - Pusztai L. Molecular Triage Help to Identify Highly Sensitive Disease? Annals Of Oncology 2012, + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups](https://doi.org/10.1016/s0923-7534(20)32783-6)Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly C, Qi Y, Motoki T, Taira N, Santarpia L, Doihara H, G. 172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups Annals Of Oncology 2012, 23: ix74-ix75. [DOI: 10.1016/s0923-7534(20)32783-6](https://doi.org/10.1016/s0923-7534(20)32783-6). [Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22890751)Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer [PMID: 22890751](https://pubmed.ncbi.nlm.nih.gov/22890751), Oncology 2012, 30: 2931-2931. [DOI: 10.1200/jco.2012.43.5990](https://doi.org/10.1200/jco.2012.43.5990). [Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping](http://www.ncbi.nlm.nih.gov/pubmed/22759093)Schwartz H, Burstein HJ, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, ReisFilho Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping E, Booser D, Hatzis C, Wallace M, Zhang Y, Gong Y, Ignatiadis M, Sotiriou C, Andre F, Peintinger F, Regitnig P, Marth C, Desmedt C, Loi S, Moulder S, Hortobagyi G, Pusztai L, Valero V. Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance [DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.](https://doi.org/10.1200/jco.2012.30.15_suppl.1012)Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. [DOI: comparison and human triple-negative noninflammatory breast cancer (TN-non-IBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.1047)Masuda H, Baggerly K, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Woodward W, Reuben J, Van Laere S, Bertucci F, Hortobagyi G, Ueno N. Molecular comparison of human triple-negative inflammatory breast cancer (TN-IBC) and human triple-negative noninflammatory breast to high frequency of targetable alterations in primary and metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.10559)Pusztai L, Yelensky R, Wang B, Avritscher R, Symmans W, Lipson D, Palmer G, Moulder S, Stephens P, Wu Y, Cronin M. Use of next-generation sequencing (NGS) to detect high frequency of targetable alterations in primary and metastatic breast cancer (MBC). Journal Clinical Oncology 2012, 30: 10559-10559. [DOI: 10.1200/jco.2012.30.15_suppl.10559](https://doi.org/10.1200/jco.2012.30.15_suppl.10559). - Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. Journal 10613-10613. 10.1200/jco.2012.30.15_suppl.10613](https://doi.org/10.1200/jco.2012.30.15_suppl.10613). - Giampaolo T, Kelly C, Zambetti M, Symmans W, Gianni L. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. Journal Of Clinical Oncology 2012, 30: 545-545. [DOI: 10.1200/jco.2012.30.15_suppl.545](https://doi.org/10.1200/jco.2012.30.15_suppl.545). - Kelly C, Parker I, McCaffrey J, Crown J, O'Connor M, McGee S, Pusztai L, Kelly C. Assessment of method of breast cancer detection and Onco type DX recurrence score. Journal Of Clinical Oncology 2012, 30: 581-581. [DOI: 10.1200/jco.2012.30.15_suppl.581](https://doi.org/10.1200/jco.2012.30.15_suppl.581). L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. for relapse in estrogen protein-A, prognostic marker for relapse in estrogen receptor-positive breast Sensitivity to Endocrine Therapy (Set)](https://doi.org/10.1016/s0923-7534(19)65684-x)Karn T, Hatzis C, Symmans W, Pusztai V, U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set) Annals Of Oncology 2012, 23: ii18. [DOI: 10.1016/s0923-7534(19)65684-x](https://doi.org/10.1016/s0923-7534(19)65684-x). - Chen W, Yousef Gallas Hsu E, Lababidi S, Tang R, Pennello G, Symmans W, Pusztai L. Uncertainty estimation with a finite dataset in the assessment of classification models Computational Statistics & Data Analysis 2012, 56: 1016-1027. [DOI: 10.1016/j.csda.2011.05.024](https://doi.org/10.1016/j.csda.2011.05.024). [Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/22538770)Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen V, GN, WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers Breast Cancer Research And and \"TCF7L2\" as novel potential biomarkers of triple negative breast cancer](https://doi.org/10.1158/1538-7445.am2012-3024)Huelsewig C, Goette M, Bernemann C, Ruckert C, Liedtke of WNT signaling pathway players \"sFRP-1\" and \"TCF7L2\" as novel potential biomarkers of triple negative breast cancer Cancer Research [DOI: 10.1158/1538-7445.am2012-3024](https://doi.org/10.1158/1538-7445.am2012-3024). [Abstract 682: Increased stearoyl-CoA desaturase 1 is associated with shorter survival in breast cancer patients](https://doi.org/10.1158/1538-7445.am2012-682)Holder A, Gonzalez-Angulo A, Chen H, Akcakanat A, Anh-Do K, Symmans F, Pusztai L, Hortobagyi G, Meric-Bernstam F. Abstract 682: Increased stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients Cancer Research 2012, 72: 682-682. [DOI: 10.1158/1538-7445.am2012-682](https://doi.org/10.1158/1538-7445.am2012-682). Swanton C. Intratumor Heterogeneity: Seeing the Wood for the Trees 2012, 4: 127ps10. clinical outcome for human HER2+:ER breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22460789)Liu JC, Voisin V, Bader GD, Deng WF, Esteva FJ, signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America Score Assay (Oncotype DX\u00ae) and EarlyStage Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22418568)Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L. Agreement in Risk Prediction Between the 21Gene Recurrence Score Assay (Oncotype DX\u00ae) and Rutgers EJ, Solin LJ, Palazzo J, Committee A. Adjuvant therapy in stage I carcinoma of the breast Cancer pathways that drive breast cancer clinical subtypes](http://www.ncbi.nlm.nih.gov/pubmed/22343619)Dutta B, Pusztai L, Qi Y, Andr\u00e9 F, Lazar V, Bianchini G, N, Agarwal WF, Bal\u00e1zsi network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes British Journal Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22235097)Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer Clinical Cancer in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry](http://www.ncbi.nlm.nih.gov/pubmed/22291085)Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by trial](http://www.ncbi.nlm.nih.gov/pubmed/22257673)Baselga Eidtmann Di Cosimo S, de Azambuja E, Aura C, G\u00f3mez H, Dinh P, Fauria K, Van Dooren V, Aktan Goldhirsch A, Chang Horv\u00e1th Z, M, Team O. Lapatinib with early breast cancer (NeoALTTO): a randomised, open-label, Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures](http://www.ncbi.nlm.nih.gov/pubmed/22220191)Karn T, Pusztai L, Holtrich U, Iwamoto Shiang M, M\u00fcller V, Solbach C, Gaetje R, Hanker L, Ahr E, Kaufmann M, Rody A. Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile](http://www.ncbi.nlm.nih.gov/pubmed/22369035)Zhao C, Shi L, Tong W, Shaughnessy JD, Oberthuer A, Pusztai L, Deng Y, Symmans WF, Shi T. Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22193884)Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer Annals Of Surgical Oncology 2011, 19: 1508-1516. [PMID: 22193884](https://pubmed.ncbi.nlm.nih.gov/22193884), [DOI: 10.1245/s10434-011-2108-2](https://doi.org/10.1245/s10434-011-2108-2). - Chang C, Wang J, Zhao C, Fostel J, Tong W, Bushel PR, Deng Y, Pusztai L, Symmans WF, Shi T. Maximizing biomarker discovery in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry.](https://doi.org/10.1158/0008-5472.sabcs11-p1-07-09)Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, Ueno N, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi G, Hatzis C, Symmans Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive Immunohistochemistry. Cancer Research 2011, A Inflammatory Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness Kinase Axl.](https://doi.org/10.1158/0008-5472.sabcs11-p2-02-01)Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward W, Reuben J, Hortobagyi G, Ueno N. P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through Lehmann-Che J, Bertheau P, Espie M, de C, Andre F, Sotiriou C, Pusztai L, de T. P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups. Cancer Research 2011, 71: p2-02-09-p2-02-09. [DOI: 10.1158/0008-5472.sabcs11-p2-02-09](https://doi.org/10.1158/0008-5472.sabcs11-p2-02-09). [P2-12-06: Nomogram To Predict with Non Metastatic Breast Carcinomas.](https://doi.org/10.1158/0008-5472.sabcs11-p2-12-06)Lousquy R, Delpech Y, Rouzier R, Gligorov E, Pusztai L, S, Hortobagyi G, Coutant C, Ibrahim N. P2-12-06: Nomogram To Predict Subsequent Bone Metastasis in Patients with Non Metastatic Breast Carcinomas. Cancer Delord M, Soulier J, Hamy A, Espie M, Andre F, Marty M, Sotiriou C, Piccart-Gebhart M, Pusztai L, Bertheau P, de T. P3-05-01: Gene Profiling of Histopathologically Characterized Apocrine Breast 2011, ApoE and Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target.](https://doi.org/10.1158/0008-5472.sabcs11-p3-17-01)Shiang C, Qi Y, Wang B, Broom B, Pusztai L. P3-17-01: ApoE and Its Receptors (LRP8, VLDLR) Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target. Cancer Research 2011, 71: p3-17-01-p3-17-01. [DOI: 10.1158/0008-5472.sabcs11-p3-17-01](https://doi.org/10.1158/0008-5472.sabcs11-p3-17-01). [P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model.](https://doi.org/10.1158/0008-5472.sabcs11-p4-03-04)Kai K, Iwamoto T, Pusztai L, Hortobagyi G, Saya H, Ueno N. P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model. Cancer Research 2011, 71: p4-03-04-p4-03-04. [DOI: 10.1158/0008-5472.sabcs11-p4-03-04](https://doi.org/10.1158/0008-5472.sabcs11-p4-03-04). [P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers.](https://doi.org/10.1158/0008-5472.sabcs11-p4-16-02)Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, Hortobagyi G, Pusztai L, Symmans F, Ueno N. P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers. Cancer Research 2011, Karn Schmidt M, Muller V, Gatje R, Hanker L, A, Holtrich A, Kaufmann M. PD03-02: Prognostic and Predictive Predictors for Triple Negative Breast Cancer. Cancer Research 2011, 71: pd03-02-pd03-02. [DOI: 10.1158/0008-5472.sabcs11-pd03-02](https://doi.org/10.1158/0008-5472.sabcs11-pd03-02). - Bianchini C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. [DOI: 10.1158/0008-5472.sabcs11-s1-7](https://doi.org/10.1158/0008-5472.sabcs11-s1-7). - Pusztai L, Qi Y, Shi W, Liu C, Wang B, Liu X, Booser D, Esteva F, Symmans F, Hortobagyi G. S6-4: Protein Kinase Mutation Patterns in Human Breast Cancer. Cancer Research 2011, 71: s6-4-s6-4. [DOI: 10.1158/0008-5472.sabcs11-s6-4](https://doi.org/10.1158/0008-5472.sabcs11-s6-4). [Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems](http://www.ncbi.nlm.nih.gov/pubmed/22132775)Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems chemotherapy sensitivity in different molecular subtypes of breast cancer](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247034)Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer Breast Cancer Research profiling in breast cancer: classification, prognostication, and prediction neoadjuvant breast cancer clinical trials: timing and specimen types](http://www.ncbi.nlm.nih.gov/pubmed/21684810)Loi S, Symmans WF, Bartlett J, Fumagalli D, Veer LJ, BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen [PMID: 21684810](https://pubmed.ncbi.nlm.nih.gov/21684810), [DOI: Integrity and Microarray Measurements From Resected Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/22034635)Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers Journal Of The National Biology: Two Complementary Sides of Breast Cancer Prognostication Journal L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, M\u00fcller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer Breast Cancer to trastuzumab and tumor presence in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/22370716)Jung E, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le X, Bast RC, Park S, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients The Value of Genomic Analysis of Breast Cancer in Drug differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes.](https://doi.org/10.1200/jco.2011.29.27_suppl.157)Chavez-MacGregor M, Liu S, Chen H, Do K, Pusztai L, Symmans W, Hortobagyi G, Mills G, Meric-Bernstam F, Gonzalez-Angulo A. Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. Journal Of Clinical Oncology 2011, 29: 157-157. [DOI: 10.1200/jco.2011.29.27_suppl.157](https://doi.org/10.1200/jco.2011.29.27_suppl.157). [Capecitabine in operable breast A subgroup analysis of a randomized phase III trial.](https://doi.org/10.1200/jco.2011.29.27_suppl.292)Kelly C, Green M, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim N, Gonzalez-Angulo A, Booser D, Hunt K, Hortobagyi G, Buzdar A. Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. Journal Of Clinical Oncology 2011, 29: 292-292. [DOI: 10.1200/jco.2011.29.27_suppl.292](https://doi.org/10.1200/jco.2011.29.27_suppl.292). [Response to Neoadjuvant Systemic for in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience](http://www.ncbi.nlm.nih.gov/pubmed/21900106)Arun B, Bayraktar S, Liu DD, Barrera A, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience INVITED Role of Gene Expression Profiling for Biomarker Discovery European Journal Of Cancer 2011, 47: s78. Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic Nature Reviews Clinical Oncology gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations](http://www.ncbi.nlm.nih.gov/pubmed/21833625)Iwamoto T, Lee JS, Bianchini G, Hubbard RE, WF, Hortobagyi GN, Pusztai L. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations Breast Cancer Research And Treatment 2011, 130: 155. [PMID: 21833625](https://pubmed.ncbi.nlm.nih.gov/21833625), Nikoloff DM, Hillman Fontecha M, Li R, Michaud L, Hortobagyi G, GonzalezAngulo A. Effect of CYP2D6 polymorphisms on breast 21823108](https://pubmed.ncbi.nlm.nih.gov/21823108), of chemotherapy response](http://www.ncbi.nlm.nih.gov/pubmed/21798043)Li Q, Eklund S, Richardson AL, Szallasi Z. Consistent metagenes from cancer expression profiles yield agent specific predictors of predict pathologic complete response in patients with breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21906370)Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer Clinical by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation](http://www.ncbi.nlm.nih.gov/pubmed/21741824)Karn T, Pusztai L, Ruckh\u00e4berle E, Liedtke C, M\u00fcller J, Coombes KR, G\u00e4tje R, Hanker U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation European Journal Of Cancer 2011, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients Breast Cancer Research And Treatment 2011, 129: 451-458. [PMID: 21710134](https://pubmed.ncbi.nlm.nih.gov/21710134), [DOI: 10.1007/s10549-011-1645-5](https://doi.org/10.1007/s10549-011-1645-5). a pre-operative, window-of-opportunity, Iwamoto G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial 21655990](https://pubmed.ncbi.nlm.nih.gov/21655990), chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.1016)Gonzalez-Angulo A, Green M, Murray J, Palla S, Koenig K, Brewster A, Valero V, Ibrahim N, Moulder S, Litton J, Crawford D, Flores P, Dryden M, Symmans W, Giordano S, Pusztai L, Buzdar A, Mills G, Hortobagyi G, Meric-Bernstam F. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer the to assess risk in ER+ breast cancers: A direct comparison to Onco type DX.](https://doi.org/10.1200/jco.2011.29.15_suppl.503)Bastien R, Ebbert M, Boucher K, Kelly C, Wang B, Iwamoto T, Krishnamurthy S, Pusztai L, Bernard P. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to Onco type DX. Of Clinical Oncology 2011, 29: 503-503. neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer.](https://doi.org/10.1200/jco.2011.29.15_suppl.534)Thompson A, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Hardie G, Pusztai L, Moulder S, Dewar J, Hadad S. Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. Journal Of Clinical Oncology 2011, 29: 534-534. [DOI: 10.1200/jco.2011.29.15_suppl.534](https://doi.org/10.1200/jco.2011.29.15_suppl.534). [A Genomic Predictor of and Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/21558518)Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chac\u00f3n JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, J, Hortobagyi GN, Symmans Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast L, Liedtke M\u00fcller V, Schmidt M, Metzler D, Wang J, Coombs K, S\u00e4nger N, G\u00e4tje R, Hanker L, Ahr U, Rody A, M. Mogushi K, Tanaka H, Iwamoto T, Pusztai L, Hortobagyi G, Saya H, Ueno N. Abstract 2376: Mouse mammary tumor model relevant to human triple negative breast cancer Cancer Research 2011, 71: as growth signals for triple-negative breast cancer and represents novel therapeutic targets](https://doi.org/10.1158/1538-7445.am2011-lb-219)Shiang C, Qi Y, Wang B, Broom B, Pusztai L. Abstract LB-219: ApoE and its' receptors (LRP8, VLDLR) function as growth signals for triple-negative breast cancer and represents novel therapeutic targets Cancer Research 2011, 71: lb-219-lb-219. [DOI: 10.1158/1538-7445.am2011-lb-219](https://doi.org/10.1158/1538-7445.am2011-lb-219). [Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/21248301)Coutant C, Rouzier R, F, de Th\u00e9 H, Pusztai L. Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers Clinical [DOI: profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure](https://doi.org/10.1002/prca.201190010)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andr\u00e9 F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure Proteomics Clinical Applications 2011, 5: 193-193. [DOI: 10.1002/prca.201190010](https://doi.org/10.1002/prca.201190010). - Desmedt C, Di Leo A, Larsimont D, Haibe-Kains B, Selleslags V, Piccart-Gebhart M, Sotiriou C. Multifactorial Approach to Predicting Resistance to 2011, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a Oncology 2011, a call for a comprehensive biomarker study registry Clinical 21364690](https://pubmed.ncbi.nlm.nih.gov/21364690), [DOI: 10.1038/nrclinonc.2011.4](https://doi.org/10.1038/nrclinonc.2011.4). - Pusztai L, Kelly C. Systemic Adjuvant Therapy for Stage I Breast Cancer 2011, 269-281. [DOI: 10.1007/978-94-007-0489-3_11](https://doi.org/10.1007/978-94-007-0489-3_11). [Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/21191116)Iwamoto T, Bianchini G, Booser D, Qi B, J, Andre F, Simon R, Pusztai L. Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer Journal Of The National Cancer Institute 2010, 103: 264-272. [PMID: 21191116](https://pubmed.ncbi.nlm.nih.gov/21191116), [DOI: and immonohistochemistry to breast cancer diagnostics](http://www.ncbi.nlm.nih.gov/pubmed/21172090)Shiang C, Pusztai L. Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics Breast Animal Model of Human Triple-Negative Breast Cancer by Retroviral Oncogene Transduction of Mouse Mammary Cells](https://doi.org/10.1158/0008-5472.sabcs10-p1-03-02)Kai Pusztai L, Hortobagyi G, Ueno N. Abstract P1-03-02: Development of a Novel Animal Model of Human Triple-Negative Breast Cancer by Retroviral Oncogene Transduction of Mouse Mammary P2-09-39: Multi-Gene Predictors Developed Cell Lines To Predict Response to Chemotherapy: A Validation Study on US Oncology Study 02-103](https://doi.org/10.1158/0008-5472.sabcs10-p2-09-39)Shen K, Pusztai L, Qi Y, Symmans W, Song N, Rice S, Gabrin M, O'Shaughnessy J, Holmes F. Abstract P2-09-39: Multi-Gene Predictors Developed from Breast Cancer Cell Lines To Predict Response to Chemotherapy: A Validation Study on US Oncology Study Leo Calin G, Symmans Esteva F, Hortobagyi G, Pusztai L. Abstract P3-09-03: microRNAs and Target Gene Networks in Breast Cancer Cell Lines Cancer Research 2010, 70: p3-09-03-p3-09-03. [DOI: Inflammatory Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p5-05-05)Wang X, Saso H, Iwamoto Pusztai P5-05-05: Tazarotene-Induced Gene 1(TIG1) Is a Novel Tumorigenic Gene of Inflammatory Breast Cancer Cancer Research 2010, 70: p5-05-05-p5-05-05. [DOI: 10.1158/0008-5472.sabcs10-p5-05-05](https://doi.org/10.1158/0008-5472.sabcs10-p5-05-05). [Abstract P5-10-02: Clinical of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC)](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-02)Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC) Cancer Research 2010, 70: p5-10-02-p5-10-02. [DOI: 10.1158/0008-5472.sabcs10-p5-10-02](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-02). [Abstract P6-14-06: Prospective Testing of Three Gene-Signatures for Patient Selection for Dasatinib Therapy in Metastatic Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p6-14-06)Pusztai L, Moulder S, Litton J, Valero V, Ueno N, Melhem-Bertrandt A, Morrow P, Dotter K, Mattair D, Strauss L, Hortobagyi G, Qi Y, Symmans W. Abstract P6-14-06: Prospective Testing of Three Different Gene-Signatures for Patient Selection for Dasatinib Therapy in Metastatic Breast Cancer Research 2010, 70: [DOI: Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis](https://doi.org/10.1158/0008-5472.sabcs10-pd07-01)Saura C, Tseng L, Chan S, Chacko R, Campone M, Liu D, Mukhopadhyay J, Mudenda B, Horak C, Xing G, Pusztai L. Abstract PD07-01: Phase 2 Study of Ixabepilone Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis Cancer Research 2010, 70: in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to Paclitaxel (pac)](https://doi.org/10.1158/0008-5472.sabcs10-pd07-02)Horak C, Pusztai L, Mudenda B, Xing G, Trifan O, Saura C, Tseng L, Chan S, Welcher R, Liu D. Abstract PD07-02: III Tubulin Expression by Immunohistochemistry (IHC) and mRNA in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to [DOI: 10.1158/0008-5472.sabcs10-pd07-02](https://doi.org/10.1158/0008-5472.sabcs10-pd07-02). [Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-s5-5)Rody A, Karn T, Liedtke L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M. Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer Cancer Research 2010, 70: s5-5-s5-5. [DOI: 10.1158/0008-5472.sabcs10-s5-5](https://doi.org/10.1158/0008-5472.sabcs10-s5-5). [Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21153052)Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer Breast Cancer Research And L, Members T. Use of standard markers and incorporation of molecular markers into breast cancer therapy Cancer 2010, 117: 1575-1582. [PMID: 21472705](https://pubmed.ncbi.nlm.nih.gov/21472705), [DOI: 10.1002/cncr.25660](https://doi.org/10.1002/cncr.25660). - Iwamoto T, Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome 2010, GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer Annals Of CA. Estrogen and HER2 Receptor Discordance Between Primary Kinase Expression Patterns in Different Subtypes of Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20959472)Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, WF, Gianni L. Prognostic and Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer 2010, Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20829329)Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, LJ, Souchon E, Paclitaxel, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer Clinical [PMID: M, Pusztai L, Sneige N. Stability of estrogen receptor status in 2010, 117: 20939012](https://pubmed.ncbi.nlm.nih.gov/20939012), [DOI: profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure](http://www.ncbi.nlm.nih.gov/pubmed/20827732)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andr\u00e9 F, Buzdar AU, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2positive breast cancer Vannucci Do K, Broom B, Kim S, Sha N, Tadesse M, Yan K, Pusztai L. Gene Selection for the Identification of Biomarkers in High- Throughput Data 2010, 259-280. [DOI: 10.1201/ebk1420070170-14](https://doi.org/10.1201/ebk1420070170-14). [Molecular Anatomy of Breast Cancer Value in Estrogen Receptor-Positive and G, Alvarez T, Coutant Ibrahim NK, Valero WF, Pusztai L. Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and [DOI: 10.1200/jco.2009.27.2419](https://doi.org/10.1200/jco.2009.27.2419). [The role tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches](http://www.ncbi.nlm.nih.gov/pubmed/20739212)Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches Drug Resistance Updates C, Domont DJ, GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer Journal Of common practices for the development and validation of microarray-based predictive models.](http://www.ncbi.nlm.nih.gov/pubmed/20676074)Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. in clinically intermediate risk hormone receptorpositive, HER2normal, grade II, lymph nodenegative breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/20665886)Kelly CM, Krishnamurthy Bianchini G, Litton JK, GonzalezAngulo A, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptorpositive, HER2normal, grade II, lymph nodenegative F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. [PMID: 20665494](https://pubmed.ncbi.nlm.nih.gov/20665494), [DOI: of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers.](https://doi.org/10.1200/jco.2010.28.15_suppl.1039)Santarpia L, Gonzalez-Angulo A, Qi Y, Stemke-Hale K, Wang B, Booser D, Hortobagyi G, Symmans W, Di Leo A, Pusztai L. Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. Journal Of Clinical Oncology 2010, 28: 1039-1039. [DOI: 10.1200/jco.2010.28.15_suppl.1039](https://doi.org/10.1200/jco.2010.28.15_suppl.1039). [Do experts agree on to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research.](https://doi.org/10.1200/jco.2010.28.15_suppl.1084)Saad E, Katz A, Pusztai L, Hoff P, Buyse M. Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research. Journal Of Clinical Oncology 2010, 28: 1084-1084. L, Mueller V, Schmidt M, Holtrich U, Kaufmann M. Clinically relevant gene signatures in triple-negative and basal-like breast cancer. Journal Of Clinical Oncology 2010, 28: 521-521. [DOI: 10.1200/jco.2010.28.15_suppl.521](https://doi.org/10.1200/jco.2010.28.15_suppl.521). [Correlation of in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.](https://doi.org/10.1200/jco.2010.28.15_suppl.522)Loi S, Haibe-Kains B, Brown D, Metallo J, Huan Desmedt C, Pusztai L, Piccart M, Esteva F, Sotiriou C. Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. Clinical Oncology and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.](https://doi.org/10.1200/jco.2010.28.15_suppl.548)Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. Journal Of Clinical Oncology 2010, 28: 548-548. [DOI: 10.1200/jco.2010.28.15_suppl.548](https://doi.org/10.1200/jco.2010.28.15_suppl.548). [Use of efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and Goubar A, Lacroix Desmedt V, Sotiriou C, Mathieu M, Delaloge S, Pusztai L. Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant Oncology 2010, 28: [DOI: ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.569)Swanton C, Juul N, Larkin J, Eklund A, Li Q, Desmedt C, Sotiriou C, Pusztai L, Szallasi Z. Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal Of Clinical Oncology 2010, 28: 569-569. Pusztai L, Gonzalez-Angulo A. The prognostic impact of age in patients with triple-negative breast cancer. Journal Of Clinical Oncology 2010, 28: 597-597. [DOI: 10.1200/jco.2010.28.15_suppl.597](https://doi.org/10.1200/jco.2010.28.15_suppl.597). - Pusztai L, Moulder Litton Valero V, Ueno N, Morrow P, Dotter K, Mattair D, Strauss L, Symmans W. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer 2010, 28: tps130-tps130. [DOI: 10.1200/jco.2010.28.15_suppl.tps130](https://doi.org/10.1200/jco.2010.28.15_suppl.tps130). [PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/20479250)Loi Haibe-Kains P, Tutt AN, CE, Mills GB, Phillips MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, cancer prognostic markers in the post-genomic era Breast Cancer Research And 2010, 125: 647-650. [PMID: 20464478](https://pubmed.ncbi.nlm.nih.gov/20464478), [DOI: 10.1007/s10549-010-0932-x](https://doi.org/10.1007/s10549-010-0932-x). F, Hatzis C, Pusztai L. Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy Cancer Breast Cancer 2010, 297-323. [DOI: 10.1201/b11127-15](https://doi.org/10.1201/b11127-15). [Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials](http://www.ncbi.nlm.nih.gov/pubmed/20421265)Andre Pusztai GN. Receptor and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four an effective therapeutic approach for triple-negative breast cancer](https://doi.org/10.1158/1538-7445.am10-lb-107)Pelicano H, Zhang W, Hammoudi N, Pusztai L, Dai J, Huang P. Abstract LB-107: Targeting the glycolytic pathway as an effective therapeutic approach for triple-negative breast cancer Cancer Research 2010, 70: lb-107-lb-107. [DOI: 10.1158/1538-7445.am10-lb-107](https://doi.org/10.1158/1538-7445.am10-lb-107). Graesslin O, Abdulkarim Gabos Z, Hsu L, NK. to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer Journal Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer Journal Of of p53 Mutant Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/20228131)LehmannChe J, Andr\u00e9 F, Desmedt C, Mazouni C, Giacchetti WF, H. Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials](http://www.ncbi.nlm.nih.gov/pubmed/20189874)Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, C, Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials 2010, 11: 358-365. Response to Neoadjuvant Chemotherapy in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20068086)Lee JK, Coutant C, Kim WF, Baggerly K, Rouzier Comparison Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya Symmans WF, Pusztai L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors Breast breast cancer and the effects of brivanib alaninate](http://www.ncbi.nlm.nih.gov/pubmed/20024612)Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate Breast Cancer Research And 20024612](https://pubmed.ncbi.nlm.nih.gov/20024612), [DOI: 10.1007/s10549-009-0677-6](https://doi.org/10.1007/s10549-009-0677-6). - Pusztai L. Gene expression profiling of breast cancer Breast Cancer 2009, 11: 315-343. [PMID: Role in ER-Positive and ER-Negative Cancers.](https://doi.org/10.1158/0008-5472.sabcs-09-105)Bianchini G, Bianchini G, Alvarez R, Qi Hatzis Iwamoto T, Shiang C, Coutant C, Hortobagyi G, Symmans W, Pusztai L. The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and 2009, [From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Samples from the 150007/150012, Das D, Lenburg Paquette Spellman P, Gray J, Gray J, Pusztai L, Symmans F, Hatzis C, Esserman L, van 't Veer L, I-SPY Investigators .. From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Samples from the [Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-101)Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. 2009, 69: 101-101. [DOI: of Axillary 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-1086)Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf Pusztai Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. [DOI: 10.1158/0008-5472.sabcs-09-1086](https://doi.org/10.1158/0008-5472.sabcs-09-1086). - Caudle L, Kau S, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. Cancer Research 2009, 69: 1090-1090. [DOI: 10.1158/0008-5472.sabcs-09-1090](https://doi.org/10.1158/0008-5472.sabcs-09-1090). [Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure.](https://doi.org/10.1158/0008-5472.sabcs-09-2037)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. Cancer Research 2009, 69: 2037-2037. [DOI: 10.1158/0008-5472.sabcs-09-2037](https://doi.org/10.1158/0008-5472.sabcs-09-2037). [Genomic Profiling of Breast Comparative Genomic Hybridization Marty V, Scott V, Pusztai L, Berrada N, Lazar V, Job B, Viehl P, Bernaudin J, Andre F. Genomic Profiling of Breast Cancer (BC) in Mali by Oligonucleotide Comparative Genomic Hybridization [DOI: 10.1158/0008-5472.sabcs-09-3059](https://doi.org/10.1158/0008-5472.sabcs-09-3059). [Consistent Principal Components from Triple Negative Breast Cancer Expression Profiles Yields Agent Specific Predictors of Chemotherapy Response.](https://doi.org/10.1158/0008-5472.sabcs-09-3163)Li Q, Eklund W, Pusztai L, Richardson A, Szallasi Z, Szallasi Z. Consistent Principal Components from Triple Negative Breast Cancer Expression Profiles Yields Agent Specific Predictors of Chemotherapy Response. Cancer Research 2009, [DOI: 10.1158/0008-5472.sabcs-09-3163](https://doi.org/10.1158/0008-5472.sabcs-09-3163). [Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy.](https://doi.org/10.1158/0008-5472.sabcs-09-4047)Liedtke C, C, Pusztai L. Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant 2009, 69: 4047-4047. [DOI: 10.1158/0008-5472.sabcs-09-4047](https://doi.org/10.1158/0008-5472.sabcs-09-4047). [Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.](https://doi.org/10.1158/0008-5472.sabcs-09-6122)Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans W, Andre F, de The H, Coutant C, Coutant C. Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers. Cancer Research 2009, 69: 6122-6122. [DOI: 10.1158/0008-5472.sabcs-09-6122](https://doi.org/10.1158/0008-5472.sabcs-09-6122). [Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-6124)Iwamoto T, Iwamoto T, Bianchini Shiang J, Symmans W, Hortobagyi G, Simon R, Pusztai L. Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer. Cancer Research 2009, 69: 6124-6124. [DOI: 10.1158/0008-5472.sabcs-09-6124](https://doi.org/10.1158/0008-5472.sabcs-09-6124). - Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada S, Michiels S, Cristofanilli M. CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence The Oncologist 2009, 14: 1182-1188. [PMID: 19939894](https://pubmed.ncbi.nlm.nih.gov/19939894), [DOI: 10.1634/theoncologist.2009-0161](https://doi.org/10.1634/theoncologist.2009-0161). - Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu U, Harbeck N. Triple-negative breast cancer\u2014current status 169 Genomics in early clinical trials European Journal Of Cancer Supplements 2009, 7: 43. [DOI: 10.1016/s1359-6349(09)70149-1](https://doi.org/10.1016/s1359-6349(09)70149-1). [Evaluation of Microtubule-Associated Protein-Tau Expression As Prognostic Predictive Marker in the NSABP-B 28 Randomized Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/19667268)Pusztai L, Jeong JH, Gong Y, Ross JS, Andre of Microtubule-Associated Protein-Tau As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial Journal Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines Breast Cancer Research And Treatment 2009, 121: 301-309. primary and recurrent breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19596702)Liedtke C, Broglio K, Moulder S, Hsu L, Kau of discordance between triple-receptor measurements in primary and recurrent breast cancer of breast cancer: implications for treatment and clinical trial design Breast Cancer Research 2009, 11: s4. [PMCID: genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.1044)Andreopoulou E, Hatzis C, Booser D, Valero V, Wallace M, Sotiriou C, Hortobagyi G, Pusztai L, Symmans W. Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer Journal Of 27: 1044-1044. 10.1200/jco.2009.27.15_suppl.1044](https://doi.org/10.1200/jco.2009.27.15_suppl.1044). triple-negative breast cancer patients](https://doi.org/10.1200/jco.2009.27.15_suppl.1028)Pusztai L, Rouzier R, Pusztai L, Ibrahim N. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients 1028-1028. [DOI: 10.1200/jco.2009.27.15_suppl.1028](https://doi.org/10.1200/jco.2009.27.15_suppl.1028). [Estrogen receptor efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials](https://doi.org/10.1200/jco.2009.27.15_suppl.1046)Mazouni Andr\u00e9 F, Broglio K, Pusztai L, Hortobagyi G. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials Of (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers](https://doi.org/10.1200/jco.2009.27.15_suppl.533)Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart M, Phillips W, McArthur G, Sotiriou C. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers Journal [DOI: 10.1200/jco.2009.27.15_suppl.533](https://doi.org/10.1200/jco.2009.27.15_suppl.533). [Functional pathways targets in triple-negative breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.569)Andre F, Dessen P, Job B, Delaloge S, Pusztai L, Lazar V. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer Journal Of Clinical Oncology 2009, 27: 569-569. [DOI: 10.1200/jco.2009.27.15_suppl.569](https://doi.org/10.1200/jco.2009.27.15_suppl.569). - Caudle Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer Journal Of Clinical Oncology 2009, 27: 603-603. [DOI: 10.1200/jco.2009.27.15_suppl.603](https://doi.org/10.1200/jco.2009.27.15_suppl.603). [Evaluation of serum breast cancer using MALDI-TOF/MS procedure](https://doi.org/10.1200/jco.2009.27.15_suppl.e22072)Hawke D, Mazouni Andr\u00e9 F, Baggerly K, Baggerly Tsavachidis S, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure Journal Of Clinical Oncology 2009, 27: e22072-e22072. [DOI: 10.1200/jco.2009.27.15_suppl.e22072](https://doi.org/10.1200/jco.2009.27.15_suppl.e22072). [Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19381845)Tordai A, Liedtke C, Pusztai L. Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer Clinical & Experimental Metastasis 2009, M, Sotiriou C, Pusztai L. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer Journal Of Clinical and Breast Cancer: Ten Years of Targeted Anti-HER2 Therapy and Personalized cancers](http://www.ncbi.nlm.nih.gov/pubmed/19272155)Rody E, Solbach C, Hanker L, Ahr A, D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers Gene-Expression Signatures in Breast Cancer New England Journal Medicine 2009, 360: 790-800. [PMID: 19228622](https://pubmed.ncbi.nlm.nih.gov/19228622), [DOI: 10.1056/nejmra0801289](https://doi.org/10.1056/nejmra0801289). [Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables](http://www.ncbi.nlm.nih.gov/pubmed/19152025)Rouzier R, Coutant C, Lesieur B, Mazouni C, Incitti R, Natowicz R, Pusztai L. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables Breast Cancer Research And Treatment 2009, 117: 325-331. [PMID: 19152025](https://pubmed.ncbi.nlm.nih.gov/19152025), Array](http://www.ncbi.nlm.nih.gov/pubmed/19147748)Andre A, Michiels S, Liedtke C, Richon C, GN, Symmans WF, Lazar Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization 10.1158/1078-0432.ccr-08-1791](https://doi.org/10.1158/1078-0432.ccr-08-1791). [Targeting of breast cancer non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer.](https://doi.org/10.1158/0008-5472.sabcs-2119)Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. [DOI: 10.1158/0008-5472.sabcs-2119](https://doi.org/10.1158/0008-5472.sabcs-2119). - Li C, Pusztai L, Cohen E, Symmans F, Wang B, Lee B, Hortobagyi G, Cristofanilli M, Reuben J. Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells. Cancer Research 2009, 69: 3084. [DOI: 10.1158/0008-5472.sabcs-3084](https://doi.org/10.1158/0008-5472.sabcs-3084). [Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.](https://doi.org/10.1158/0008-5472.sabcs-54)Pusztai L, Jeong J, Gong Y, Ross J, Kim C, Hortobagyi G, Paik S, Symmans W. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Cancer Research 2009, 69: 54. [DOI: 10.1158/0008-5472.sabcs-54](https://doi.org/10.1158/0008-5472.sabcs-54). [p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials.](https://doi.org/10.1158/0008-5472.sabcs-6064)Lehmann-Che J, Andre F, Desmedt C, Giacchetti S, Sotiriou C, Turpin E, Espie M, Marty M, Piccart M, Pusztai L, De The H. p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical 69: 6064. [DOI: 10.1158/0008-5472.sabcs-6064](https://doi.org/10.1158/0008-5472.sabcs-6064). [The Bimodality Index: A criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data](http://www.ncbi.nlm.nih.gov/pubmed/19718451)Wang J, Wen Symmans WF, Pusztai L, Coombes KR. Bimodality Index: A criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer 2009, 101-110. 10.1007/978-0-387-87366-4_10](https://doi.org/10.1007/978-0-387-87366-4_10). - Sotiriou C, Pusztai L. Advances in translational research in breast cancer; a bridge to future therapies European Journal Of Cancer 2008, 44: 2705-2706. W. Molecular Pathology and Transcriptional Profiling in Early Drug Development 2008, 47-84. [DOI: 10.1002/9780470475959.ch3](https://doi.org/10.1002/9780470475959.ch3). - Pusztai L. Individualized therapy of breast cancer: are we there yet? Personalized Medicine 2008, R. Are short-term or long-term recurrence rates more important in breast cancer screening? Annals Of Internal Medicine 2008, 149: Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin Symmans WF, de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast 6084-6091. L, Hortob\u00e1gyi G. Commercialized Multigene Predictors of Clinical Outcome Breast The 13: 921-921. [DOI: 10.1634/theoncologist.2007-0248erratum](https://doi.org/10.1634/theoncologist.2007-0248erratum). - Pusztai Promises and caveats of in silico biomarker discovery British Journal HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/18667396)Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, GN, WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18662965)Pusztai GN. of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer L. Paclitaxel-induced sickle cell 1333-6. L. Lost translation\u2014prognostic signatures for breast cancer Nature Reviews Clinical Oncology 2008, 363-363. [PMID: 18583992](https://pubmed.ncbi.nlm.nih.gov/18583992), [DOI: 10.1038/ncponc1177](https://doi.org/10.1038/ncponc1177). - Oncology 2008, 26: 3288-3288. [DOI: 10.1200/jco.2008.17.2502](https://doi.org/10.1200/jco.2008.17.2502). [Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers](http://www.ncbi.nlm.nih.gov/pubmed/18560403)Mazouni C, Arun B, Andr\u00e9 F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers British Journal Of Cancer 2008, and Pathologic Assessment of Response [PMID: Expression Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis](http://www.ncbi.nlm.nih.gov/pubmed/18509176)Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis Journal clinical activity and biological correlations](http://www.ncbi.nlm.nih.gov/pubmed/18515258)Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez R, Valero GN. mesylate (Gleevec\u00ae) in advanced chemotherapy in phenotypic subsets of Liedtke Kuerer A, Hortobagyi G, Pusztai L, Symmans W. Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast 544-544. [DOI: 10.1200/jco.2008.26.15_suppl.544](https://doi.org/10.1200/jco.2008.26.15_suppl.544). [Use of (GGI) predict pathologic response to preoperative chemotherapy in breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.541)Symmans W, Hatzis C, Liedtke C, C, G, Gebhart M, Pusztai L, Sotiriou C. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer Journal Of Clinical Oncology 2008, 541-541. M, Hortobagyi G, Veer L, Symmans W. Combined use of genomic prognostic and treatment response predictors in breast cancer and ER-positive/HER2-negative breast cancers](https://doi.org/10.1200/jco.2008.26.15_suppl.571)Hatzis C, Symmans W, Lin F, Zheng B, Yan K, Booser D, Gong Y, Valero V, Hortobagyi G, Pusztai L. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast Oncology 2008, 26: 571-571. [DOI: 10.1200/jco.2008.26.15_suppl.571](https://doi.org/10.1200/jco.2008.26.15_suppl.571). [Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy](https://doi.org/10.1200/jco.2008.26.15_suppl.576)Peintinger F, Hatzis C, Morkowski J, Hubbard Qureshi G, Pusztai L, Symmans W. Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy Journal Of Clinical Oncology chemotherapy with paclitaxel/FAC-FEC in breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.11078)Gonzalez-Angulo A, Hennessy B, Ju Z, Meric-Bernstam F, Lajos P, Symmans W, Coombes K, Hortobagyi G, Mills G. Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer Journal Of Clinical Oncology 2008, 26: 11078-11078. [DOI: 10.1200/jco.2008.26.15_suppl.11078](https://doi.org/10.1200/jco.2008.26.15_suppl.11078). [Cross-platform performance of response to doxorubicin-paclitaxel containing regimens](https://doi.org/10.1200/jco.2008.26.15_suppl.11061)Bianchini G, Zhao Y, Zambetti Pusztai L, Mariani G, Carcangiu M, Valagussa P, Gianni L, Simon R. Cross-platform performance of genes predictive of pathologic response to doxorubicin-paclitaxel containing regimens Journal Symmans W, Levy A, Delaloge S, Dessens P, Michiels S, Pusztai L. High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer Journal Clinical Oncology by tissue microarrays](https://doi.org/10.1200/jco.2008.26.15_suppl.560)Zoubir M, Mathieu M, Liedtke Bidard biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue Of Clinical (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)](https://doi.org/10.1200/jco.2008.26.15_suppl.504)Gianni L, Eiermann W, Pusztai L, Semiglazov V, Hoegel G, M, P, Baselga J. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) Journal Of Clinical 26: 504-504. Arun Pusztai L, Valero V, Hortobagyi G, Albarracin C. Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers Oncology 10.1200/jco.2008.26.15_suppl.618](https://doi.org/10.1200/jco.2008.26.15_suppl.618). [Transcriptional profiles Are Caucasian, Hispanic, and African-American women different?](https://doi.org/10.1200/jco.2008.26.15_suppl.22014)Dean-Colomb W, Yan K, Liedtke C, Symmans W, Holmes F, O'Shaughnessy J, Asmar G, Pusztai L, Gonzalez-Angulo A. Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women Of Clinical Oncology 2008, 26: 22014-22014. 10.1200/jco.2008.26.15_suppl.22014](https://doi.org/10.1200/jco.2008.26.15_suppl.22014). - Ibrahim N, Abdulkarim Huguet Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom E, Hortobagyi G, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients [Prognostic impact triple-receptor between primary tumor and metastasis in patients with metastatic breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.1001)Broglio K, Moulder S, Hsu L, Kau W, G, C. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer Journal Of Clinical 2008, 477-493. [PMID: 18515733](https://pubmed.ncbi.nlm.nih.gov/18515733), K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer Breast Cancer 2008, and chemotherapy sensitivity in stage II-III breast cancer Breast Cancer of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses](http://www.ncbi.nlm.nih.gov/pubmed/18366635)Natowicz R, Incitti R, Horta EG, Charles B, Guinot P, Yan K, Coutant C, Andre F, Pusztai L, Rouzier R. Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses BMC Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer Journal Of in Patients With Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18250347)Liedtke C, Mazouni C, Hess GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal Of Clinical Histopathologic and Molecular Markers of Prognosis and Response to Therapy 2008, 323-343. [DOI: 10.1007/978-0-387-34952-7_11](https://doi.org/10.1007/978-0-387-34952-7_11). - Peintinger F, L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer British Journal 2007, 95: 433-437. [PMID: by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/18086299)Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing predicting clinical benefit in breast cancer from microtubule-targeting agents Annals Of Hess KR. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer Clinical Cancer Research 2007, 13: 6080-6086. [PMID: 17947471](https://pubmed.ncbi.nlm.nih.gov/17947471), [DOI: 10.1158/1078-0432.ccr-07-0809](https://doi.org/10.1158/1078-0432.ccr-07-0809). - Pusztai L. Limitations pharmacogenomic predictor discovery in Phase II trials Pharmacogenomics 2007, microarrays provide new prognostic 2007, Boulet T, Aziz M, Yuan LX, S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy Journal Of Clinical DCIS of the Breast: A Look towards Discovery and Advancements in the Field Annals Of Surgical Cancer Burden after Preoperative Chemotherapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17634532)Peintinger F, Anderson K, Mazouni C, L. Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer Clinical Cancer [PMID: 17634532](https://pubmed.ncbi.nlm.nih.gov/17634532), [DOI: 10.1158/1078-0432.ccr-06-2600](https://doi.org/10.1158/1078-0432.ccr-06-2600). [Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome](http://www.ncbi.nlm.nih.gov/pubmed/17602071)Mazouni C, Peintinger F, Wan-Kau S, Andre F, V, Hortobagyi GN, Pusztai L. Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome Journal Of Oncology 2007, 25: 2650-2655. [PMID: 17602071](https://pubmed.ncbi.nlm.nih.gov/17602071), status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab](https://doi.org/10.1200/jco.2007.25.18_suppl.533)Peintinger F, Buzdar A, Kuerer H, Gonzalez-Angulo A, Hatzis L, Esteva F, Green M, Hortobagyi G, Symmans W. The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab Journal Of Clinical Oncology 2007, 25: 533-533. [DOI: 10.1200/jco.2007.25.18_suppl.533](https://doi.org/10.1200/jco.2007.25.18_suppl.533). [Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer](https://doi.org/10.1200/jco.2007.25.18_suppl.10519)Liedtke C, Mazouni C, Hess K, Tordai A, Andr\u00e9 F, Symmans W, Gonzalez-Angulo A, Green M, Hortobagyi G, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer Journal Of Clinical Oncology 2007, 25: 10519-10519. [DOI: 10.1200/jco.2007.25.18_suppl.10519](https://doi.org/10.1200/jco.2007.25.18_suppl.10519). [Gene response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients](https://doi.org/10.1200/jco.2007.25.18_suppl.10564)Desmedt C, Andr\u00e9 F, Azambuja E, Haibe-Kains B, Larsimont D, V, Di Leo A, Piccart M, Pusztai L, Sotiriou C. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients Journal Of Clinical Oncology 2007, 25: 10564-10564. [DOI: 10.1200/jco.2007.25.18_suppl.10564](https://doi.org/10.1200/jco.2007.25.18_suppl.10564). [Identification of paclitaxel activity in ER-negative breast cancer patients](https://doi.org/10.1200/jco.2007.25.18_suppl.2525)Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans W, Zerba K, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients Clinical Oncology 2007, 25: 2525-2525. [DOI: 10.1200/jco.2007.25.18_suppl.2525](https://doi.org/10.1200/jco.2007.25.18_suppl.2525). [Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy](https://doi.org/10.1200/jco.2007.25.18_suppl.530)Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy Journal Of Clinical Oncology 2007, 25: 530-530. [DOI: 10.1200/jco.2007.25.18_suppl.530](https://doi.org/10.1200/jco.2007.25.18_suppl.530). [Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials](https://doi.org/10.1200/jco.2007.25.18_suppl.537)Andre F, Broglio K, Roche H, Martin M, Penault-Lorca F, Hortobagyi G, Berry D, Pusztai L. Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials Journal Of Clinical Oncology 2007, 25: doxorubicin chemotherapy in F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in 25: 548-548. [DOI: chemotherapy-induced neutropenic fever in breast cancer patients](https://doi.org/10.1200/jco.2007.25.18_suppl.574)Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer Clinical Oncology 2007, 25: 574-574. [DOI: 10.1200/jco.2007.25.18_suppl.574](https://doi.org/10.1200/jco.2007.25.18_suppl.574). [Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes](https://doi.org/10.1200/jco.2007.25.18_suppl.586)Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes Journal Of Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes Clinical Cancer Research 2007, 13: 2831-2835. [PMID: 17504980](https://pubmed.ncbi.nlm.nih.gov/17504980), efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Research 108: Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17404087)Andre F, Hatzis C, Anderson K, Sotiriou Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer Cancer S. New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer Seminars In 34: s10-s16. [PMID: The use of microarray technology in the management of breast cancer. Clinical Advances In Hematology And Oncology 2007, 5: 193-4, 197. [PMID: 17519880](https://pubmed.ncbi.nlm.nih.gov/17519880). of breast carcinoma: a gene-expression profiling study](http://www.ncbi.nlm.nih.gov/pubmed/17329190)Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, ERBB2 status of breast carcinoma: a gene-expression [PMID: 17329190](https://pubmed.ncbi.nlm.nih.gov/17329190), [DOI: 10.1016/s1470-2045(07)70042-6](https://doi.org/10.1016/s1470-2045(07)70042-6). Saad E, Porter P, Pusztai L. P135 Primary systemic therapy of invasive lobular cancer: Is there a role for chemotherapy? s51-s52. pathologic complete response rate in estrogen receptor-positive breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/17293601)Mazouni C, Kau S, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive patients with HER2positive primary breast cancer after initiation of primary chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/17149760)Mazouni C, Hall A, Broglio K, Fritsche H, Andre HER2/neu changes in patients with HER2positive primary breast cancer after initiation of primary chemotherapy Cancer 2007, 109: 496-501. [PMID: 17149760](https://pubmed.ncbi.nlm.nih.gov/17149760), expression-based predictors of response to preoperative chemotherapy Breast Cancer Research 2007, 9: s5. [DOI: 10.1186/bcr1688](https://doi.org/10.1186/bcr1688). - Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast The Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen](http://www.ncbi.nlm.nih.gov/pubmed/17200359)Buzdar AU, Valero V, Ibrahim NK, Francis Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen Clinical Cancer Research 2007, 13: 228-233. [PMID: 17200359](https://pubmed.ncbi.nlm.nih.gov/17200359), [DOI: 10.1158/1078-0432.ccr-06-1345](https://doi.org/10.1158/1078-0432.ccr-06-1345). - Ross Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer 2007, 269-278. [DOI: 10.1007/978-0-387-33227-7_24](https://doi.org/10.1007/978-0-387-33227-7_24). - Symmans W, Pusztai L. Chapter 1 Selection of patients for endocrine therapies 2007 [DOI: 10.1093/med/9780199218141.003.0001](https://doi.org/10.1093/med/9780199218141.003.0001). - Pusztai L. Chips to Bedside: Incorporation of Microarray Data into Clinical Practice Clinical Cancer Research 2006, [PMID: Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy Nature Reviews Clinical Oncology 2006, 3: Personalized medicine for breast cancer: moving forward and going back Personalized Medicine 2006, 3: [PMID: 29788594](https://pubmed.ncbi.nlm.nih.gov/29788594), [DOI: 10.2217/17410541.3.4.363](https://doi.org/10.2217/17410541.3.4.363). [Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16948128)Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer Cancer 2006, [DOI: 10.1002/cncr.22177](https://doi.org/10.1002/cncr.22177). Wu Y, Symmans WF. Molecular Classification of Breast Cancer: Limitations intraplatform reproducibility of gene expression measurements.](http://www.ncbi.nlm.nih.gov/pubmed/16964229)Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies TS, G, Deng Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y, Slikker W. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16926572)Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt I, Lucci Kuerer HM. Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer Annals Of Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16906452)Andre F, Pusztai L. Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy Pharmaceutical Research 2006, adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design](http://www.ncbi.nlm.nih.gov/pubmed/16962247)Andre F, Mazouni C, Hortobagyi GN, Pusztai L. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16896004)Hess KR, Anderson K, Symmans WF, Valero Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer Valero V, Hennessy B, Green M, Singletary E, Hortobagyi G, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy Journal Of Clinical Oncology 2006, 24: 536-536. 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.10000)Pusztai L, Hess K, Anderson K, Valero V, Ibrahim N, Mejia J, Vidaurre T, Gomez H, Hortobagyi G, Symmans W. Pharmacogenomic predictor complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in Clinical Oncology 2006, 24: 10000-10000. [DOI: 10.1200/jco.2006.24.18_suppl.10000](https://doi.org/10.1200/jco.2006.24.18_suppl.10000). - Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. [DOI: 10.1200/jco.2006.24.18_suppl.10541](https://doi.org/10.1200/jco.2006.24.18_suppl.10541). [Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)](https://doi.org/10.1200/jco.2006.24.18_suppl.10576)Green M, Pusztai L, Theriault M, Mita A, Bindra N, Hortobagyi G. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC) Journal Of Clinical Oncology 2006, 24: 10576-10576. [DOI: (TX/FEC) chemotherapy for breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.10595)Holmes J, Vukelja E, Lin F, Symmans W, Pusztai L. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer 24: 10595-10595. [DOI: 10.1200/jco.2006.24.18_suppl.10595](https://doi.org/10.1200/jco.2006.24.18_suppl.10595). [Pharmacogenomic Mejia J, Altundag K, Buzdar A, Hortobagyi G, Symmans W, Pusztai L. Pharmacogenomic analysis of HER2 and [RefSeq Refinements of UniGene-Based Gene Matching the Correlation of Expression Measurements Between Two Microarray Platforms](http://www.ncbi.nlm.nih.gov/pubmed/16722773)Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq Refinements of UniGene-Based Gene Matching Improve the Correlation of Expression Measurements Between Two Microarray Platforms Applied Bioinformatics 2006, 5: 89-98. M, Tirrell S, Courtemanche J, Wang Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of Gene Expression Signature-Based Predictions in Replicate Experiments Clinical new staging classification: is it useful for S CH, Gonzalez-Angulo AM, Reuben JM, Booser breast cancer: pharmacodynamics, biological effects, and prediction of clinical 2006, 17: 813-817. Therapy in HER-2-Positive Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16619408)Pusztai L, Esteva FJ. Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in TA, Sahin A, Hunt KK, MericBernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative highrisk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breastconserving with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human M, Sahin AA. The Nuclear Transcription Factor B/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer Clinical Cancer Research and Clinical Biomarkers in Drug Discovery and Development American Journal Of Clinical cancers associated with immature cell type and short duration of prior breastfeeding](http://www.ncbi.nlm.nih.gov/pubmed/16322343)Symmans W, Fiterman D, Anderson S, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross J, Wagner P, Theriault R, Arun B, Kuerer H, Hess K, Zhang W, Hortobagyi G, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding Endocrine Survival After Preoperative Chemotherapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16293864)Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre M, Mathieu MC, Symmans D, V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer Journal HER2-positive breast cancer: the molecular rationale. Oncology 2005, 19: 4. [PMID: 19364050](https://pubmed.ncbi.nlm.nih.gov/19364050). - Esteva FJ, Pusztai L. Optimizing outcomes in Oncology Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16145055)Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer Journal Of Clinical Oncology 2005, 23: 7265-7277. [PMID: 16145055](https://pubmed.ncbi.nlm.nih.gov/16145055), [DOI: 10.1200/jco.2005.02.0818](https://doi.org/10.1200/jco.2005.02.0818). [Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicinbased neoadjuvant chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/15981280)Buchholz TA, Tu X, Ang KK, Esteva GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicinbased neoadjuvant inhibitor, in patients with chemotherapyresistant, advanced breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15986399)Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective Pglycoprotein inhibitor, in patients with chemotherapyresistant, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Clinical in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks](http://www.ncbi.nlm.nih.gov/pubmed/16087943)Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks Journal Of 5983-5992. [PMID: 16087943](https://pubmed.ncbi.nlm.nih.gov/16087943), cDNA Arrays and J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross G, Hortobagyi GN, Symmans W, Pusztai of Array-Based Multigene Classifiers across cDNA Arrays Mediator of Paclitaxel Sensitivity In Vitro and In Vivo](http://www.ncbi.nlm.nih.gov/pubmed/16103753)Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo Cell Cycle 2005, 1149-1152. [PMID: 16103753](https://pubmed.ncbi.nlm.nih.gov/16103753), [DOI: 10.4161/cc.4.9.2038](https://doi.org/10.4161/cc.4.9.2038). - Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. [PMID: 16166938](https://pubmed.ncbi.nlm.nih.gov/16166938). [Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial](https://doi.org/10.1200/jco.2005.23.16_suppl.623)Rouzier R, Andre F, Arriagada Pusztai M, Marsiglia H, Dunant A, Hortobagyi G, Delaloge S. Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial Journal Of Clinical Garbay J, Spielmann M, Mathieu M, Valero V, Hortobagyi G. Predictive and prognostic nomograms for breast cancer treated with primary chemotherapy (PC) Journal Of Clinical Oncology 2005, 23: 599-599. [DOI: 10.1200/jco.2005.23.16_suppl.599](https://doi.org/10.1200/jco.2005.23.16_suppl.599). - Symmans W, Sotiriou C, Anderson K, Valero V, Booser D, Hess K, Ross J, Piccart M, Hortobagyi G, Pusztai L. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer Journal Of Clinical Oncology 2005, 23: 546-546. [DOI: 10.1200/jco.2005.23.16_suppl.546](https://doi.org/10.1200/jco.2005.23.16_suppl.546). - Pusztai L. Gene expression profile-based predictors of response to chemotherapy Cancer [PMCID: PMC4231888](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231888), [DOI: P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, A marker of paclitaxel sensitivity in breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer Breast Cancer 2005, 12: 73-85. [DOI: 10.1007/bf02966817](https://doi.org/10.1007/bf02966817). - Pusztai L. The Role of Receptor in Breast Cancer 2005 [DOI: 10.21236/ada436919](https://doi.org/10.21236/ada436919). [Oncogenomics 2005--Dissecting Cancer through Genome Research. Diego, CA, USA.](http://www.ncbi.nlm.nih.gov/pubmed/15772892)Pusztai L. Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 8: 215-8. [PMID: 15772892](https://pubmed.ncbi.nlm.nih.gov/15772892). [Significantly Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15738535)Buzdar AU, Ibrahim NK, Francis D, Booser Thomas KK, Singletary SE, AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer Journal Morandi P, Pusztai L. Gene expression profiling of primary breast cancer Current Oncology Reports 2005, of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. 2005, 12: 15858436](https://pubmed.ncbi.nlm.nih.gov/15858436), [DOI: 10.1007/bf02966817](https://doi.org/10.1007/bf02966817). [Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry](http://www.ncbi.nlm.nih.gov/pubmed/15692757)Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry Breast Cancer Research And Treatment Albarracin C, Sahin A, Wagner P, Yang Y, Smith T, Meric-Bernstam F, Aldaz C, Hortobagyi G, Pusztai L. Expression of sigma 1 receptor in human breast cancer Breast Cancer Research And Treatment 2005, 89: 95-95. [DOI: 10.1007/s10549-004-8255-4](https://doi.org/10.1007/s10549-004-8255-4). - Pusztai L, Rouzier R, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Clinical trial design for microarray predictive marker discovery and assessment Annals to preoperative chemotherapy in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16264799)Pusztai L, Gianni L. Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer Nature Reviews Clinical Oncology 2004, L, Hortobagyi GN. Targeted Therapies for Cancer 2004 American Journal Of Clinical Pathology 2004, 122: 598-609. [PMID: 15487459](https://pubmed.ncbi.nlm.nih.gov/15487459), van De Vijver M. Improving patient care through molecular diagnostics Seminars In Oncology 2004, 31: 14-20. Albarracin C, Sahin A, Wagner P, Yang Y, Smith T, Bernstam F, Marcelo A, Hortobagyi G, Pusztai L. Expression of sigma 1 receptor in human breast cancer Breast Cancer Research And Treatment 2004, 87: 205-214. [PMID: 15528963](https://pubmed.ncbi.nlm.nih.gov/15528963), [DOI: 10.1007/s10549-004-6590-0](https://doi.org/10.1007/s10549-004-6590-0). [Her2/neu-positive disease does not of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy](http://www.ncbi.nlm.nih.gov/pubmed/15275718)Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy International Journal Of response to preoperative taxanes in patients with breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15241821)GonzalezAngulo A, Krishnamurthy between amplification of her2 and response to preoperative taxanes in patients samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer](https://doi.org/10.1200/jco.2004.22.14_suppl.2109)Pusztai L, Gregory B, Baggerly K, Esteva F, Laronga C, Gabriel H, Semmes O, Wright G, Richard D, Vlahou A. Pharmacoproteomic analysis of pre-and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer Journal Of Clinical Oncology 2004, 22: 2109-2109. Pusztai L, Walters R, Hortobagyi G, Reuben J, Esseltine D, Wright J. A phase II trial of PS-341 in metastatic breast cancer (MBC) response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips](https://doi.org/10.1200/jco.2004.22.14_suppl.503)Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer](https://doi.org/10.1200/jco.2004.22.90140.2109)Pusztai L, Gregory B, Baggerly K, Esteva F, Laronga C, Gabriel H, Semmes O, Wright G, Richard D, Vlahou A. Pharmacoproteomic analysis of pre-and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer Journal Of Clinical Oncology 2004, 22: 2109-2109. Pusztai L, Walters R, Hortobagyi G, Reuben J, Esseltine D, Wright J. A phase II trial of PS-341 in metastatic breast cancer (MBC) response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips](https://doi.org/10.1200/jco.2004.22.90140.503)Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays [DOI: - Pusztai L. Perspectives and challenges cancer Pharmacogenomics 2004, 10.1097/01.pap.0000131825.77317.ee](https://doi.org/10.1097/01.pap.0000131825.77317.ee). - Whitman G, Iyer R, Reeve C, Patel P, Phelps M, Pusztai L. Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer: Imaging Considerations Seminars In Breast Disease 2004, 7: 61-74. [DOI: 10.1053/j.sembd.2005.01.005](https://doi.org/10.1053/j.sembd.2005.01.005). [Gene Expression Profiles Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15136595)Ayers M, Symmans W, Stec J, Damokosh A, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi G, Pusztai L. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15112261)Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma Cancer 2004, [PMID: 15112261](https://pubmed.ncbi.nlm.nih.gov/15112261), [DOI: breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response](http://www.ncbi.nlm.nih.gov/pubmed/15042669)Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, GalGombos E, Whitman G, H, AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response Cancer 2004, 100: 1365-1373. [PMID: 15042669](https://pubmed.ncbi.nlm.nih.gov/15042669), [DOI: 10.1002/cncr.20134](https://doi.org/10.1002/cncr.20134). - Pusztai L. The of Sigma Receptor in Breast Cancer 2004 [DOI: 10.21236/ada425685](https://doi.org/10.21236/ada425685). - Ross JS, Linette GP, Stec WF, GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II Expert Review Of Molecular Diagnostics 2004, 4: 169-188. [PMID: 14995904](https://pubmed.ncbi.nlm.nih.gov/14995904), [DOI: 10.1586/14737159.4.2.169](https://doi.org/10.1586/14737159.4.2.169). agent taxanes and HER-2 gene amplification in patients with breast carcinoma](https://doi.org/10.1016/s1359-6349(04)90651-9)Gonzalez-Angulo A, Krishnamurthy S, Yamamura Y, Pusztai L, Buzdar A, Hortobagyi G, Esteva F. Correlation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma European Journal Of Cancer Supplements 2004, 2: 70. [DOI: 10.1016/s1359-6349(04)90651-9](https://doi.org/10.1016/s1359-6349(04)90651-9). - Ross JS, Fletcher Pusztai Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein Molecular & Cellular Proteomics 2004, [PMID: J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/14745865)Esteva FJ, Sahin AA, Smith TL, Yang and HER2 and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15199607)Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva M, Breitenfelder P, RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer Cancer Investigation 2004, 22: 248-256. [PMID: 15199607](https://pubmed.ncbi.nlm.nih.gov/15199607), Stec J, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of 2003, 120 Suppl: s53-71. [PMID: 15298144](https://pubmed.ncbi.nlm.nih.gov/15298144), [DOI: 10.1309/949fpq1aq3p0rlc0](https://doi.org/10.1309/949fpq1aq3p0rlc0). [Jun activation domain binding 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/14654548)Esteva FJ, Sahin M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. [PMID: 14654548](https://pubmed.ncbi.nlm.nih.gov/14654548). [Her2-Neu overexpression does not increase the of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation](https://doi.org/10.1016/s0360-3016(03)01004-6)Buchholz T, Huang E, Berry D, Strom E, McNeese M, Pusztai L, Kuerer H, Buzdar A, Hortobagyi G, Valero V, Perkins G, Sahin A. Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation International Journal Of Radiation Oncology Biology Physics 2003, 57: s201. [DOI: 10.1016/s0360-3016(03)01004-6](https://doi.org/10.1016/s0360-3016(03)01004-6). [Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12972520)Pusztai L, Zhen JH, Arun B, Rivera E, A, Symmans WF, V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. Journal WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine Expert Review Of Molecular Diagnostics 2003, 3: 573-585. [PMID: with gemcitabine in patients with metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12947059)Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Journal J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of obtained fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.](http://www.ncbi.nlm.nih.gov/pubmed/12855612)Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical Cancer Research 2003, 9: 2406-15. Pusztai L, from fineneedle aspiration biopsy and coreneedle biopsy samples of breast Stec J, Hess Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fineneedle aspiration biopsy and coreneedle biopsy samples chemotherapy with 5fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/12655533)Zhang F, Yang Y, Smith T, Kau response to neoadjuvant chemotherapy with 5fluorouracil, doxorubicin, and cyclophosphamide in patients profiles of invasive mucinous and ductal carcinomas of the breast a molecular case Cancer Genetics 2003, 141: 148-153. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse Breast Cancer Research And Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/12602766)Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy The Cancer Journal 2003, 9: 33-41. J, Ayers M, Clark E, Meric F, Stivers D, Hess K. Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer 2003, 257-275. [DOI: 10.1007/0-306-47825-0_15](https://doi.org/10.1007/0-306-47825-0_15). - Buchholz TA, Stivers DN, Stec A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, GN, Pusztai L. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer The Cancer Journal 2002, 461-468. J, Ayers M, Brown J, Pusztai L. Global Gene Expression Changes during Neoadjuvant Chemotherapy of Human Breast Cancer The Cancer Journal 2002, 8: 488. [DOI: 10.1097/00130404-200211000-00026](https://doi.org/10.1097/00130404-200211000-00026). [Phase II Study of Weekly Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/11919237)Esteva Valero Booser N, TL, GN. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast L, Hortobagyi G. Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance Breast 2001, 10: 492-500. [PMID: 14965629](https://pubmed.ncbi.nlm.nih.gov/14965629), [DOI: 10.1054/brst.2001.0310](https://doi.org/10.1054/brst.2001.0310). [Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11839324)Kuerer H, Singletary S, Buzdar A, Ames F, Valero V, Buchholz T, Ross M, Pusztai L, Hortobagyi G, Hunt K. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma The American Journal Of Surgery 2001, 182: breast cancer using quantitative immunohistochemistry](http://www.ncbi.nlm.nih.gov/pubmed/11692142)Esteva F, Hortobagyi G, Sahin A, Smith T, Chin D, Liang S, Pusztai L, Buzdar A, Bacus S. Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry breast cancer (IBC)](https://doi.org/10.1016/s0959-8049(01)81123-0)Cristofanilli M, Fratarcangeli T, Esteva F, Rosales M, Booser D, Ibrahim N, Pusztai L, Bast R, Rivera E, Hortobagyi G. Weekly high-dose paclitaxel(HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) European Journal Of Cancer 2001, 37: s173. [DOI: 10.1016/s0959-8049(01)81123-0](https://doi.org/10.1016/s0959-8049(01)81123-0). - Esteva Buzdar A, Hortobagyi G. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and 6: 133-146. cancer (MBC)](https://doi.org/10.1016/s0959-8049(01)81198-9)Esteva F, Valero Guerra L, Murray J, Pusztai L, Cristofanilli M, Sneige N, Smith T, Hortobagyi G. Phase II study of weekly docetaxel (Taxotere; txt) (HER2+) metastatic 37: s193. [DOI: 10.1016/s0959-8049(01)81198-9](https://doi.org/10.1016/s0959-8049(01)81198-9). [Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/11693900)Buchholz T, Hill B, Tucker S, Frye Kuerer Buzdar A, McNeese M, Singletary S, Ueno N, Pusztai L, Valero V, Hortobagyi G. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. The pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/10778954)Madden T, Tran H, Beck D, Huie R, Newman R, Pusztai L, Wright J, Abbruzzese J. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research 2000, 6: 1293-301. [PMID: 10778954](https://pubmed.ncbi.nlm.nih.gov/10778954). - Pusztai Hung M, Hortobagyi G. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer Cancer Treatment Reviews 1999, 25: extracellular domain of cerbB2 (HER2/neu) gene product p185](http://www.ncbi.nlm.nih.gov/pubmed/10404066)Boyer C, Pusztai L, Wiener J, Xu F, Dean G, Bast B, O'Briant K, Greenwald M, DeSombre K, Bast R. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the cerbB2 (HER2/neu) gene product p185 10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j](https://doi.org/10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j). chemotherapy in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/10472774)Pusztai L, Asmar L, Smith T, Hortobagyi G. Relapse after complete response to anthracyclinebased combination chemotherapy in metastatic breast cancer Breast Cancer Research Treatment 1999, 55: [PMID: infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy](http://www.ncbi.nlm.nih.gov/pubmed/9923546)Pusztai L, Holmes F, Fraschini G, Hortobagyi G. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy Cancer Chemotherapy And 1999, breast cancer The Lancet 1998, 352: 1552. [DOI: 10.1016/s0140-6736(05)60360-1](https://doi.org/10.1016/s0140-6736(05)60360-1). - Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer American susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/9796989)Dean G, Pusztai L, Xu F, O'Briant K, DeSombre K, Conaway M, Boyer C, Mendelsohn J, Bast R. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clinical Cancer Research 1998, 4: 2545-50. [PMID: 9796989](https://pubmed.ncbi.nlm.nih.gov/9796989). - Pusztai L, Hortobagyi G. Discouraging news for high-dose chemotherapy in high-risk breast cancer The Lancet 1998, [PMID: and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues](http://www.ncbi.nlm.nih.gov/pubmed/9790065)Bast R, Pusztai L, Kerns B, MacDonald J, Jordan P, Daly L, Boyer C, Mendelsohn J, Berchuck A. Coexpression of the HER-2 Gene Product, pl85HER-2, and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues Monoclonal Antibodies how resistant is breast 1: 62-72. [PMID: [COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE](http://www.ncbi.nlm.nih.gov/pubmed/9474132)ANDERSON C, PUSZTAI L, PALMER J, CABANILLAS F, ELLERHORST J. COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE Investigative Urology 1998, 159: 714-717. [PMID: 9474132](https://pubmed.ncbi.nlm.nih.gov/9474132), PALMER J, CABANILLAS F, ELLERHORST J. COINCIDENT RENAL CELL CARCINOMA Drug in Carcinoma: A Hypothesis Based on a Clonal Progression Model](http://www.ncbi.nlm.nih.gov/pubmed/10050979)Pusztai L, Siddik Z, Mills G, Bast R. Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Breast Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, CT 06511 Biography Lajos Pusztai, MD, DPhil, is a medical oncologist who specializes in breast cancer. He is the co-director of the Genomics, Genetics, and Epigenetics Program at the Yale Cancer Center. He says he enjoys the delicate work of helping patients overcome the fear and shock of a breast cancer diagnosis. \"I ensure that they maximize their chance of cure through the best available treatments,\" he says. \"I also love the research component of my job, to push the boundaries of existing knowledge and developing new therapies.\" Dr. Pusztai says he gravitated to medical oncology at the beginning of his career because of an inspiring mentor, and that the best part of his job is seeing patients remain disease-free for years and continuing with their life. He is chair of the Breast Cancer Research Committee of the South West Oncology Group (SWOG), a global cancer research community that designs and conducts publicly funded clinical trials. His research group has made important contributions to establish that estrogen receptor-positive and-negative breast cancers have fundamentally different molecular, clinical, and epidemiological characteristics. He has been a pioneer in evaluating gene expression profiling as a diagnostic technology to predict chemotherapy and endocrine therapy sensitivity and has shown that different biological processes are involved in determining the prognosis and treatment response in different breast cancer subtypes. Dr. Pusztai is also the principal investigator of several clinical trials investigating new drugs, including immunotherapies for breast cancer. Titles - Professor of Medicine (Medical Oncology) - Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center Education & Training - FellowUniversity of Texas MD Anderson Cancer Center (1999) - ResidencyUniversity of Rochester St. Mary's Hospital (1996) - InternUniversity of Rochester St. Mary's Hospital (1994) - DPhilUniversity of Oxford (1993) - MDSemmelweis University School of Medicine (1987) Languages Spoken - English - Magyar (Hungarian) Additional Information - Clinical Science Research Prize: Yale Cancer Center (2022) - Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, Liu J, Frank M, McCabe T, Higgins-Chen A, Hofstatter E, Pusztai L, Beckman K, Gerstein M, Levine M. More than bad luck: Cancer and aging are linked to replication-driven changes to the epigenome in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.](http://www.ncbi.nlm.nih.gov/pubmed/37433103)Litton J, Regan M, Pusztai Rugo H, Tolaney Garrett-Mayer E, Amiri-Kordestani L, Basho R, Best A, Boileau J, Denkert C, Foster J, Harbeck N, Jacene H, King T, Mason G, O'Sullivan C, Prowell T, Richardson A, Sepulveda K, Smith M, Tjoe J, Turashvili G, Woodward W, Butler L, Schwartz E, Korde L. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. [Radiotherapy Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial](http://www.ncbi.nlm.nih.gov/pubmed/37410451)Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein S, Zeidan P, Pusztai L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the with the Rest](http://www.ncbi.nlm.nih.gov/pubmed/37400619)Kim L, Coman M, Pusztai L, Park T. ASO Visual Abstract: Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancers\u2014Catching up with 2023, [PMID: 37400619](https://pubmed.ncbi.nlm.nih.gov/37400619), [DOI: 10.1245/s10434-023-13842-4](https://doi.org/10.1245/s10434-023-13842-4). [Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37391697)Foldi J, Tsagianni A, M, C, Brufsky A, van Londen G, Pusztai L, Sanft T. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer early-stage cancer](http://www.ncbi.nlm.nih.gov/pubmed/37378695)Kahn R, M, spatial in programmed death-ligand 1 (PD-L1) protein expression in early-stage breast cancer Breast Cancer Research Treatment 2023, 1-10. [PMID: 37378695](https://pubmed.ncbi.nlm.nih.gov/37378695), [DOI: 10.1007/s10549-023-06977-1](https://doi.org/10.1007/s10549-023-06977-1). [Incorporating clinicopathological and molecular risk tools to improve outcomes in early HR+/HER2- breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37380659)Curigliano G, Dent R, Llombart-Cussac A, Pegram M, Pusztai L, Turner N, Viale G. Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer Npj Breast T. Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest Annals Of Oncology 2023, 1-9. [PMID: 37349612](https://pubmed.ncbi.nlm.nih.gov/37349612), [DOI: 10.1245/s10434-023-13714-x](https://doi.org/10.1245/s10434-023-13714-x). - Pusztai L. Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look? Journal [Oncotype recommendations for early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/37291235)Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Bianchini G. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer Npj Kumar Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic Clinical 2023, I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. [DOI: 10.1200/jco.2023.41.16_suppl.e18855](https://doi.org/10.1200/jco.2023.41.16_suppl.e18855). [Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history.](https://doi.org/10.1200/jco.2023.41.16_suppl.576)Rozenblit M, Suwalska A, Hofstatter E, Reisenbichler E, M, Pusztai L. Somatic mutations in tumor-adjacent normal breast tissue in young women with high risk family history. Journal Of Clinical Oncology 2023, 41: 576-576. [DOI: 10.1200/jco.2023.41.16_suppl.576](https://doi.org/10.1200/jco.2023.41.16_suppl.576). [Biomarkers the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).](https://doi.org/10.1200/jco.2023.41.16_suppl.102)Wolf D, Yau C, Campbell M, Glas A, Mittempergher L, Kuilman M, Barcaru A, Brown Swigart Nanda Chien Pusztai Stringer-Reasor E, Shatsky R, Isaacs C, Perlmutter J, DeMichele A, Yee D, Esserman L, van 't Veer L. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS). Journal Of 2023, 41: 102-102. thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.](https://doi.org/10.1200/jco.2023.41.16_suppl.1076)Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in 1076-1076. Rugo Pohlmann P, Pusztai L, Symmans W, Borowsky A, Finestone S, Yee D, Hylton N, van 't Veer L, Esserman L, DeMichele A. Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. Journal Of Clinical Oncology 2023, 41: 514-514. [DOI: 10.1200/jco.2023.41.16_suppl.514](https://doi.org/10.1200/jco.2023.41.16_suppl.514). [MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST.](https://doi.org/10.1200/jco.2023.41.16_suppl.521)Beitsch P, Pellicane J, Pusztai L, Baron P, Cobain E, Murray M, Ashikari A, Kelemen P, Mislowsky A, Barone J, Cowan K, Layeequr Rahman R, Dooley W, Menicucci A, Finn C, Audeh M, Whitworth P. MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Journal Of Clinical signature and landscape tumors from 896 patients with early-stage breast cancer (BC).](https://doi.org/10.1200/jco.2023.41.16_suppl.539)Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Oxnard G, Huang R, Pusztai L. HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC). Journal Of Clinical Oncology [DOI: 10.1200/jco.2023.41.16_suppl.539](https://doi.org/10.1200/jco.2023.41.16_suppl.539). complete response in SWOG S0800 neoadjuvant chemotherapy trial](http://www.ncbi.nlm.nih.gov/pubmed/37179362)Fanucci Y, Pelekanou Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Liu Y, Wang L, Wei W, Pusztai L, Blenman K. Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy](https://doi.org/10.1016/s0960-9776(23)00137-6)Bardia A, Pusztai L, Albain K, Kalinsky W, Tokunaga E, Ciruelos E, Loirat D, Isaacs C, Testa L, Dry H, Kozarski R, (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant s23. [DOI: 10.1016/s0960-9776(23)00137-6](https://doi.org/10.1016/s0960-9776(23)00137-6). [P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study](https://doi.org/10.1016/s0960-9776(23)00242-4)K\u00fcmmel S, Schmid P, Harbeck N, Takahashi M, Untch Boileau J, Cortes J, McArthur H, Dent R, O'Shaughnessy J, Pusztai L, Foukakis T, Park Y, Hui R, Cardoso F, Denkert C, Zhu Y, Pan W, Karantza V, Fasching P. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study The Breast 2023, 68: s63-s64. [DOI: 10.1016/s0960-9776(23)00242-4](https://doi.org/10.1016/s0960-9776(23)00242-4). [Response to Neoadjuvant Therapy and in Patients With Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/36989609)Liedtke C, Mazouni C, Hess K, Andr\u00e9 F, Tordai A, Mejia J, Symmans W, Gonzalez-Angulo A, Hennessy B, Green M, Cristofanilli M, Hortobagyi G, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal Of early-stage breast cancer (DESTINY-Breast11)](https://doi.org/10.1016/s0960-9776(23)00228-x)Harbeck N, Boileau J, Modi S, Kelly C, Ohno S, Wu J, Konpa A, Herbolsheimer P, Safdar S, Zhang Y, Pusztai L. 10.1016/s0960-9776(23)00228-x](https://doi.org/10.1016/s0960-9776(23)00228-x). [BPI23-012: Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 Therapy Related Cardiac Events in HER2+ Breast Cancer Patients](https://doi.org/10.6004/jnccn.2022.7224)Hood A, Mukallari B, Majeski J, Pusztai L, Adelson K, Amin K. BPI23-012: Real-World Frequency of ECHO Monitoring and Incidence of Anti-HER2 Therapy Related Cardiac Events in HER2+ Breast Cancer Patients Journal Of The National Comprehensive Cancer Network 2023, 21: bpi23-012. [DOI: 10.6004/jnccn.2022.7224](https://doi.org/10.6004/jnccn.2022.7224). [Variable Landscape of PD-L1 Expression as Detected by the DAKO 22C3 Immunohistochemistry Assay](http://www.ncbi.nlm.nih.gov/pubmed/36866462)Danziger N, Sokol E, Graf Maule J, Parimi V, Palmieri C, Pusztai L, Ross J, Huang R. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the (MBC)](https://doi.org/10.1158/1538-7445.sabcs22-p2-23-09)Fanucci K, lustberg M, Fischbach M, Sivapiragasam M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Research 2023, 83: p2-23-09-p2-23-09. from placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: S1207](https://doi.org/10.1158/1538-7445.sabcs22-gs1-07)Chavez J, Wendt A, Carney J, Sharma P, Gralow J, Lew D, Barlow W, Hortobagyi G. Abstract GS1-07: Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative immune response Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-12)Blenman K, Marczyk M, Foldi J, Gunasekharan V, Silber A, Pusztai L. Abstract P1-04-12: Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC Cancer Research 2023, 83: p1-04-12-p1-04-12. [DOI: 10.1158/1538-7445.sabcs22-p1-04-12](https://doi.org/10.1158/1538-7445.sabcs22-p1-04-12). Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott A, Shak S, Sharma P, Lew D, Miao J, Unger J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K. Abstract GS1-01: Race and clinical outcomes in the RxPONDER Trial RxPONDER trial (SWOG S1007) by menopausal status](https://doi.org/10.1158/1538-7445.sabcs22-gs1-04)Kang I, Forschmiedt J, Loch M, Barlow W, Lew D, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Rastogi P, Schott A, Shak S, Sharma P, Miao J, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K, Henry N. Abstract GS1-04: Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal [Abstract HER2-19: HER2-19 Impact of status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score </25 randomized +/- G, Kalinsky K. Abstract HER2-19: HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score 25 randomized to endocrine therapy +/- chemotherapy: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study](https://doi.org/10.1158/1538-7445.sabcs22-p2-11-11)Shao D, Barlow W, Li H, Lu C, Albain K, Rae J, Hayes D, Godwin A, Thompson A, Madabhushi A, Pusztai L. Abstract P2-11-11: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814](https://doi.org/10.1158/1538-7445.sabcs22-p2-11-16)Chen Y, Barlow W, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain K, Pusztai L, Rae J, Hayes D, Godwin A, Thompson A, Madabhushi A. Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from characterization carcinoma by quantitative RT-PCR using Oncotype DX\u00ae](https://doi.org/10.1158/1538-7445.sabcs22-p2-23-14)Rozenblit M, Lin H, Can N, Flannery C, Hoag J, Akkunuri A, Bailey H, Baehner F, Pusztai L. Abstract P2-23-14: Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using in the ALTTO and NeoALTTO clinical trials](https://doi.org/10.1158/1538-7445.sabcs22-p4-09-05)Rediti M, Venet D, Garcia A, Agbor-Tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Ueno T, Cosimo S, Piccart S, R, Viale G, Roth\u00e9 F, C. Abstract P4-09-05: Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO 10.1158/1538-7445.sabcs22-p4-09-05](https://doi.org/10.1158/1538-7445.sabcs22-p4-09-05). [Abstract P6-05-06: Patient-reported anxiety in the RxPONDER trial (SWOG S1007) by menopausal status](https://doi.org/10.1158/1538-7445.sabcs22-p6-05-06)Loch M, Forschmiedt J, Kang I, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Rastogi P, Schott A, Shak S, Sharma P, Lew D, Miao J, Barlow W, Tripathy D, Pusztai L, Hortobagyi G, Kalinsky K, Henry N. Abstract P6-05-06: Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal [Abstract PD3-01: Neoadjuvant pembrolizumab placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study](https://doi.org/10.1158/1538-7445.sabcs22-pd3-01)McArthur H, Cort\u00e9s J, Dent R, O'Shaughnessy J, Pusztai L, K\u00fcemmel S, Foukakis T, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Denkert C, Zhu Y, Ding Y, Pan W, Schmid P. Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study Cancer predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents](https://doi.org/10.1158/1538-7445.sabcs22-pd5-04)Wolf D, Yau C, Wulfkuhle J, Gallagher R, Swigart L, Hirst G, Coppe J, Magbanua M, Sayaman R, Investigators I, Sit L, Hylton N, DeMichele A, Berry D, Pusztai L, Yee D, Esserman L, Petricoin E, Van 't Veer L. Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents Cancer Research 2023, 83: pd5-04-pd5-04. [DOI: 10.1158/1538-7445.sabcs22-pd5-04](https://doi.org/10.1158/1538-7445.sabcs22-pd5-04). [Abstract receptor positive/human epidermal growth factor receptor-2 negative Karn Rozenblit M, Foldi Marczyk K, U, Kalinsky K, Meric-Bernstam F, Pusztai L. Abstract PD9-09: Molecular differences between younger versus older estrogen receptor positive/human epidermal growth factor receptor-2 negative onapristone in patients with estrogen receptor-positive, receptor-positive, K, N. OT2-01-04: ELONA: An open-label, phase 1b-2 study of elacestrant, in onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced Research 2023, 83: ot2-01-04-ot2-01-04. [DOI: 10.1158/1538-7445.sabcs22-ot2-01-04](https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-04). - Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)](http://www.ncbi.nlm.nih.gov/pubmed/36647745)Bergqvist M, Nordmark A, Williams A, Paoletti C, Barlow W, Cobain E, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of of breast cancer for whole transcriptome and targeted messenger RNA sequencing](http://www.ncbi.nlm.nih.gov/pubmed/36650408)Marczyk M, Fu C, Lau R, Du L, Trevarton A, Sinn B, Gould R, Pusztai L, Hatzis C, Symmans W. Assessment of stained direct cytology smears of breast cancer for whole transcriptome and targeted Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial](http://www.ncbi.nlm.nih.gov/pubmed/36649570)Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial Cancer risk and aging are linked to replication-driven changes to the epigenome](https://doi.org/10.1158/1538-7445.agca22-pr009)Minteer C, Thrush K, Niimi P, Rozowsky J, Liu J, Frank M, McCabe T, Hofstatter E, Rozenblit M, Pusztai L, Beckman K, Gerstein M, Levine M. Abstract PR009: Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome Circulating Tumor Cells in Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/36634296)Nanou A, Miao J, Coumans F, Dolce E, Darga E, Barlow W, Smerage J, Paoletti C, Godwin A, Pusztai L, Sharma P, Thompson A, Hortobagyi G, Terstappen L, Hayes D. Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast double-blind, Barlow Gralow J, Puhalla S, Anders C, Goldstein L, Tripathy D, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Pusztai L, Hayes D, Hortobagyi G. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer (S1416): randomised, double-blind, and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/36634607)Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn M, L, B, K, Saura Untch M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. Journal Of The National Comprehensive Cancer Network 2023, 21: 33-41.e16. [PMID: 36634607](https://pubmed.ncbi.nlm.nih.gov/36634607), Marczyk M, Shan K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L. Molecular differences between younger versus older ER-positive and HER2-negative breast cancers on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer](https://doi.org/10.1016/j.ijrobp.2022.07.410)Jagsi R, Barlow W, Woodward W, Connolly E, Shumway D, Speers C, Stecklein S, Zhang H, Sharma P, L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer International Journal Of 114: s43. [DOI: 10.1016/j.ijrobp.2022.07.410](https://doi.org/10.1016/j.ijrobp.2022.07.410). and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021](http://www.ncbi.nlm.nih.gov/pubmed/36445704)Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021 JAMA L. Intratumour heterogeneity, from hypothesis to the clinic of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy](http://www.ncbi.nlm.nih.gov/pubmed/36206298)Ibrahim EY, Munshani Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during in the neoadjuvant and post-neoadjuvant breast cancer settings.](http://www.ncbi.nlm.nih.gov/pubmed/36125946)Pusztai L. The effectiveness of immune checkpoint inhibitors in the neoadjuvant and post-neoadjuvant breast cancer settings. Clinical vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522](https://doi.org/10.1016/j.annonc.2022.07.170)Dent H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Haiderali A, Jia L, Nguyen A, Pan W, O'Shaughnessy J, Schmid P. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial](https://doi.org/10.1016/j.annonc.2022.07.174)Rediti M, Venet D, Garcia A, Agbor-tarh D, Maetens M, Vincent D, Majjaj S, El-Abed S, Liu M, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, F, Sotiriou C. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial Reisenbichler E, Singh K, Qing T, Ibrahim E, Ramkissoon S, Asmelash S, Lin HK, Roberts M, Ross J, Huang RSP, Pusztai L. PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer Breast Cancer Research And 196: 221-227. den Heuvel R. Analysis by residual cancer burden further clarifies effect of pembrolizumab 2022 [DOI: 10.55788/70fdb2dd](https://doi.org/10.55788/70fdb2dd). [Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.](http://www.ncbi.nlm.nih.gov/pubmed/35903931)Foldi J, Kahn A, Silber A, Qing T, Reisenbichler Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy and non-African American triple negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/35869114)Marczyk M, Qing T, O'Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer in early TNBC: Asian subgroup](https://doi.org/10.1016/j.annonc.2022.05.066)Takahashi M, Cort\u00e9s J, Dent R, Pusztai L, Mcarthur H, K\u00fcmmel S, Denkert C, Park Y, Im S, Ahn J, Mukai H, Huang C, Chen S, Kim M, Jia L, Li X, Tryfonidis K, Karantza V, Iwata H, Schmid P. PS2-3 Neoadjuvant + chemo, followed by adjuvant pembrolizumab/placebo in subgroup Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. [DOI: 10.1200/jco.2022.40.16_suppl.e18834](https://doi.org/10.1200/jco.2022.40.16_suppl.e18834). [Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.](https://doi.org/10.1200/jco.2022.40.16_suppl.516)Foldi J, Kahn A, Silber A, Qing T, Reisenbichler Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy Pavlick D, Huang R, Pelletier M, Levy M, Pusztai L, Lacy J, Eder J, Zhang J, Ross J. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements.](https://doi.org/10.1200/jco.2022.40.16_suppl.594)Blenman Bai Y, Pelekanou V, Nahleh Z, Shafi S, Burela S, Barlow W, Sharma P, Thompson A, Godwin A, Rimm D, Hortobagyi G, Pusztai L. Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating peripheral neuropathy risk factor in white and black patients in SWOG 0221.](https://doi.org/10.1200/jco.2022.40.16_suppl.12023)Chen C, Zirpoli G, McCann S, Barlow W, Budd G, Pusztai L, Hortobagyi G, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.](https://doi.org/10.1200/jco.2022.40.16_suppl.12084)Lambertini M, Ceppi M, Anderson R, Cameron D, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, L, Mastro L, Partridge A, Saura C, Untch Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the 40: 12084-12084. burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.](https://doi.org/10.1200/jco.2022.40.16_suppl.503)Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kuemmel S, Bergh J, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. by molecular subtype in the I-SPY2 Trial.](https://doi.org/10.1200/jco.2022.40.16_suppl.504)Huppert L, Rugo H, Pusztai L, Mukhtar R, Chien A, Yau C, Wolf D, Berry D, van 't Veer L, Yee D, DeMichele A, Esserman L. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 and maximize response: Predictive biomarkers across 10 cancer therapies](http://www.ncbi.nlm.nih.gov/pubmed/35623341)Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu R, O'Grady N, Basu A, Delson A, JP, Lu R, Braun J, Investigators I, Asare SM, Sit L, Matthews JB, GL, cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 Delaloge S, Harbeck N, Hayes D, Kalinsky K, Pusztai L, Regan M, Sestak I, Spanic T, Sparano J, S, modulation through de-intensification to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials](http://www.ncbi.nlm.nih.gov/pubmed/35513244)Marczyk M, Mrukwa A, Yau C, Wolf D, Chen Y, Balassanian R, Nanda R, Parker B, Krings G, Sattar H, Zeck J, Albain K, Boughey J, Liu M, Elias A, Clark A, Venters S, Shad S, Basu A, Asare A, Rugo H, Perlmutter J, DeMichele A, Yee D, Berry D, Veer L, Symmans W, Esserman L, Pusztai L, Consortium I. Treatment Efficacy Score\u2014continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer HER2-positive breast cancer S, Ciniselli C, de Azambuja E, Venet D, De Cecco L, Pong N, Cappelletti V, Tagliabue E, Wang Y, Manich C, Nuciforo P, Kuemmel S, Pusztai P. 2MO Development of a prognostic gene-expression signature for early stage HER2-positive breast A, Mayer Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: Rozenblit M, Foldi J, Kluger Y, Gerstein M, Pusztai L. Cancer Relevance of Human Genes. Journal Of The National Cancer Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert Sinn M, Foldi J, Rimm DL, Loibl S, Pusztai Predictive Markers Response with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide O, Hanley MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression L, Hern\u00e1ndez-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Pe\u00f1a R, Monta\u00f1\u00e9s DM, Morey L, Voorwerk L, Arribas J, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celi\u00e0-Terrassa T. LCOR mediates tumor immunogenicity and responsiveness to immune-checkpoint blockade 10.1038/s43018-022-00339-4](https://doi.org/10.1038/s43018-022-00339-4). [Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors](http://www.ncbi.nlm.nih.gov/pubmed/35263168)Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Rodriguez A, Billings PR, Grothey A, Taieb J, Cunningham D, Yoshino T, Kopetz S. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Bai Y, Li FY, Rimm DL, Pusztai L, Lu L, Sanft T, Irwin ML. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors Npj Breast Chakraborty R, Lustberg M, Pusztai L, Campbell S, Zhao H, Halene S, Hwa J. MYOCARDIAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) SECRETOMES IN CARDIO-ONCOLOGY PATIENTS Journal Of The American College Of 2022, 1912. [DOI: 10.1016/s0735-1097(22)02903-5](https://doi.org/10.1016/s0735-1097(22)02903-5). Pusztai L. Comprehensive Analysis of aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes](http://www.ncbi.nlm.nih.gov/pubmed/35209953)Rozenblit M, Hofstatter E, Liu Z, O'Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes](https://doi.org/10.1158/1538-7445.sabcs21-p3-07-01)Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. Abstract P3-07-01: Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes Cancer Research 2022, 82: p3-07-01-p3-07-01. [DOI: 10.1158/1538-7445.sabcs21-p3-07-01](https://doi.org/10.1158/1538-7445.sabcs21-p3-07-01). - Fernandez Fadare O, Hanley K, Harigopal J, Kuba M, Ly A, Podoll M, Rabe K, Sanders M, Singh K, Snir O, Soong R, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm D. Abstract P1-02-02: Examination of low Her2 expression in breast tumors](https://doi.org/10.1158/1538-7445.sabcs21-p1-05-02)Foldi J, Reisenbichler E, Pan L, Sorg K, Church S, Pusztai L. Abstract P1-05-02: Intratumor molecular tumor heterogeneity in low [Abstract P2-08-03: PD-L1 protein expression relation to Recurrence Score values in early stage ER+HER2- breast cancer](https://doi.org/10.1158/1538-7445.sabcs21-p2-08-03)Blenman K, Harigopal M, Huang R, Reisenbichler E, Qing T, Ibrahim E, Singh K, Ramkissoon S, Mustimbo R, Ross J, Pusztai L. Abstract P2-08-03: PD-L1 protein expression in relation to Recurrence Score values in early stage ER+HER2- breast cancer for metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs21-p5-08-16)Pusztai L, Danziger N, Sokol E, Pavlick D, Graf R, Ramkissoon S, Huang R, Decker B, Ross J. Abstract P5-08-16: MTAP deletion and synthetic lethality-based drug development for Sehgal R, Shan N, Muthusamy V, Umlau S, Surovtseva P5-17-01: Targeting Acetyl-CoA signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies](https://doi.org/10.1158/1538-7445.sabcs21-pd10-07)Soliman H, Wolf D, Chien J, Yau C, Campbell M, Magbanua M, Lu R, O'Grady N, Brown-Swigart L, Hirst G, Parker B, Sit L, Asare S, Yee D, DeMichele A, Nanda R, Pusztai L, Berry D, Esserman Veer L. Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score\u00ae assay in node-positive postmenopausal breast in the SWOG S8814 trial](https://doi.org/10.1158/1538-7445.sabcs21-pd9-06)Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner F, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score\u00ae assay in node-positive postmenopausal breast cancer: Results from an chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses](https://doi.org/10.1158/1538-7445.sabcs21-gs1-01)Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M, Im S, Ahn J, Gion M, Baron-Hay S, Boileau J, Zhu Y, Pan W, Tryfonidis K, Karantza V, O'Shaughnessy J. Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity gs1-01-gs1-01. [DOI: 10.1158/1538-7445.sabcs21-gs1-01](https://doi.org/10.1158/1538-7445.sabcs21-gs1-01). [Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) 25 randomized to endocrine therapy (ET) +/- chemotherapy W, Gralow J, Meric-Bernstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly C, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas C, Brain E, Lee E, Pierga J, Bermejo B, Ramos-Vasquez M, Jung K, Ferrero J, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G. Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) 25 randomized to endocrine therapy (ET) of clinical and expression-based immune signatures by race in the I-SPY 2 trial](https://doi.org/10.1158/1538-7445.sabcs21-gs4-02)Kyalwazi B, Yau C, Olopade O, Chien A, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van 't Veer L, Berry D, Esserman L. Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 Research 2022, in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11)](https://doi.org/10.1158/1538-7445.sabcs21-ot1-12-04)Harbeck N, Boileau J, Modi S, Kelly C, Ohno S, Wu J, Brekenridge M, Herbolsheimer P, Yu T, Pusztai L. Abstract OT1-12-04: in patients with high-risk HER2-positive alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial](https://doi.org/10.1158/1538-7445.sabcs21-pd5-05)Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn S, Azambuja E, Demeestere I. Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of pd5-05-pd5-05. [DOI: 10.1158/1538-7445.sabcs21-pd5-05](https://doi.org/10.1158/1538-7445.sabcs21-pd5-05). L, McArthur H, K\u00fcmmel S, Bergh J, Denkert N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay J. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer New K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. and macrophage-mediated immune suppression](http://www.ncbi.nlm.nih.gov/pubmed/35108062)Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-B signaling and as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study](https://doi.org/10.1016/j.ejso.2021.12.430)K\u00fcmmel S, Cort\u00e9s Dent R, Pusztai L, McArthur H, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso G, Karantza V, O'Shaughnessy J, Schmid P. Pembrolizumab vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC): Phase 3 KEYNOTE-522 study 10.1016/j.ejso.2021.12.430](https://doi.org/10.1016/j.ejso.2021.12.430). [Quantitative assessment of African American Triple Negative Breast Cancer: a case-control study](http://www.ncbi.nlm.nih.gov/pubmed/34906209)Yaghoobi V, Moutafi M, Aung E, Vathiotis Shafi S, Sharma A, O'Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study Breast and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients](http://www.ncbi.nlm.nih.gov/pubmed/34902335)Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze L\u00f3pez-Tarruella Consortium Adamson K, Albain K, Asare A, Asare S, Balassanian R, Beckwith H, Berry S, Berry D, Boughey J, Buxton M, Chen Y, Chen B, Chien A, Chui S, Clark A, Clennell J, Datnow B, DeMichele A, Duan X, Edmiston K, Elias A, Ellis E, Esserman L, Euhus D, Fadare O, Fan F, Feldman M, Forero-Torres A, Haley B, Han H, Harada S, Haugen T, Hirst G, Hylton N, Isaacs C, Kemmer K, Khan Q, Khazai L, Klein M, Krings G, Lang J, LeBeau L, Leyland-Jones B, Liu M, Lo S, Lu J, Magliocco A, Matthews J, Melisko M, Mhawech-Fauceglia P, Moulder I, Olopade O, Pambuccian S, Paoloni M, Park J, Parker B, Perlmutter J, Peterson G, Pusztai L, Rendi M, Rugo H, Sahoo S, Sams E, Symmans W, Tawfik M, Veer L, Venters S, Vinh T, Viscusi R, Wallace A, Wei S, Wilson A, Yau C, Yee D, Zeck J, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Edge S, Abraham J, Bartlett J, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut S, Thomas J, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Cole K, Pusztai L, Kim M, van 't Veer L, Esserman L, Symmans W. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of KS, SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Pusztai L, Hortobagyi GN. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer New England Journal the Front-line Treatment of Patients Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222SWOG L, Dy PA, Yeon CH, Conlin AK, Balcueva E, Lew DL, Tripathy Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, Survival in Neoadjuvant Treatment for High-risk Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34529000)Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace A, Clark AS, Kemmer K, Isaacs JE, Han Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for Type of Neoadjuvant Chemotherapy Regimen](http://www.ncbi.nlm.nih.gov/pubmed/34644277)Olawoyin OM, Mehta S, Chouairi F, Gabrick T, Pusztai L, Alperovich M. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen waterfall plots to increase value of response data generated by small single arm Phase II trials](http://www.ncbi.nlm.nih.gov/pubmed/34634476)Han G, Pusztai L, Hatzis C. Data augmentation based on waterfall plots to increase value of response data generated by small single arm Phase II trials Contemporary Clinical Trials 2021, 110: 106589. [PMID: 34634476](https://pubmed.ncbi.nlm.nih.gov/34634476), Surovtseva Y, Negahban Z, Pusztai L, Gerstein MB. Network propagation-based prioritization of long tail genes in 17 cancer DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, KK, Petricoin L, DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer for Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34638323)Iwase X, Reisenbichler E, R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial](http://www.ncbi.nlm.nih.gov/pubmed/34521624)Paoletti C, Barlow L, DF, Rae JM. Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Wang X, Jun T, Ding L, Pusztai L, Huang K. Genomic Determinants of Homologous Recombination Deficiency Profiling for Breast Cancer Research with the GeoMx\u00ae Digital Spatial Profiler](http://www.ncbi.nlm.nih.gov/pubmed/34503266)Bergholtz H, Carter JM, Cesano Church J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin \u00d6, SM, Warren SE, Consortium O. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx\u00ae Digital neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC](https://doi.org/10.1016/j.annonc.2021.06.014)Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso G, Karantza V, J. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for Tkaczuk K, Assad H, Pusztai L, Hurvitz J, Krop I, Medgyesy D, Abraham J, Modi S, Li H, Wu S, Garfin P, Weekly ladiratuzumab to trastuzumab in with early-stage cancer](http://www.ncbi.nlm.nih.gov/pubmed/34465600)Vathiotis IA, Moutafi Divakar Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, DL. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical Rediti M, Maetens L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Roth\u00e9 F, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34315723)Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman K, Balko JM, Institute A, Leyland-Jones B, Agency C, Chia S, Serpanchy R, Yu C, University E, McMillan S, Mosley R, Nguyen K, Wood E, Zelnak A, University G, Dillis C, Donnelly R, Harrington T, Isaacs C, Kallakury B, Liu M, Lynce F, Oppong B, Pohlmann P, Tousimis E, Warren R, Willey S, Wong J, Zeck J, Center L, Albain K, Bartolotta M, Bova D, Brooks C, Busby B, Czaplicki K, Duan X, Gamez R, Ganesh K, Gaynor E, Godellas C, Grace-Louthen C, Kuritza T, Lo S, Nagamine A, Perez C, Robinson P, Rosi D, Vaince F, Ward K, Hospital I, Choquette K, Edmiston K, Gallimore H, McGovern J, Mokarem K, Pajaniappan M, Rassulova S, Scott K, Sherwood K, Wright J, Clinic A, Anderson K, Gray R, Myers S, Northfelt D, Pockaj B, Roedig J, Wasif N, Clinic R, Arens A, Boughey J, Brandt K, Carroll J, Chen B, Connors A, Degnim A, Farley D, Greenlee S, Haddad T, Hieken T, Hobday T, Jakub J, Liberte L, Liu M, Loprinzi C, Menard L, Moe M, Moynihan T, O'Sullivan C, Olson E, Peethambaram P, Ruddy K, Russell B, Rynearson A, Smith D, Visscher D, Windish A, Institute H, Cox K, Dawson K, Newton O, Ramirez W, University O, Bengtson H, Bucher J, Chui S, Gilbert-Ghormley B, Hampton R, Kemmer K, Kurdyla D, Nauman D, Spear J, Wilson A, Institute S, Beatty D, Dawson P, Ellis E, Fer M, Hanson J, Goetz M, Haddad T, Iriarte D, Kaplan H, Porter B, Rinn K, Thomas H, Thornton S, Tickman R, Varghis N, Birmingham U, Caterinichia V, Santos J, Falkson C, Forero A, Krontiras H, Vaklavas C, Wei S, University of Arizona, Bauland A, Inclan L, Lewallen D, Powell A, Roney C, Schmidt K, Viscusi R, Wright H, San Diego University of California, Blair S, Boles S, Bykowski J, Datnow B, Densley P, Ojeda-Fournier H, Onyeacholem I, Parker B, Podsada K, Schwab R, Wallace A, Yashar C, San Francisco University of California, Alvarado M, Au A, Balassanian R, Benz C, Buxton M, Chen Y, Chien J, D'Andrea C, Davis S, Esserman L, Ewing C, Goga A, Hirst G, Hwang M, Hylton N, Joe B, Lyandres J, Kadafour M, Krings G, Melisko M, Moasser M, Munter P, Ngo Z, Park J, Price E, Rugo H, Veer L, Wong J, Yau C, University of Chicago, Abe H, Jaskowiak N, Nanda R, Olopade F, Schacht D, University of Colorado D, Borges V, Colvin T, Diamond J, Elias A, Finlayson C, Fisher C, Hardesty L, Kabos P, Kounalakis N, Mayordomo J, McSpadden T, Murphy C, Rabinovitch R, Sams S, Shagisultanova E, University of Kansas, Baccaray S, Khan Q, University of Minnesota, Beckwith H, Blaes A, Emory T, Haddad T, Hui J, Klein M, Kuehn-Hajder J, Nelson M, Potter D, Tuttle T, Yee D, Zera R, University of Pennsylvania, Bayne L, Bradbury A, Clark A, DeMichele A, Domchek S, Fisher C, Fox K, Frazee D, Lackaye M, Matro J, McDonald E, Rosen M, Shah P, Tchou J, Volpe M, Center U, Alvarez R, Barcenas C, Berry D, Booser D, Brewster A, Brown P, Gonzalez-Angulo A, Ibrahim N, Karuturi M, Koenig K, Moulder S, Murray J, Murthy R, Pusztai L, Saigal B, Symmans W, Tripathy D, Theriault R, Ueno N, Valero V, California U, Brown M, Carranza M, Flores Y, Lang J, Luna A, Perez N, Tripathy D, Watkins K, Center U, Armstrong S, Boyd C, Chen L, Clark V, Frankel A, Euhus D, Froehlich T, Goudreau S, Haley B, Harker-Murray A, Klemow D, Leitch A, Leon R, Li H, Morgan T, Qureshi N, Rao R, Reeves M, Rivers A, Sadeghi N, Seiler S, Staves B, Tagoe V, Thomas G, Tripathy D, Unni N, Weyandt S, Wooldridge R, Zuckerman J, Universty of Washington, Korde L, Griffin M, Butler B, Cundy A, Rubinstein L, Hixson C. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast CancerMHC-II Is an Immunotherapy Biomarker in Early CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy Current Treatment Options alpha-smooth muscle actin expression in the stroma of patients with HER2+ breast cancer](https://doi.org/10.1158/1538-7445.am2021-339)Vathiotis I, Moutafi M, Divakar P, Aung T, Fernandez A, Yaghoobi V, Shafi S, Syrigos K, Fountzilas G, Pusztai L, Warren S, Rimm D. Abstract 339: Resistance to trastuzumab is associated with alpha-smooth muscle actin expression in the stroma of patients with 339-339. [DOI: 10.1158/1538-7445.am2021-339](https://doi.org/10.1158/1538-7445.am2021-339). [Abstract 423: Pooled analysis patient outcome in I-PREDICT and WINTHER studies](https://doi.org/10.1158/1538-7445.am2021-423)Casadevall D, Marczyk M, Monzonis X, Pusztai L, Albanell J. Abstract 423: Pooled analysis of matching score and patient outcome in I-PREDICT and WINTHER studies Cancer - Huang RSP, Decker B, Hiemenz MC, Lechpammer M, Danziger N, Schiavone GJ, Razis ED, Bartsch R, Giannoudis JS, Palmieri C, Ramkissoon SH. Clinicopathologic and from the adaptively randomized I-SPY2 trial](http://www.ncbi.nlm.nih.gov/pubmed/34143979)Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Sanil AL, Matthews Melisko for cancer: Lou B, T, Pusztai L. The Way of the Future: Personalizing Treatment Plans Through Technology. American Society Of scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations](http://www.ncbi.nlm.nih.gov/pubmed/34040000)Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L, Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations Npj Breast Bai Y, Rimm D, Pusztai L, Lu L, Sanft T, Irwin M. Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors. Journal Of Clinical Oncology 2021, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? 2021, triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).](https://doi.org/10.1200/jco.2021.39.15_suppl.564)Blenman K, Marczyk M, Qing T, O'Meara T, Yaghoobi V, Pelekanou V, Bai Y, Reisenbichler E, Li X, Gunasekharan V, Ibrahim E, Rimm D, Pusztai L, Cole K. Characterization of the tumor immune microenvironment of triple-negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African Efficacy Score continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.](https://doi.org/10.1200/jco.2021.39.15_suppl.587)Marczyk M, Mrukwa A, Yau C, Wolf D, van 't Veer L, Esserman L, Symmans W, Pusztai L. Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial. Journal Of Clinical Oncology 2021, 39: 587-587. 10.1200/jco.2021.39.15_suppl.587](https://doi.org/10.1200/jco.2021.39.15_suppl.587). Lujambio A, Marczyk M, Pusztai L, Huang KL. Diverse immune response of DNA damage repair-deficient tumors Cell similar genomic alterations to non-inflammatory breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/33902690)Li X, Kumar S, Harmanci A, Li S, Kitchen RR, Zhang Y, Wali VB, Reddy SM, Woodward WA, Reuben JM, Rozowsky Gerstein M. Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast protein expression between primary and metastatic lesions in patients with lung cancer](http://www.ncbi.nlm.nih.gov/pubmed/33833050)Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross JS, Syrigos K, Wei W, Pusztai L, Rimm DL, Vathiotis IA. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer Journal For Cancer: Systematic Review and Meta-Analysis](http://www.ncbi.nlm.nih.gov/pubmed/33810205)Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, Rimawi MF, Schiff R, Arpino G, De Placido S, Prat A, Generali D. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic Breast Cancer Research And Between Primary and Metastatic Lesions in Lung Cancer Patients](https://doi.org/10.1016/j.jtho.2021.01.671)Moutafi M, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, Ross J, Syrigos K, Wei W, Pusztai L, Rimm D, Vathiotis I. P33.02 Comparison of PD-L1 Protein Expression Between Primary and Metastatic Lesions in Lung Cancer Patients and HER2-negative (HR+/HER2) breast cancer before chemo-endocrine therapy](http://www.ncbi.nlm.nih.gov/pubmed/33617937)Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst G, Bedrosian I, Layman R, Carter J, Klein M, Venters S, Shad S, van der Noordaa M, Chien A, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu M, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Veer L, Valero V, Esserman L, Symmans W. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2) perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-ss2-05)Park K, Gregory M, Lustberg M, Bazan J, Shen C, Rosenberg S, Blinder V, Sharma P, Pusztai L, Partridge A, Thompson A. Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer Cancer Research 2021, 81: ss2-05-ss2-05. [DOI: 10.1158/1538-7445.sabcs20-ss2-05](https://doi.org/10.1158/1538-7445.sabcs20-ss2-05). [Abstract GS3-00: First results from phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)](https://doi.org/10.1158/1538-7445.sabcs20-gs3-00)Kalinsky K, Barlow W, Meric-Bernstam F, Gralow J, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Mart\u00edn M, Gil M, Arce-Salinas C, Brain E, Park I, Pierga J, Lluch A, Vasquez M, Borrego M, Jung K, Ferrero J, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Hortobagyi G, Pusztai L. Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence of triple breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial](https://doi.org/10.1158/1538-7445.sabcs20-gs3-05)Stecklein S, Barlow Pusztai L, Timms K, Kennedy R, Badve S, G\u00f6kmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore](https://doi.org/10.1158/1538-7445.sabcs20-gs4-07)van der Noordaa M, Yau C, Shad S, Osdoit M, Steenbruggen T, de Croze D, Hamy A, Lae M, Reyal F, Del Monte-Mill\u00e1n M, Martin M, Tarruella S, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin A, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-03)Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk L, Modi S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo Z, Garfin P, Burris H. Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer Cancer Research 2021, 81: ot-03-03-ot-03-03. [DOI: 10.1158/1538-7445.sabcs20-ot-03-03](https://doi.org/10.1158/1538-7445.sabcs20-ot-03-03). - M, de Croze D, Hamy A, Lae M, Reyal F, Martin M, Del Monte-Mill\u00e1n M, L\u00f3pez-Tarruella S, Boughey J, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen T, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin A, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, Van't Veer L, Symmans F, Esserman L, Yau C. Abstract PD13-02: Site of recurrence after neoadjuvant therapy: A olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer](https://doi.org/10.1158/1538-7445.sabcs20-pd14-02)Wolf D, Yau C, Brown-Swigart L, O'Grady N, Hirst G, Sit L, Asare S, Berry D, Esserman L, Han H, Pusztai L, van 't Veer L. Abstract PD14-02: Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer Cancer Research 2021, 81: pd14-02-pd14-02. [DOI: 10.1158/1538-7445.sabcs20-pd14-02](https://doi.org/10.1158/1538-7445.sabcs20-pd14-02). - Qing M, Foldi J, Blenman K, Gunasekharan V, Pusztai L. Abstract PS19-05: Functional importance of long-tail mutations in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial](https://doi.org/10.1158/1538-7445.sabcs20-ps2-04)Paoletti C, Barlow W, Bergqvist M, Mehta J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG expression between primary tumors and metastatic lesions in triple negative breast cancers](https://doi.org/10.1158/1538-7445.sabcs20-ps5-08)Rozenblit M, Huang R, Danziger N, Alexander B, Ramkissoon S, Blenman K, Ross J, Rimm D, Pusztai L. Abstract PS5-08: Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Cancer Research 2021, 81: ps5-08-ps5-08. [DOI: 10.1158/1538-7445.sabcs20-ps5-08](https://doi.org/10.1158/1538-7445.sabcs20-ps5-08). - Pusztai L. Abstract K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples](http://www.ncbi.nlm.nih.gov/pubmed/33541297)Fu C, Marczyk M, Samuels M, Trevarton AJ, Qu J, Lau R, Du L, Pappas T, Sinn BV, Gould RE, Pusztai L, Hatzis WF. Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples BMC M, Cristofanilli M, Pusztai G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy](http://www.ncbi.nlm.nih.gov/pubmed/33514405)Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy Breast Cancer Research 2021, 23: 14. Dynamic clustering of cancer genomics datasets beyond pre-defined human 29: pr12-pr12. [DOI: 10.1158/1538-7755.disp20-pr12](https://doi.org/10.1158/1538-7755.disp20-pr12). [Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/33239417)Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers Journal For ImmunoTherapy vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients](https://doi.org/10.1136/jitc-2020-sitc2020.0323)Pusztai L, Lu H, Hale C, Grosse-Wilde A, Specht J, Modi S, Han H, Cortes J, Oliveira M, Garfin P, Wang Z, Onsum M. 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in metastatic breast cancer patients 2020, a198-a199. [DOI: 10.1136/jitc-2020-sitc2020.0323](https://doi.org/10.1136/jitc-2020-sitc2020.0323). of Treatment Strategies (HER2)-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/33226431)Kunst N, Wang SY, Hood MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)](https://doi.org/10.1016/j.annonc.2020.10.021)Dent R, Cortes J, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Jensen E, V, G, O'Shaughnessy J, Schmid P. of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast 31: s1241-s1242. [DOI: 10.1016/j.annonc.2020.10.021](https://doi.org/10.1016/j.annonc.2020.10.021). [PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32709714)Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer Wildiers H, Curigliano T, Ciruelos E, Rottey S, Rugo H. Expected medium and long term impact of the COVID-19 outbreak in oncology Annals Comprehensive Genomic Profiling and PDL1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32869930)Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Williams E, Elvin J, Vergilio J, Killian J, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen M, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom J, Alexander B, Brown C, Pusztai L, Ross J, Ramkissoon S. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PDL1 Immunohistochemistry Biomarkers in 312 Patients Zhao J, Qu R, Li X, Wali VB, Gupta AK, Pillai MM, Kluger Y, Yan Q, Hatzis C, Pusztai L, Gunasekharan V. Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32701140)Consortium I, Yee D, DeMichele A, Yau C, Isaacs C, Symmans W, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman I, Tawfik S, Vinh T, Chien A, Forero-Torres A, Stringer-Reasor E, Wallace A, Pusztai L, Boughey J, Ellis E, Elias A, Lu J, Lang J, Han H, Clark A, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Park J, Liu M, Olopade O, Leyland-Jones B, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton N, Veer L, Perlmutter J, Melisko M, Wilson A, Peterson G, Asare A, Buxton M, Paoloni M, Clennell J, Hirst R, Steeg K, Matthews J, Asare S, Sanil A, Berry S, Esserman L, Berry D. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast R, Mougalian SS. Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer Cancer Cell 32931742](https://pubmed.ncbi.nlm.nih.gov/32931742), [DOI: 10.1016/j.ccell.2020.08.006](https://doi.org/10.1016/j.ccell.2020.08.006). [Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer](https://doi.org/10.1016/j.annonc.2020.08.309)Licata L, Viale G, Criscitiello C, Giordano A, Chavez-MacGregor M, Curigliano G, Foldi J, Oke O, Giuliano M, Collins R, Del Mastro L, Puglisi F, Montemurro Vernieri L, Pusztai L, Bianchini G. Impact of oncotype DX on agreement and confidence in adjuvant treatment decision making in breast cancer Annals Of Oncology 2020, 31: s317-s318. [DOI: 10.1016/j.annonc.2020.08.309](https://doi.org/10.1016/j.annonc.2020.08.309). [Abstract 4973: Comparison immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients](https://doi.org/10.1158/1538-7445.am2020-4973)Yaghoobi V, Pelekanou V, O'Meara T, Silber A, Pusztai L, Rimm D, Blenman K. Abstract 4973: Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients Cancer 2020, cells after Navitoclax treatment](https://doi.org/10.1158/1538-7445.am2020-6333)Marczyk M, Gunasekharan V, Zhao J, Qu R, Li X, Patwardhan G, Wali V, Gupta A, Pillai M, transcriptomic, epigenetic profiling of triple-negative breast cancer Navitoclax treatment Cancer Research 2020, 6333-6333. [DOI: 10.1158/1538-7445.am2020-6333](https://doi.org/10.1158/1538-7445.am2020-6333). L, Tripathy D, G, Bartholomeusz C. Abstract 1897: Mechanism of MEK inhibitor resistance in triple negative breast Cancer Research 80: 1897-1897. [DOI: 10.1158/1538-7445.am2020-1897](https://doi.org/10.1158/1538-7445.am2020-1897). [Abstract 1998: Predictive and and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial](https://doi.org/10.1158/1538-7445.am2020-1998)Rediti M, Venet D, Roth\u00e9 F, Qing M, Harbeck N, Untch M, Rimm D, Chia S, Liu M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Abstract 1998: Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical Qing T, Samstein R, Cordon-Cardo C, L, Huang K. Abstract 2226: Precise stratification of immunotherapy outcomes using paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL](https://doi.org/10.1158/1538-7445.am2020-ct011)Pusztai L, Han H, Yau C, Wolf D, Wallace A, Shatsky R, Helsten T, Boughey J, Haddad T, Stringer-Reasor E, Falkson C, Chien A, Mukhtar R, Elias A, Virginia B, Nanda R, Yee D, Kalinsky K, Albain K, Muller A, Kemmer K, Clark A, Isaacs C, Thomas A, Hylton N, Symmans W, Perlmutter J, Melisko M, Rugo H, Schwab R, Wilson A, Wilson A, Singhrao R, Asare S, van't Veer L, DeMichele A, Sanil A, Berry D, Esserman L. Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY TRIAL Cancer Yaghoobi Blenman K, Cole K, Pelekanou V, endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.](https://doi.org/10.1200/jco.2020.38.15_suppl.527)Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. [DOI: 10.1200/jco.2020.38.15_suppl.527](https://doi.org/10.1200/jco.2020.38.15_suppl.527). Gralow J, Huggins-Puhalla Anders C, Goldstein L, Brown-Glaberman U, Huynh T, Szyarto C, Godwin A, Pathak H, Swisher E, Radke M, Timms K, Lew D, Miao J, Pusztai L, Hayes D, Hortobagyi G. Results of a phase II randomized trial of cisplatin +/- of to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.3117)Iwase T, Pusztai L, Blenman K, Li X, Seitz R, Nielsen T, Schweitzer B, Hout D, Bailey D, Zhang X, Shen Y, Ueno N. Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy in patients with primary triple-negative breast cancer. Clinical Oncology 2020, 38: 10.1200/jco.2020.38.15_suppl.3117](https://doi.org/10.1200/jco.2020.38.15_suppl.3117). molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.](https://doi.org/10.1200/jco.2020.38.15_suppl.511)Rediti M, Venet D, Rothe F, Qing T, M, I, M, Cosimo S, Hilbers Bajji Harbeck Untch M, Saura C, Huober J, Nuciforo P, Salgado R, Loi S, Pusztai L, Sotiriou C. Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial. Of Clinical Oncology 2020, 38: 511-511. [DOI: 10.1200/jco.2020.38.15_suppl.511](https://doi.org/10.1200/jco.2020.38.15_suppl.511). [SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps1104)Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk L, Modi S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo H, Mitri Z, Garfin P, Burris III H. SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. Journal Of Clinical Oncology 2020, 38: tps1104-tps1104. [DOI: 10.1200/jco.2020.38.15_suppl.tps1104](https://doi.org/10.1200/jco.2020.38.15_suppl.tps1104). [EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3647)Bruce J, Pusztai L, Braiteh F, Gorla S, Wu C, Baranda J. EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3647-tps3647. 10.1200/jco.2020.38.15_suppl.tps3647](https://doi.org/10.1200/jco.2020.38.15_suppl.tps3647). [A phase neoadjuvant chemotherapy and adjuvant endocrine therapy in Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast 10.1200/jco.2020.38.15_suppl.tps604](https://doi.org/10.1200/jco.2020.38.15_suppl.tps604). [Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden](http://www.ncbi.nlm.nih.gov/pubmed/32415133)Qing T, Mohsen H, Marczyk M, Ye Y, O'Meara T, Zhao H, Townsend JP, Gerstein M, Hatzis C, Kluger Y, Pusztai L. Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden Nature Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.](http://www.ncbi.nlm.nih.gov/pubmed/32407488)Schettini F, Giudici F, M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, Pusztai L, Prat A, Jerusalem G, Di Leo A, Generali D. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal Of The Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale TO, Badve SS, Symmans Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi L, Beck Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert F, Swanton C, Braybrooke JP, Hanna MG, Soler-Mons\u00f3 MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma S, Thagaard P, Brogi Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale TO, Badve SS, Symmans Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi L, Beck Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert F, Swanton C, Braybrooke JP, Hanna MG, Soler-Mons\u00f3 MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma S, Thagaard P, Brogi Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Complete Response in Women With Early-Stage Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/32053137)Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Singhrao Asare A, S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with neoadjuvant chemotherapy and adjuvant endocrine therapy in Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Loi S. 134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2 Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer](https://doi.org/10.1201/9780429137723-6)Liedtke C, Pusztai L. Gene Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer 2020, 77-96. [DOI: 10.1201/9780429137723-6](https://doi.org/10.1201/9780429137723-6). [Prospective multi-institutional evaluation of pathologist assessment of assays for patient selection in triple negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/32300181)Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome](http://www.ncbi.nlm.nih.gov/pubmed/31919134)Powles RL, Wali VB, Li X, Barlow WE, Nahleh Z, Thompson AM, Godwin AK, Hatzis C, Pusztai L. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome Clinical K\u00fcmmel S, Bergh J, Denkert M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J. Pembrolizumab for Early Triple-Negative Breast Cancer New England with J, M, la L, FS, Azambuja Untch Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy International Journal Of cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-pd1-01)Pusztai L, Reisenbichler E, Bai Y, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Killelea B, Chagpar A, Frederick C, Burello A. Abstract dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative Research 2020, 80: pd1-01-pd1-01. [DOI: 10.1158/1538-7445.sabcs19-pd1-01](https://doi.org/10.1158/1538-7445.sabcs19-pd1-01). [Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer](https://doi.org/10.1158/1538-7445.sabcs19-p2-09-02)Hofstatter E, Levine M, Liu Z, O'Meara T, Dalela D, Pusztai L. Abstract P2-09-02: Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer Cancer Research 2020, 80: p2-09-02-p2-09-02. [DOI: 10.1158/1538-7445.sabcs19-p2-09-02](https://doi.org/10.1158/1538-7445.sabcs19-p2-09-02). [Abstract PD10-05: Cost-effectiveness of different neoadjuvant by adjuvant treatment combination strategies for women with HER2-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-pd10-05)Kunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, Pusztai L. Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer Cancer Research 2020, 80: pd10-05-pd10-05. [DOI: 10.1158/1538-7445.sabcs19-pd10-05](https://doi.org/10.1158/1538-7445.sabcs19-pd10-05). [Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis](https://doi.org/10.1158/1538-7445.sabcs19-gs5-01)Yau C, van der Noordaa M, Wei J, Osdoit M, Reyal F, Hamy A, Lae M, Martin M, del Monte M, Boughey J, Gould R, Wesseling J, Steenbruggen T, van Seijen M, Sonke G, Edge S, Sammut S, Provenzano E, Abraham J, Hall P, Graham A, Mackintosh L, Cameron D, Wang A, Sharma P, Cole K, Pusztai L, Kim M, van 't Veer L, Esserman L, Symmans W. Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis Pusztai Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. Abstract OT2-04-03: Nivolumab with neoadjuvant chemotherapy therapy in of exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy](https://doi.org/10.1158/1538-7445.sabcs19-p1-19-12)Rozenblit M, Pusztai L, Adelson K, Mougalian S. Abstract P1-19-12: Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy Cancer Research 2020, 80: p1-19-12-p1-19-12. [DOI: 10.1158/1538-7445.sabcs19-p1-19-12](https://doi.org/10.1158/1538-7445.sabcs19-p1-19-12). [Abstract P2-20-02: Site of recurrence Clues to biology and impact on endpoints](https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02)Yau C, DeMichele A, Symmans W, Pusztai L, Yee D, Clark A, Hatzis C, Matthews J, Carter J, Chen Y, Cole K, Khazai L, Klein M, Kokh D, Krings G, Sahoo S, Albain K, Chien A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Hylton N, Boughey J, Melisko M, Perlmutter J, Rugo H, Schwab R, van' t Veer L, Berry D, Esserman L. Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on 2020, 80: p2-20-02-p2-20-02. [DOI: 10.1158/1538-7445.sabcs19-p2-20-02](https://doi.org/10.1158/1538-7445.sabcs19-p2-20-02). [Abstract markers of nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-05)Blenman K, Li X, Marczyk M, O'Meara T, Yaghoobi V, Gunasekharan V, Park T, Rimm D, Pusztai L. Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple negative 2020, 80: p3-09-05-p3-09-05. [DOI: 10.1158/1538-7445.sabcs19-p3-09-05](https://doi.org/10.1158/1538-7445.sabcs19-p3-09-05). assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.sabcs19-p4-10-14)Ahmed F, McGuire J, Gaule P, Blenman K, Pusztai L, Rimm D. Abstract P4-10-14: Quantitative assessment of PD-L1 protein expression on macrophages and tumor cells as predictive markers of response to neoadjuvant durvalumab and chemotherapy in triple negative breast cancer 2020, 80: PD-L1 assays in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs19-pd5-01)Reisenbichler E, Han G, Pelekanou V, Yaghoobi V, Ahmed F, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison B, Kuba M, Ly A, Miller D, Podoll M, Roden A, Sanders M, Singh K, Wei S, Wen H, Pusztai L, Rimm D. Abstract PD5-01: Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer Cancer Research 2020, 80: pd5-01-pd5-01. [DOI: 10.1158/1538-7445.sabcs19-pd5-01](https://doi.org/10.1158/1538-7445.sabcs19-pd5-01). [The impact of RNA accurate RNA sequencing from formalin-fixed paraffin-embedded tissues](http://www.ncbi.nlm.nih.gov/pubmed/31805884)Marczyk M, Fu C, Lau R, Du L, Trevarton AJ, Sinn BV, Gould RE, Pusztai L, Hatzis C, Symmans WF. The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed Promotes Resistance to HER2-Targeted Therapies](http://www.ncbi.nlm.nih.gov/pubmed/31825825)Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, del Genio C, Canfield K, DiRenzo J, Wells Kurokawa M. CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.](http://www.ncbi.nlm.nih.gov/pubmed/31657982)Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, P, AM, Tripathy D, Hortobagyi GN, Hayes DF. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure](http://www.ncbi.nlm.nih.gov/pubmed/31653660)Criscione J, Ji Jeffries L, McGrath JM, Soloway S, Pusztai L, Lakhani S. Identification of a novel MYOC variant in a Hispanic family with early-onset primary open-angle glaucoma with elevated intraocular pressure Molecular Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer Scientific (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)](https://doi.org/10.1093/annonc/mdz394.003)Schmid P, Cort\u00e9s J, Dent R, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, V, Zhao J, Aktan G, O'Shaughnessy J. LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast Of Oncology treatment sequencing of triple-negative and NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/31196152)Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer AC, Hirsch Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer Breast Cancer level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial\"](http://www.ncbi.nlm.nih.gov/pubmed/30624555)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann DL, Baselga J, Pusztai L. Corrections to \"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2019.37.15_suppl.e14180)O'Meara T, Yaghoobi Blenman K, Pelekanou V, Silber A, Rimm D, Pusztai L. Quantitative assessment of immune cell populations and associations with clinical outcomes in African-American (AA) versus Caucasian triple-negative breast cancer (TNBC). [DOI: MHC II protein expression levels epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.](https://doi.org/10.1200/jco.2019.37.15_suppl.2631)Wulfkuhle J, Yau C, Wolf D, Gallagher R, Brown Swigart L, Hirst G, Campbell M, Nanda R, Liu M, Pusztai L, Esserman L, Berry D, van 't Veer L, Petricoin E. Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 (NAT) and clinical outcome.](https://doi.org/10.1200/jco.2019.37.15_suppl.574)Luen S, Griguolo G, Nuciforo P, Campbell C, Fasani R, Cortes J, Untch M, Lin S, Savas P, Fox S, Di Cosimo S, Llombart Cussac A, Azambuja C, Salgado A, changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical Of Clinical Oncology 2019, 37: 574-574. [DOI: 10.1200/jco.2019.37.15_suppl.574](https://doi.org/10.1200/jco.2019.37.15_suppl.574). [Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade](http://www.ncbi.nlm.nih.gov/pubmed/32914041)Casadevall D, Li F, Hatzis C, Pusztai L. Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Cancer 2019, 297-324. [DOI: 10.1201/9780429066504-14](https://doi.org/10.1201/9780429066504-14). - Karn T, Denkert of metagene KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. The impact of communication style on patient satisfaction Breast Cancer Research And Treatment 2019, 176: 349-356. [PMID: function assessment among breast cancer patients undergoing anthracycline-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/31020471)Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy Breast Cancer Research And Treatment 2019, 176: 261-270. 31020471](https://pubmed.ncbi.nlm.nih.gov/31020471), [DOI: 10.1007/s10549-019-05178-z](https://doi.org/10.1007/s10549-019-05178-z). [Immune profiling tissues from the SWOG S0800 neoadjuvant trial](http://www.ncbi.nlm.nih.gov/pubmed/30967156)Li X, Warren S, Pelekanou V, Wali A, Liu M, DF, Hortobagyi GN, Barlow WE, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial Journal For Cancer: Clinical Versus Marczyk M, Sanft T, Silber A, Pusztai L. Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Index into extended endocrine therapy decision-making](https://doi.org/10.2217/bmt-2019-0001)Sanft T, Berkowitz A, Schroeder B, Hatzis C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making Breast Cancer Management 2019, 8: bmt22. FJ, Hubbard-Lucey VM, Tang Pusztai L. Immunotherapy and targeted therapy combinations in metastatic breast evaluating the use of adjuvant endocrine therapy\u00b1everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)](https://doi.org/10.1016/s0960-9776(19)30460-6)Chavez-Macgregor Mamounas E, Bandos H, Miao J, Gralow J, Hortobagyi G, investigators S. P359 Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy\u00b1everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): L. Abstract P3-05-01: Age-related methylation signals of breast cancer risk in Research 2019, 79: p3-05-01-p3-05-01. [DOI: 10.1158/1538-7445.sabcs18-p3-05-01](https://doi.org/10.1158/1538-7445.sabcs18-p3-05-01). [Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer](https://doi.org/10.1158/1538-7445.sabcs18-p2-06-06)Marczyk M, Gunasekharan V, Wali V, Shi W, Patwardhan G, Qing T, Pusztai L, Hatzis C. Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer Cancer Research 2019, 79: p2-06-06-p2-06-06. [DOI: 10.1158/1538-7445.sabcs18-p2-06-06](https://doi.org/10.1158/1538-7445.sabcs18-p2-06-06). [Abstract P3-10-01: Single-cell of an immunosuppressive VEGFA metagene](https://doi.org/10.1158/1538-7445.sabcs18-p3-10-01)Karn T, Denkert C, Sinn B, Weber V, Rody A, Meissner T, Hatzis C, El-Balat A, S, C, M, A, von Minckwitz Holtrich U. Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of VEGFA metagene Cancer Research 2019, Patwardhan G, Pusztai P4-03-01: Pathway level complementarity of germline and somatic events in 2019, 79: p4-03-01-p4-03-01. [DOI: 10.1158/1538-7445.sabcs18-p4-03-01](https://doi.org/10.1158/1538-7445.sabcs18-p4-03-01). [Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort](https://doi.org/10.1158/1538-7445.sabcs18-pd5-10)Szekely B, Bareche Y, Van den Eynden G, Salgado C, Pusztai L, Desmedt C. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort Cancer Research 79: pd5-10-pd5-10. [DOI: 10.1158/1538-7445.sabcs18-pd5-10](https://doi.org/10.1158/1538-7445.sabcs18-pd5-10). distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden](https://doi.org/10.1158/1538-7445.sabcs18-p2-07-03)Hylton N, Symmans W, Yau C, Li W, Hatzis C, Isaacs C, Albain K, Chen Y, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, H, J, I, Tawfik O, Grasso LeBeau L, Sahoo S, Vinh T, Yang S, Adams A, Chien A, Ferero-Torres A, Stringer-Reasor E, Wallace A, Boughey J, Ellis E, Elias A, Lang J, Lu J, Han H, Clark A, Korde L, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Wood W, Park J, Liu M, Olopade O, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, van't Veer L, Perlmutter J, Melisko M, Wilson A, Peterson G, Asare A, Buxton M, Paoloni M, Clennell J, Hirst G, Singhrao R, Steeg K, Matthews J, Sanil A, Berry S, Abe H, Wolverton D, Crane E, Ward K, Nelson M, Niell B, Oh K, Brandt K, Bang D, Ojeda-Fournier H, Eghtedari M, Sheth P, Bernreuter W, Umphrey H, Rosen M, Dogan B, Yang W, Joe B, Yee D, Pusztai L, DeMichele A, Asare S, Berry D, Esserman L. Abstract P2-07-03: Refining neoadjuvant predictors of three year distant metastasis free survival: Integrating volume change as measured by MRI with residual cancer burden Cancer Research 2019, 79: p2-07-03-p2-07-03. [DOI: 10.1158/1538-7445.sabcs18-p2-07-03](https://doi.org/10.1158/1538-7445.sabcs18-p2-07-03). [Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL](https://doi.org/10.1158/1538-7445.sabcs18-p2-14-01)Silverstein J, Suleiman L, Yau C, Price E, Singhrao R, Yee D, DeMichele A, Isaacs C, Albain K, Chien A, Forero-Torres A, Wallace A, Pusztai L, Ellis E, Elias A, Lang J, Lu J, Han H, Clark A, Korde L, Nanda R, Northfelt D, Khan Q, Viscusi R, Euhus D, Edmiston K, Chui S, Kemmer K, Wood W, Park J, Liu M, Olopade O, Leyland-Jones B, Tripathy D, Moulder S, Rugo H, Schwab R, Lo S, Helsten T, Beckwith H, Berry D, Asare S, Esserman L, Boughey J, Mukhtar R. Abstract P2-14-01: The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL Cancer Research 2019, 79: Piccart J, M, la L, F, Azambuja E, Untch M, Pusztai Pritchard K, Nuciforo P, A, F, Apolone G, de Braud F, Verderio P, Daidone 10.1158/1538-7445.sabcs18-p4-01-03](https://doi.org/10.1158/1538-7445.sabcs18-p4-01-03). [Abstract Impact of long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313](https://doi.org/10.1158/1538-7445.sabcs18-p4-08-06)Sharma P, Barlow W, Hout D, Seitz R, Bailey D, Godwin A, Pathak H, Timms K, Solimeno C, Linden H, Porter P, Tripathy D, Hortobagyi G, Thompson A, Pusztai L, Hayes D. Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG L, G, C. Abstract P5-03-06: Overcoming MEK inhibitor resistance leukemia-1 ( A, B, Hatzis C, Pusztai L. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women Breast Cancer Research And microenvironment predicts survival in and -negative cancers](http://www.ncbi.nlm.nih.gov/pubmed/30558648)Pelekanou 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers Breast Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options](http://www.ncbi.nlm.nih.gov/pubmed/30652574)Gershkovich P, Platt J, Knopf J, Tasoulis MK, Shi W, Pusztai L, Hatzis C. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options JCO Clinical [Association Receptor Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/29902299)Powles RL, Redmond D, Sotiriou C, D, Nuciforo P, Harbeck N, de Azambuja E, Piccart-Gebhart Elemento O, Pusztai L, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Immunological differences between primary and metastatic level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial](http://www.ncbi.nlm.nih.gov/pubmed/29701764)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann DL, Baselga J, Pusztai L. correction to: Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients](https://doi.org/10.1093/annonc/mdy272.278)Specht J, Pusztai Mita M, Weise A, Krop I, Grosse-Wilde A, Wang Z, Li M, Hengel S, Garfin P, Means G, Onsum M, Modi S. 286PD Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients Annals Of Oncology [DOI: 10.1093/annonc/mdy272.278](https://doi.org/10.1093/annonc/mdy272.278). with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/29793946)Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)](http://www.ncbi.nlm.nih.gov/pubmed/30137196)Mateo J, Chakravarty D, Dienstmann CKY, Bedard PL, Tortora G, Douillard J, Van Allen EM, Schultz N, Swanton C, Andr\u00e9 F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular VB, AM, Butler Epstein Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Increased epigenetic age in normal breast tissue from luminal breast cancer patients Clinical Epigenetics Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2Targeted Therapy](http://www.ncbi.nlm.nih.gov/pubmed/30139836)Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega Horowitz N, Barcenas CH, V, Tripathy D, Pusztai L, Murthy RK. LongTerm Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study](http://www.ncbi.nlm.nih.gov/pubmed/30062572)Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu A, Ferrucci LM, Pusztai L, Irwin ML. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study Breast Cancer Research And Treatment 2018, 172: and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial](http://www.ncbi.nlm.nih.gov/pubmed/29588392)Pelekanou V, Barlow Z, Wasserman Szekely Rimm DL, Pusztai L. Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.](https://doi.org/10.1200/jco.2018.36.15_suppl.578)Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh Z, Hayes D, Hortobagyi G, Barlow W, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.586)Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick T, Harigopal M. dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast Of Clinical Oncology 2018, 36: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2018.36.15_suppl.tps602)Schmid P, Cortes J, Bergh J, Pusztai L, Denkert C, Verma S, McArthur H, Kummel S, Ding Y, Karantza V, Dang T, Dent R. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). Journal Of Clinical Veitch Z, Bedard PL. Incorporating Genomics Into the Care of Patients With Advanced Breast Cancer American Society Of Clinical Oncology Educational Book 2018, vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies](http://www.ncbi.nlm.nih.gov/pubmed/29372234)Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies JAMA non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes](http://www.ncbi.nlm.nih.gov/pubmed/29559730)Gyrffy B, Pongor L, Bottai G, Li X, Budczies J, C, Pusztai L, Santarpia L. integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes British Journal Of T, Cheng CJ, Pusztai L, Irwin ML. Exercise and weight loss interventions and miRNA expression in women with breast cancer Breast Cancer Research And Treatment 2018, C, L. Abstract PD6-02: Immunological differences between primary and metastatic 2018, 78: pd6-02-pd6-02. [DOI: 10.1158/1538-7445.sabcs17-pd6-02](https://doi.org/10.1158/1538-7445.sabcs17-pd6-02). [Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-04-02)Hofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, V, Storniolo A, C, G, Wahlde M, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer Cancer Research 2018, 78: p2-04-02-p2-04-02. [DOI: 10.1158/1538-7445.sabcs17-p2-04-02](https://doi.org/10.1158/1538-7445.sabcs17-p2-04-02). [Abstract P2-09-01: T-cell receptor beta chain region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-01)Powles R, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, C, Pusztai L. Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial Cancer [DOI: 10.1158/1538-7445.sabcs17-p2-09-01](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-01). [Abstract to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial](https://doi.org/10.1158/1538-7445.sabcs17-gs1-04)Sotiriou Roth\u00e9 F, Maetens M, Fumagalli Brown I, Pusztai L, Harbeck N, Ignatiadis M, S, la L, Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Venet D. Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy](https://doi.org/10.1158/1538-7445.sabcs17-ot1-02-04)Pusztai L, Barlow W, Ganz P, Henry N, White J, Jagsi R, Mammen J, Lew D, Mejia J, Karantza V, Aktan G, Sharon E, Korde OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy Cancer [Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-ot1-03-06)Shagisultanova E, Diamond J, Stopeck P, Borges V. Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer Cancer Research [Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial](https://doi.org/10.1158/1538-7445.sabcs17-p2-05-04)Venet D, Roth\u00e9 F, Dupont F, Maetens R, Bradbury I, Pusztai N, M, la L, M, Azambuja E, Huober J, Nuciforo P, Baselga J, Piccart M, Loi S, Sotiriou C. Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial Cancer Research 2018, 78: p2-05-04-p2-05-04. [DOI: 10.1158/1538-7445.sabcs17-p2-05-04](https://doi.org/10.1158/1538-7445.sabcs17-p2-05-04). [Abstract P2-09-03: Identifying clinically relevant subgroups women with HER2-positive breast cancer: An analysis of Neo-ALTTO using E, Fumagalli D, Pusztai Harbeck Izquierdo L, Huober J, Baselga J, Piccart M, Verderio P, Tagliabue E. Abstract P2-09-03: Identifying clinically relevant subgroups of women with HER2-positive breast cancer: An analysis of Neo-ALTTO using the [DOI: P2-09-06: Quantitative spatial profiling of associated macrophages and the PD-1/PD-L1 interaction in breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-06)Pelekanou V, Neumeister V, Pusztai L, Rimm D. Abstract P2-09-06: Quantitative spatial profiling of tumor associated macrophages and the PD-1/PD-L1 interaction in breast cancer Cancer Research 2018, 78: 10.1158/1538-7445.sabcs17-p2-09-06](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-06). [Abstract P2-09-07: compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast cancer](https://doi.org/10.1158/1538-7445.sabcs17-p2-09-07)Rimm D, Carvajal-Hausdorf J, J, Piccart M, Holmes E, Pusztai L. Abstract P2-09-07: Low levels of HER2 extracellular domain (ECD) compared to intracelluar domain (ICD) in NeoALTTO may segregate benefit from lapatinib and trastuzumab in breast Cancer Research 2018, 78: p2-09-07-p2-09-07. [DOI: with Pusztai K, Weise A, Krop I, Burris H, Kalinsky K, Tsai M, Liu M, Hurvitz S, Wilks S, Ademuyiwa F, Diab S, Han H, Kato G, Nanda R, O'Shaughnessy J, Kostic A, Li M, Specht J. Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated neoadjuvant, phase II administered concomitantly with weekly paclitaxel followed A, Lannin Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft C, DiGiovanna neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast 333-340. [PMID: 29396664](https://pubmed.ncbi.nlm.nih.gov/29396664), [DOI: 10.1007/s10549-017-4653-2](https://doi.org/10.1007/s10549-017-4653-2). therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR](http://www.ncbi.nlm.nih.gov/pubmed/29344722)Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR Journal Of Cancer Research And lapatinib-induced cardiotoxicity in patients C, H, D, Cosimo Baselga MR, DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients a El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L. Association Between Genomic Metrics and Immune Infiltration in C. germline variants Patient-Reported Outcomes in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/30657377)Mougalian SS, Epstein LN, Jhaveri ALM, Adelson K, L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer Testing on Adjuvant Therapy Decision Making](http://www.ncbi.nlm.nih.gov/pubmed/29048991)Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin O, L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference](http://www.ncbi.nlm.nih.gov/pubmed/29667990)Woodward WA, Cristofanilli M, Merajver SD, Van Laere Polyak GR, X, van Golen KL, El-Zein R, Rahal Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference Journal Of AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?\"](http://www.ncbi.nlm.nih.gov/pubmed/28987415)Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter Chung G, Pusztai L, Lannin DR. Discussion of: \"Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?\" The American Journal lymphocytes and PD-L1 expression in breast cancer and its clinical significance](http://www.ncbi.nlm.nih.gov/pubmed/28946899)Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf L, chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance Breast Cancer Research status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?](http://www.ncbi.nlm.nih.gov/pubmed/28939252)Chagpar AB, Horowitz N, Sanft T, Wilson LD, Silber A, Killelea B, Moran MS, DiGiovanna MP, Hofstatter E, Chung G, Pusztai L, Lannin DR. Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer? The American Journal pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC)](https://doi.org/10.1093/annonc/mdx364.015)Schmid P, Castan J, Bergh J, Pusztai Denkert C, Verma S, McArthur H, Zhao J, Aktan G, Dang T, Dent R. 233TiP KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/28945887)Chung Young L, Forcier B, Ye P, Levin MK, Goldberg M, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, Ganesan S, Park LT, Leyland-Jones B, Mughal TI, L, VA, Ross JS, Ali SM. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic PD-L1 expression in breast cancer and its clinical significance](http://www.ncbi.nlm.nih.gov/pubmed/28784153)Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf H, Brown J, Lannin D, Pusztai L, Rimm DL. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance Breast Cancer Research Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28766195)Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer Annals mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) Study](https://doi.org/10.1158/1538-7445.am2017-5321)Ferrucci L, Cartmel B, Harrigan M, Sanft T, Playdon M, Jia W, Yu H, Johnson C, Pusztai L, Chagpar A, Irwin M. Abstract 5321: Metabolomics and body mass index among breast cancer survivors in The Lifestyle, Exercise, and Nutrition (LEAN) Study Cancer Research 2017, 77: 5321-5321. L. Abstract 1141: Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer Cancer Research 2017, 77: 1141-1141. [DOI: 10.1158/1538-7445.am2017-1141](https://doi.org/10.1158/1538-7445.am2017-1141). [Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells](https://doi.org/10.1158/1538-7445.am2017-2073)Patwardhan G, Wali V, Pusztai L, Hatzis C. Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells Cancer Research 2017, 77: 2073-2073. [DOI: 10.1158/1538-7445.am2017-2073](https://doi.org/10.1158/1538-7445.am2017-2073). B, Karn T, Hatzis C, Pusztai L. Immune Gene Expression Is Associated with Genomic Aberrations in Breast using somatic mutations and copy number aberrations](http://www.ncbi.nlm.nih.gov/pubmed/28585536)Brown D, Dank M, Szentm\u00e1rtoni G, Udvarhelyi C. Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial.](https://doi.org/10.1200/jco.2017.35.15_suppl.572)Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage S, Silber A, Lannin Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach D, E, DiGiovanna (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III genomic characteristics of TNBC in African American women compared to other races.](https://doi.org/10.1200/jco.2017.35.15_suppl.e13028)Szekely B, Safonov A, Karn T, Bhagwagar S, Killelea B, Silber A, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. Journal Of Clinical Oncology 2017, 35: e13028-e13028. [DOI: 10.1200/jco.2017.35.15_suppl.e13028](https://doi.org/10.1200/jco.2017.35.15_suppl.e13028). [Long-term survival of de stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.](https://doi.org/10.1200/jco.2017.35.15_suppl.1021)Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas C, Chavez-Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy R. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. Journal A, G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. [DOI: 10.1200/jco.2017.35.15_suppl.1522](https://doi.org/10.1200/jco.2017.35.15_suppl.1522). [Genomic profiling (ctDNA) from patients (pts) with metastatic breast cancer (mBC).](https://doi.org/10.1200/jco.2017.35.15_suppl.1016)Pusztai L, Chung J, Young L, Schrock A, Hartmaier R, Frampton G, Gay L, Stephens P, Miller V, Ali S, Ross J, Vahdat L, O'Shaughnessy J. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer gene signatures characterized by varying levels of chromosomal instability.](https://doi.org/10.1200/jco.2017.35.15_suppl.1096)Gyorffy B, Bottai G, Nagy A, Pusztai L, Santarpia L. Immune gene signatures in triple-negative breast cancers characterized by varying levels of chromosomal instability. Of lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.](https://doi.org/10.1200/jco.2017.35.15_suppl.519)Pelekanou V, Barlow W, von Wahlde M, Wasserman B, Lo Y, Hayes D, Hortobagyi G, Gralow J, Tripathy D, Livingston R, Porter P, Nahleh Z, Rimm D, Pusztai L. Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer Journal 2017, 35: e12129-e12129. El-Balat A, Rody A, Holtrich U, Becker S, G, L. 40P Immune using somatic mutations and copy number aberrations](http://www.ncbi.nlm.nih.gov/pubmed/28429735)Brown D, Dank M, Szentm\u00e1rtoni G, Udvarhelyi C, Desmedt C. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and C, Gu P, Wu J, Chen X, Niu S, Sun H, Wu L, Li N, Peng J, Shi S, Fan C, Huang M, Wong CC, Gong Q, Kumar-Sinha C, Zhang R, Pusztai L, Rai R, Chang S, Lei M. Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in NT. pathways in breast cancers stratified by estrogen receptor of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).](https://doi.org/10.1200/jco.2017.35.8_suppl.25)Sanft T, Berkowitz A, Schroeder B, Hatzis C, B, Brufsky A, Pusztai L, Gustavsen G, Van Londen G. Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET). Early-Stage Breast Cancer Treated With Aromatase Inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/28267392)Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Hofstatter E, Pusztai L. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer Cancer Research 2017, of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy](https://doi.org/10.1158/1538-7445.sabcs16-p2-09-15)Sanft T, Berkowitz A, Schroeder B, Hatzis B, A, Pusztai L, vanLonden G. Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs16-p6-09-49)Gy\u00f6rffy B, Ocana A, Herman Pandiella A, Pusztai L. Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer Cancer Research 2017, El-Balat A, Holtrich U, Becker S, Bianchini G, Pusztai L. Abstract S1-07: Immune sculpting of the triple negative breast cancer breast cancer eligible for targeted checkpoint inhibition](https://doi.org/10.1158/1538-7445.sabcs16-p2-04-16)Bottai G, Loi S, Sotiriou C, Roncalli M, T-cells identify a subset of triple-negative breast cancer of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)](https://doi.org/10.1158/1538-7445.sabcs16-p4-21-09)de Azambuja E, Bradbury I, Ewer M, Campbell R, Sutter T. Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-10-03)Nanda R, Specht J, Dees C, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Ray A, Karantza V, Buisseret L. Abstract P6-10-03: KEYNOTE-012: Long-lasting responses phase study of patients (pts) with FGF aberrant metastatic breast cancer (MBC)](https://doi.org/10.1158/1538-7445.sabcs16-p6-11-03)Mayer I, Arteaga Jhaveri K, Morganstern D, Vogel C, Connolly R, Gradishar W, Patel R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF SGN-LIV1A in patients with heavily pretreated metastatic cancer](https://doi.org/10.1158/1538-7445.sabcs16-p6-12-04)Forero-Torres A, Modi S, Specht J, Miller Weise A, Burris H, Liu M, Krop I, Pusztai L, Kostic A, Li M, Mita M. Abstract P6-12-04: Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily cancer whole-genome sequences](https://doi.org/10.1158/1538-7445.sabcs16-p1-05-01)Li X, Krishnamurthy S, Kumar S, Reddy S, Woodward W, Reuben J, Hatzis C, Ueno N, Gerstein M, Pusztai L. Abstract P1-05-01: Landscape of somatic mutations in inflammatory prognosis in triple-negative breast cancer subtypes](https://doi.org/10.1158/1538-7445.sabcs16-p1-07-06)Bottai G, Balazs G, Nagy A, Pusztai L, Szallasi Z, Reis-Filho J, Santarpia L. Abstract P1-07-06: Immune signatures define and affect prognosis in triple-negative breast Analysis of the Venet R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Pe\u00f1a L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary of KEYNOTE-012 study](https://doi.org/10.1016/s0959-8049(17)30206-x)Nanda R, Specht J, Dees E, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Ray A, Karantza V, Pembrolizumab for metastatic triple-negative (mTNBC): long-lasting responses in the phase [Long-Term Prognostic Risk After Neoadjuvant With Residual Cancer Burden and Breast Cancer Subtype](http://www.ncbi.nlm.nih.gov/pubmed/28135148)Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, S, Pusztai C, Hortobagyi GN. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype Journal ER-Negative/HER2-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/28106823)Bottai Diao GA, Santarpia L. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer International Journal Of in Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27872098)Wali VB, Langdon Held B, Pusztai L, Stern DF, Hatzis C. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial](http://www.ncbi.nlm.nih.gov/pubmed/28177460)Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Pe\u00f1a L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients](http://www.ncbi.nlm.nih.gov/pubmed/27192352)Chagpar AB, Horowitz NR, Killelea BK, Tsangaris T, Longley P, Grizzle S, Loftus M, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin DR, Pusztai L, Davidoff AJ, Gross CP. Economic Impact of Routine Cavity Margins Versus Standard Partial Mastectomy in Breast Cancer Patients Annals Of Wali VB, Pongor L, Li C, Lau R, Gyrffy WF, Pusztai L, Negative Breast Cancer: precision medicine ready for use in breast cancer? Clinical Advances In Hematology And Pusztai L. Clinical Utility of Biomarker Tests in Decisions on Extended Endocrine Therapy Journal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab](http://www.ncbi.nlm.nih.gov/pubmed/27298406)Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra AS, Tripathy D, Valero V, Hatzis C, L, Murthy R. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab Journal D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27658825)Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer BMC Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss Trial](https://doi.org/10.1016/j.jand.2016.06.326)Harrigan M, Playdon M, Cartmel B, Loftfield E, Sanft T, Chagpar A, Zhou Y, Anderson C, Pusztai L, Irwin M. Predictors of Weight Change in Breast Cancer Survivors: The Lifestyle, Exercise and Nutrition (LEAN) Randomized Weight Loss Trial Journal Of The Academy Of Nutrition And Dietetics 2016, 116: a90. [DOI: M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer Breast cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/27393622)Nahleh ZA, WE, cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer Breast Cancer Research And Treatment 2016, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer New England Journal 375: 23-34. [PMID: Yau C, van 't Veer MB, AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, GL, LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer New England Journal Sz\u00e9kely B, Pusztai L. Deciphering and Targeting Oncogenic Mutations and Li F, Loftfield E, Playdon M, Zhou Y, Gross C, Ligibel J, SCHMITZ K, Hershman D, Pusztai L, Irwin M. Impact of weight loss and exercise on VEGF levels in breast cancer survivors. Journal Of Clinical Oncology 2016, 34: 10103-10103. [DOI: 10.1200/jco.2016.34.15_suppl.10103](https://doi.org/10.1200/jco.2016.34.15_suppl.10103). [Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.](https://doi.org/10.1200/jco.2016.34.15_suppl.e18136)Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. [DOI: 10.1200/jco.2016.34.15_suppl.e18136](https://doi.org/10.1200/jco.2016.34.15_suppl.e18136). - Safonov A, Jiang Bianchini Platt J, Shi W, Rimm D, Pusztai L, Hatzis C. Association between DNA level aberrations and immune cell infiltration in breast cancer. Journal Of Clinical Oncology 2016, 34: 3078-3078. [DOI: 10.1200/jco.2016.34.15_suppl.3078](https://doi.org/10.1200/jco.2016.34.15_suppl.3078). - Fujii Dong Litton J, Moulder S, Tripathy D, Hunt K, Iwamoto T, Pusztai L, Lim B, Shen Y, Ueno N. New threshold of ER positivity in early stage HER2- breast cancer. Journal Of Clinical 2016, 34: 1067-1067. [DOI: 10.1200/jco.2016.34.15_suppl.1067](https://doi.org/10.1200/jco.2016.34.15_suppl.1067). [Effect of DNA hypermethylation on immune escape through downregulation of antigen presentation genes in breast cancer.](https://doi.org/10.1200/jco.2016.34.15_suppl.11547)Gyorffy B, Nagy A, Pongor L, Locatelli A, Vigano' L, Safonov A, Pusztai L, Gianni L, Bianchini G. Effect of DNA hypermethylation on immune escape through downregulation of antigen presentation genes in breast cancer. Journal Of Clinical Oncology 2016, 34: 11547-11547. [DOI: taselisib (GDC-0032) combined with fulvestrant HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).](https://doi.org/10.1200/jco.2016.34.15_suppl.520)Dickler M, Saura C, Richards D, Krop I, Cervantes A, Bedard P, Patel M, Pusztai L, Oliveira M, Ware J, Jin H, Wilson T, Stout T, Wei M, Hsu J, Baselga J. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer 520-520. [DOI: 10.1200/jco.2016.34.15_suppl.520](https://doi.org/10.1200/jco.2016.34.15_suppl.520). [T-DM1 activity in that received prior therapy with trastuzumab and pertuzumab.](https://doi.org/10.1200/jco.2016.34.15_suppl.585)Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra A, Tripathy D, Valero V, Pusztai L, Murthy R. T-DM1 activity in metastatic HER2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. Journal Of Clinical Oncology density breast cancer on aromatase inhibitors.](https://doi.org/10.1200/jco.2016.34.15_suppl.6599)Stratton J, Hu X, Soulos P, Davidoff A, Pusztai L, Gross C, Mougalian S. Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors. Journal Clinical Oncology - Nanda Gupta S, Geva R, Pusztai Pathiraja K, Aktan G, Cheng JD, V, L. With Advanced Triple-Negative Breast Cancer: Phase Ib Bianchini G. New Strategies in Breast L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling Cancer 2016, 122: 1588-1597. [PMID: 26970385](https://pubmed.ncbi.nlm.nih.gov/26970385), [DOI: sequencing data: a comparison of web tools](http://www.ncbi.nlm.nih.gov/pubmed/26980737)Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein Chung A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation sequencing data: a comparison of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) study](https://doi.org/10.1158/1538-7445.sabcs15-p3-08-01)Sanft T, Lu L, Harrigan M, Cartmel B, Zhou Y, Chagpar A, Pusztai L, Irwin M. Abstract P3-08-01: Randomized controlled trial of weight loss vs. usual care on telomere length in women with breast cancer: The lifestyle, exercise and nutrition (LEAN) study Cancer Research 2016, 76: p3-08-01-p3-08-01. [DOI: 10.1158/1538-7445.sabcs15-p3-08-01](https://doi.org/10.1158/1538-7445.sabcs15-p3-08-01). [Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial](https://doi.org/10.1158/1538-7445.sabcs15-p3-13-01)Chagpar A, Longley P, Horowitz N, Killelea B, Tsangaris T, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin D, Pusztai L, Loftus M, Davidoff A, Gross C. Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial Cancer Research 2016, 76: p3-13-01-p3-13-01. [DOI: 10.1158/1538-7445.sabcs15-p3-13-01](https://doi.org/10.1158/1538-7445.sabcs15-p3-13-01). [Abstract P6-13-06: Novel combination therapies for negative breast cancer identified by high-throughput screening](https://doi.org/10.1158/1538-7445.sabcs15-p6-13-06)Wali V, Langdon C, Held M, Platt J, Safonov A, Aktas B, Stern D, Pusztai L, Hatzis C. Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening Cancer Research 2016, 76: p6-13-06-p6-13-06. [DOI: 10.1158/1538-7445.sabcs15-p6-13-06](https://doi.org/10.1158/1538-7445.sabcs15-p6-13-06). [Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study](https://doi.org/10.1158/1538-7445.sabcs15-p5-11-03)Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot have different immune milieu in primary and metastatic tumors](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-04)Bianchini G, Riba M, Zambelli S, Safonov N, P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors Cancer Research 2016, 76: p4-04-04-p4-04-04. [DOI: 10.1158/1538-7445.sabcs15-p4-04-04](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-04). [Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p4-07-01)Jiang T, Safonov A, Bianchini G, Shi W, Wali V, Pusztai L, Hatzis C. Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancer Cancer Research 2016, 76: p4-07-01-p4-07-01. [DOI: 10.1158/1538-7445.sabcs15-p4-07-01](https://doi.org/10.1158/1538-7445.sabcs15-p4-07-01). [Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker](https://doi.org/10.1158/1538-7445.sabcs15-p5-07-09)Mani N, Schalper K, Hatzis C, Chagpar A, Pusztai D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker Cancer Research 2016, 76: p5-07-09-p5-07-09. [DOI: 10.1158/1538-7445.sabcs15-p5-07-09](https://doi.org/10.1158/1538-7445.sabcs15-p5-07-09). [Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy](https://doi.org/10.1158/1538-7445.sabcs15-p6-11-03)Safonov A, Hatzis C, Stratton J, Gross C, Russell R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy Cancer Research the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies](https://doi.org/10.1158/1538-7445.sabcs15-s5-01)Pusztai L, Shi W, Jiang T, Nuciforo P, Holmes E, Harbeck N, Sotiriou C, Rimm D, Hatzis C, de la L, J. Abstract exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies Cancer Research 2016, 76: s5-01-s5-01. [DOI: 10.1158/1538-7445.sabcs15-s5-01](https://doi.org/10.1158/1538-7445.sabcs15-s5-01). [Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p1-09-01)Killelea B, Chagpar A, Horowitz N, Pusztai L, Wang S, Mougalian S, Lannin D. Abstract P1-09-01: African American women have lower pathologic complete response rates to neoadjuvant chemotherapy compared to white women for triple negative and HER 2 positive breast cancer Cancer Research 2016, 76: p1-09-01-p1-09-01. [DOI: 10.1158/1538-7445.sabcs15-p1-09-01](https://doi.org/10.1158/1538-7445.sabcs15-p1-09-01). [Abstract OT1-03-11: Phase III evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)](https://doi.org/10.1158/1538-7445.sabcs15-ot1-03-11)Chavez-MacGregor P, Mamounas S, H, Gralow J, D, Hortobagyi G. Abstract OT1-03-11: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor (HR) positive and HER2-negative breast cancer (BC): V, intracellular extracellular domain spatial co-localization [DOI: 10.1158/1538-7445.sabcs15-p3-07-06](https://doi.org/10.1158/1538-7445.sabcs15-p3-07-06). [Abstract P3-14-05: Interim analysis 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast III H, Mita M, Specht Weise A, Liu M, Modi S, Pusztai L, Kostic A, Yang J, Li M, Hengel S, Miller K. Abstract P3-14-05: Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic p3-14-05-p3-14-05. retrovirus elements in breast cancer](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-20)Safonov A, Bianchini Jiang T, Pusztai L, Hatzis C. Abstract P4-04-20: Subtype specific differential expression and immunogenicity of endogenous retrovirus elements in breast 10.1158/1538-7445.sabcs15-p4-04-20](https://doi.org/10.1158/1538-7445.sabcs15-p4-04-20). [Abstract PD6-06: Somatic cancer molecular subtypes](https://doi.org/10.1158/1538-7445.sabcs15-pd6-06)Gyorffy B, Pongor L, Szabo A, Bottai G, L. Abstract PD6-06: Somatic mutation patterns differentially affect survival in breast cancer molecular subtypes Cancer Research 2016, 76: pd6-06-pd6-06. Silences c-SRC to Attenuate Tumor Growth in Triple-Negative cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen](https://doi.org/10.1158/1557-3125.advbc15-a32)Ross J, Wang K, Johnson A, Watson J, Hatzis C, Pusztai L, Chmielecki J, Yelensky R, Lipson J, Vergilio J, Suh J, Miller V, Dicke K, Stephens P, Ali S. Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen Molecular Cancer Research 2016, 14: a32-a32. [DOI: 10.1158/1557-3125.advbc15-a32](https://doi.org/10.1158/1557-3125.advbc15-a32). Safonov Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach Breast Cancer Research Survival in Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26286912)Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer Clinical Cancer 2016, Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer European Journal Of Cancer Prevention and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base](http://www.ncbi.nlm.nih.gov/pubmed/26598753)Killelea BK, Yang VQ, Wang SY, Hayse NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base Journal Of Oncology 2015, 33: the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/26578401)Sanft T, Aktas B, Schroeder B, Bossuyt DiGiovanna M, Abu-Khalaf M, Chung G, Silber S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer Breast Cancer Research Pusztai L. Tumor profiling and the incidentalome: patient decisions and Future 26562094](https://pubmed.ncbi.nlm.nih.gov/26562094), biomarkers for precision medicine](http://www.ncbi.nlm.nih.gov/pubmed/26502353)Zheng Y, Qing T, Song Y, Zhu J, Yu Y, Shi W, Pusztai L, Shi L. Standardization efforts enabling next-generation sequencing and microarray based biomarkers for to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26474971)Pongor L, Kormos M, Hatzis C, Pusztai L, Szab\u00f3 A, Gyrffy B. A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients Rouzier R. Predictive and Prognostic Value of the TauProtein in Cancer. Anticancer of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer](https://doi.org/10.1093/annonc/mdv336.21)Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A21 A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer Annals Of Oncology 2015, 26: vi9. [DOI: 10.1093/annonc/mdv336.21](https://doi.org/10.1093/annonc/mdv336.21). - Agarwal D, Qi Y, Jiang T, Liu X, Shi W, Wali VB, Turk B, Ross JS, Fraser Symmans W, Pusztai L, Hatzis C. Characterization of DNA variants in the human kinome in breast cancer Scientific C, E, FJ, Ueno NT, NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma British Journal NeoSphere G, A, Galeota Magazz\u00f9 B, JL, P, complete response after neoadjuvant HER2-directed therapies in Commentary: Divide and Conquer\u2014Breast Cancer Subtypes and Response to Therapy [PMID: 26275950](https://pubmed.ncbi.nlm.nih.gov/26275950), [DOI: 10.1158/1078-0432.ccr-14-3121](https://doi.org/10.1158/1078-0432.ccr-14-3121). [Abstract 3879: Patient incidental genetic information discovered through high-throughput sequencing](https://doi.org/10.1158/1538-7445.am2015-3879)Yushak M, Bouberhan S, Han G, Epstein L, Mougalian Abu-Khalaf M, Chung G, DiGiovanna M, Sanft T, Pusztai L, Hofstatter E. Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing triple-negative breast cancer](https://doi.org/10.1158/1538-7445.am2015-lb-300)Adams B, Wali V, Cheng C, Inukai S, Rimm D, Pusztai L, Saltzman M, Slack F. Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancer 2015, lb-300-lb-300. [DOI: 10.1158/1538-7445.am2015-lb-300](https://doi.org/10.1158/1538-7445.am2015-lb-300). - Phan L, Chou PC, Velazquez-Torres G, Samudio I, Parreno K, Huang Y, Tseng C, Vu T, Gully C, Su CH, Wang E, Chen J, Choi HH, Fuentes-Mattei E, Shin JH, Shiang C, Grabiner S, Shao Cody D, Delacerda J, Kingsley C, Webb D, Carlock C, Zhou Z, Hsieh YC, Lee J, Elliott A, Ramirez M, Bankson J, Hazle J, Wang Y, Li L, Weng S, Rizk N, Wen YY, Lin X, Wang H, Wang H, Zhang A, Xia X, Wu Y, Habra M, Yang W, Pusztai L, Yeung SC, Lee MH. The cell cycle regulator 14-3-3 opposes and reverses cancer metabolic Wang B, Hess KR, Symmans WF, Shi W, Pusztai L. Reproducibility of Variant Calls in Replicate Next Generation Rognoni Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer Stavris K, Li F, Yao X, Bossuyt V, Harigopal M, Lannin DR, Pusztai L, Horowitz NR. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer New England Journal Of Medicine (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM).](https://doi.org/10.1200/jco.2015.33.15_suppl.1012)Chagpar A, Killelea B, Tsangaris T, Butler M, Stavris K, Yao X, Li F, Bossuyt V, Pusztai L, Horowitz N. Can routine cavity shave margins (CSM) improve local control in breast cancer? Initial results of the SHAVE trial, a prospective randomized controlled trial of routine CSM vs. standard partial mastectomy (SPM). Journal Of Clinical Oncology 33: 1012-1012. [DOI: 10.1200/jco.2015.33.15_suppl.1012](https://doi.org/10.1200/jco.2015.33.15_suppl.1012). [Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.](https://doi.org/10.1200/jco.2015.33.15_suppl.538)Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna Abu-Khalaf M, Chung G, Silber S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. [Mutation-based treatment recommendations A comparison of web tools.](https://doi.org/10.1200/jco.2015.33.15_suppl.e12564)Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter P, Hatzis C, L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. [DOI: 10.1200/jco.2015.33.15_suppl.e12564](https://doi.org/10.1200/jco.2015.33.15_suppl.e12564). [A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).](https://doi.org/10.1200/jco.2015.33.15_suppl.6621)Safonov A, Shi W, Platt J, Aktas B, Kurita T, Pusztai L, Hatzis C. A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER). Clinical Oncology 2015, 33: 6621-6621. [DOI: 10.1200/jco.2015.33.15_suppl.6621](https://doi.org/10.1200/jco.2015.33.15_suppl.6621). [Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.](https://doi.org/10.1200/jco.2015.33.15_suppl.1091)Timms K, Chagpar A, Wali V, Bossuyt V, Reid Gutin A, Neff C, Hofstatter E, Lanchbury J, Pusztai L. Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors. Journal Of Clinical Oncology 2015, 33: 1091-1091. [DOI: 10.1200/jco.2015.33.15_suppl.1091](https://doi.org/10.1200/jco.2015.33.15_suppl.1091). [Discovery and disclosure of incidental genetic information obtained through high throughput sequencing.](https://doi.org/10.1200/jco.2015.33.15_suppl.e17779)Hofstatter E, Yushak M, Bouberhan S, Han G, Epstein L, Pusztai L. Discovery and disclosure of incidental genetic information obtained through high throughput sequencing. Journal Of Clinical Oncology 2015, 33: e17779-e17779. [DOI: 10.1200/jco.2015.33.15_suppl.e17779](https://doi.org/10.1200/jco.2015.33.15_suppl.e17779). Mougalian Hall J, Adelson K, Abu-Khalaf M, Pusztai L, Gross C. Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. Journal Of Clinical Oncology 2015, 33: 1009-1009. [DOI: 10.1200/jco.2015.33.15_suppl.1009](https://doi.org/10.1200/jco.2015.33.15_suppl.1009). [Contribution of immune epirubicin response in triple-negative (TN) M, Karn T, Pusztai L, Gianni L. Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast 2015, 33: [DOI: 10.1200/jco.2015.33.15_suppl.1081](https://doi.org/10.1200/jco.2015.33.15_suppl.1081). [A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.](https://doi.org/10.1200/jco.2015.33.15_suppl.578)Thompson A, Hadad S, Jordan L, Roy P, Purdie C, Iwamoto T, Pusztai L, Moulder S. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. Journal Of Clinical Oncology in Schalper HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer Journal Of The National Cancer Institute 107 [PMID: (pts) with metastatic triple-negative breast cancer (mTNBC)](https://doi.org/10.1093/annonc/mdv115.02)Buisseret L, Specht J, Dees E, Berger R, Gupta S, Geva R, L, Gause C, Karantza V, phase pembrolizumab in patients (pts) with metastatic diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-pd3-2)Jiang T, Shi W, Symmans W, Li C, Platt J, Lau R, Wali V, Lifton R, Pusztai L, Hatzis C. Abstract PD3-2: Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer 2015, pd3-2-pd3-2. [DOI: 10.1158/1538-7445.sabcs14-pd3-2](https://doi.org/10.1158/1538-7445.sabcs14-pd3-2). [Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes](https://doi.org/10.1158/1538-7445.sabcs14-p2-03-05)Bianchini G, Galeota E, Jiang T, Callari T, T, Hatzis C, Pusztai L, Gianni L. Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes 2015, p2-03-05-p2-03-05. [DOI: 10.1158/1538-7445.sabcs14-p2-03-05](https://doi.org/10.1158/1538-7445.sabcs14-p2-03-05). C, Rody A, M\u00fcller V, Schmidt M, Holtrich U, Becker S. Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patients 2015, p2-05-04-p2-05-04. [DOI: 10.1158/1538-7445.sabcs14-p2-05-04](https://doi.org/10.1158/1538-7445.sabcs14-p2-05-04). heterogeneity from breast tumor biopsies](https://doi.org/10.1158/1538-7445.sabcs14-pd3-4)Shi W, Chagpar A, Jiang T, Lannin D, Killelea B, Horowitz N, Lim R, Platt J, Ng C, Wali V, Weigelt B, Reis-Filho J, Hatzis L. of whole exome sequencing for assessing intratumor [DOI: 10.1158/1538-7445.sabcs14-pd3-4](https://doi.org/10.1158/1538-7445.sabcs14-pd3-4). [Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database](https://doi.org/10.1158/1538-7445.sabcs14-p3-07-11)Chagpar A, Mougalian S, Lannin D, Abu-Khalaf M, Killelea T, Pusztai L. Abstract P3-07-11: Trends in clinicopathologic features and systemic therapy use in breast cancer patients: Findings from the National Cancer Database 2015, p3-07-11-p3-07-11. [Abstract OT1-1-13: A Phase 2, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway](https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-13)Abu-Khalaf M, Mayer I, Litten J, Raponi M, Allen A, Pusztai L, Arteaga C. Abstract OT1-1-13: A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in FGF pathway 2015, ot1-1-13-ot1-1-13. [DOI: 10.1158/1538-7445.sabcs14-ot1-1-13](https://doi.org/10.1158/1538-7445.sabcs14-ot1-1-13). [Abstract OT2-3-01: 1 novel antibody-drug conjugate in patients with LIV-1-positive breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-ot2-3-01)Forero A, Burris III H, LoRusso P, Specht J, Miller K, Mita M, Liu M, Modi S, Pusztai L, Sussman D, Kostic A. Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast HER2 (ERBB2) expression chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-02)Yang V, Han G, Mougalian S, Killelea B, Horowitz N, Chagpar A, Hayse B, L, Lannin D. Abstract P3-11-02: Predictors of pathological response to neoadjuvant chemotherapy for breast cancer: 19,310 cases from the national cancer database treated in 2010 and 2011 without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131)](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-16)Nahleh Z, Barlow W, Hayes D, Schott A, Gralow J, Perez E, Sikov W, Chennuru S, Mirshahidi H, Vidito S, Lew pegfilgrastim with or without bevacizumab in treating women with inflammatory or locally advanced breast cancer (NCI CDR0000636131) 2015, p3-11-16-p3-11-16. [DOI: 10.1158/1538-7445.sabcs14-p3-11-16](https://doi.org/10.1158/1538-7445.sabcs14-p3-11-16). [Abstract P4-07-12: Re-introduction of tumor miR-34a therapeutic efficacy in triple negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-p4-07-12)Adams B, Pusztai L, Rimm D, Slack F. Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer 2015, p4-07-12-p4-07-12. [DOI: 10.1158/1538-7445.sabcs14-p4-07-12](https://doi.org/10.1158/1538-7445.sabcs14-p4-07-12). [Abstract S1-09: A phase in patients with advanced triple-negative breast cancer](https://doi.org/10.1158/1538-7445.sabcs14-s1-09)Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez J, Pathiraja K, Karantza V, Iannone R, Gause C, Cheng J, Buisseret L. Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative cancer 10.1158/1538-7445.sabcs14-s1-09](https://doi.org/10.1158/1538-7445.sabcs14-s1-09). CP, Chagpar AB. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States Cancer 2015, 121: 2544-2552. Response to Neoadjuvant Chemotherapy in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25527356)Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer Care Plans: A Feasibility Study](http://www.ncbi.nlm.nih.gov/pubmed/25784577)Bulloch KJ, M, Chung GG, Sanft TB. Systematic Approach to Providing Breast Cancer Survivors With Survivorship Care Plans: A Feasibility for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database](http://www.ncbi.nlm.nih.gov/pubmed/25868410)Killelea BK, Yang VQ, Mougalian S, Horowitz NR, Pusztai L, Chagpar AB, Lannin DR. Neoadjuvant Chemotherapy for Breast Cancer Increases the Rate of Breast Conservation: Results from the National Cancer Database Journal Of The American College Of Surgeons 2015, 220: 1063-1069. 25859546](https://pubmed.ncbi.nlm.nih.gov/25859546), [PMCID: PMC4381696](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381696), [DOI: 10.18632/oncoscience.129](https://doi.org/10.18632/oncoscience.129). [Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive S, Pusztai L, Hatzis C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers Breast Cancer Research And N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab Clinical EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph Jhaveri A, Pusztai L. New targets in breast cancer Memo - Magazine Of European Medical Oncology 2015, 8: 86-91. L. Multigene prognostic tests in breast cancer: past, present, future Breast Bi-Objective Function: Method and Application to Prediction in Oncogenomics](http://www.ncbi.nlm.nih.gov/pubmed/25983540)Gardeux V, Chelouah R, Wanderley MF, Siarry F, Rouzier R, Pusztai L, Natowicz R. Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.](http://www.ncbi.nlm.nih.gov/pubmed/26452382)Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Drug Targets T, Hatzis C, Pusztai L. Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets Breast Cancer Research And Treatment 2014, 148: 477-488. EE, Rem\u00e9dios C, Fend L, Hannani D, F, Kroemer G, Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Nature Medicine 2014, 20: 1301-1309. Schmidt M, Becker S, Holtrich U, Pusztai L. Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer Data In Brief 2014, 2: 354-356. Valero V, Ueno NT, Esteva FJ, Avritscher R, Y, WF. Gene Signature-Guided Dasatinib [DOI: 10.1158/1078-0432.ccr-14-0800](https://doi.org/10.1158/1078-0432.ccr-14-0800). [Dynamic classification using casespecific cohorts outperforms static gene expression signatures in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/25274406)Gyrffy B, Karn T, Sztupinszki Z, Weltz B, M\u00fcller V, Pusztai L. Dynamic classification using casespecific training cohorts outperforms static gene expression signatures in breast cancer International Journal Of Cancer 2014, 136: 2091-2098. [PMID: 25274406](https://pubmed.ncbi.nlm.nih.gov/25274406), Wali VB, Kluger Y, Pusztai transcriptional activates Akt/mTOR signaling accelerating breast carcinogenesis and tumor growth](https://doi.org/10.1158/1538-7445.am2014-3927)Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou P, Shin J, Choi H, Chen J, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva F, Luo Y, McKeehan W, Ensor J, Hortobagyi G, Pusztai L, Symmans W, Lee M, Yeung S. Abstract 3927: Obesity induces changes in adipokines profile and activates Akt/mTOR signaling accelerating breast frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC)](https://doi.org/10.1158/1538-7445.am2014-920)Huelsewig C, Bernemann C, Ruckert C, Kiesel L, Goette M, G, C. Abstract 920: Secreted frizzled related protein 1 (SFRP1) as potential regulator of chemotherapy response for patients with triple negative breast cancer (TNBC) 2014, 920-920. [DOI: 10.1158/1538-7445.am2014-920](https://doi.org/10.1158/1538-7445.am2014-920). - Desmedt Szasz M, Adnet P, Roth\u00e9 D, Kulka J, Sotiriou C. Abstract 986: Unraveling breast cancer progression through geographical and temporal sequencing 2014, 986-986. [DOI: 10.1158/1538-7445.am2014-986](https://doi.org/10.1158/1538-7445.am2014-986). [Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential](http://www.ncbi.nlm.nih.gov/pubmed/25209360)Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, Pusztai L, Huang P. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential Breast Cancer 2014, L. Unvalidated antibodies and misleading results Breast Cancer Research Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24957076)Fuentes-Mattei E, Velazquez-Torres G, Phan L, Zhang F, Chou PC, Shin JH, Choi HH, Chen JS, Zhao R, Chen J, Gully C, Carlock C, Qi Y, Zhang Y, Wu Y, Esteva FJ, Luo Y, McKeehan WL, Ensor J, Hortobagyi GN, Pusztai L, Symmans W, Lee MH, Yeung SC. Effects of Obesity on Transcriptomic Changes and Cancer Hallmarks in Estrogen Receptor-Positive Breast Cancer Journal Of The dju158. [PMID: DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Impact of Financial Burden of Cancer on Survivors' Quality of Life advanced breast and tumors.](https://doi.org/10.1200/jco.2014.32.15_suppl.2561)Jhaveri Abu-Khalaf M, DiGiovanna M, Pusztai N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Of Clinical Oncology 2014, 32: 2561-2561. [DOI: 10.1200/jco.2014.32.15_suppl.2561](https://doi.org/10.1200/jco.2014.32.15_suppl.2561). [Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients.](https://doi.org/10.1200/jco.2014.32.15_suppl.1065)Gyorffy B, Karn T, Sztupinszki Z, Weltz B, Muller V, Pusztai L. Application of a dynamic retraining for each patient using case-specific training cohorts to predict survival in breast cancer patients. Journal Of Clinical Oncology 2014, 32: 1065-1065. [DOI: 10.1200/jco.2014.32.15_suppl.1065](https://doi.org/10.1200/jco.2014.32.15_suppl.1065). [An immune-related signature for of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.](https://doi.org/10.1200/jco.2014.32.15_suppl.530)Bianchini G, Rossi G, Callari M, Iwamoto T, Galeota E, Karn T, Kelly C, M, Santarpia L, Pusztai L, Gianni L. An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer. Journal Of Clinical 10.1200/jco.2014.32.15_suppl.530](https://doi.org/10.1200/jco.2014.32.15_suppl.530). - Nanda Berger R, Elfiky A, Pusztai L, Buisseret L, Geva R, Pai S, Pathiraja K, Iannone R, Gause C, Brown H, Houp J, Cheng J, Chow L. A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. Journal Of Clinical Oncology 2014, 32: tps3119-tps3119. [DOI: 10.1200/jco.2014.32.15_suppl.tps3119](https://doi.org/10.1200/jco.2014.32.15_suppl.tps3119). [In Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas](http://www.ncbi.nlm.nih.gov/pubmed/24647569)Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, Rimm DL. In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas Clinical Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice](http://www.ncbi.nlm.nih.gov/pubmed/24710307)Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L. A Targeted NextGeneration Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications Next generation sequencing: From bench to bedside AACR Education Book 2014, [DOI: D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA. Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer ](http://www.ncbi.nlm.nih.gov/pubmed/24669015)Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24619174)Shi W, Balazs B, Gy\u00f6rffy B, Jiang T, Symmans WF, Hatzis C, Pusztai L. Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers Breast Cancer Research And Treatment 2014, 144: 561-568. [PMID: 24619174](https://pubmed.ncbi.nlm.nih.gov/24619174), [DOI: 10.1007/s10549-014-2904-z](https://doi.org/10.1007/s10549-014-2904-z). [Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue](http://www.ncbi.nlm.nih.gov/pubmed/24602449)Aktas B, Sun H, Yao H, Shi W, Hubbard R, Zhang Y, Jiang T, Ononye SN, Wali VB, Pusztai L, Symmans WF, Hatzis C. Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes](http://www.ncbi.nlm.nih.gov/pubmed/24296856)Chavez-MacGregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes Cancer Epidemiology of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53mutated breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24462521)Gyrffy Bottai L, T, C, G, Th\u00e8 H, Andr\u00e9 F, Sotiriou C, Hortobagyi Pusztai L, Santarpia L. TP53 mutationcorrelated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in receptor-positive and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers Breast Cancer chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype](https://doi.org/10.1158/0008-5472.sabcs13-p4-06-05)Jiang T, Shi W, Ononye S, Han G, Wali V, Pusztai L, Hatzis C. Abstract P4-06-05: Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype Cancer Research 2013, 73: p4-06-05-p4-06-05. [DOI: 10.1158/0008-5472.sabcs13-p4-06-05](https://doi.org/10.1158/0008-5472.sabcs13-p4-06-05). [Abstract P6-06-09: Baseline assessment of left function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-09)Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline Research 2013, 73: p6-06-09-p6-06-09. [DOI: 10.1158/0008-5472.sabcs13-p6-06-09](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-09). [Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-37)Hatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer Cancer Research 2013, 73: p6-06-37-p6-06-37. [DOI: 10.1158/0008-5472.sabcs13-p6-06-37](https://doi.org/10.1158/0008-5472.sabcs13-p6-06-37). [Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-03)Abu-Khalaf M, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James Y, Veronica C. Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience Cancer Research 2013, 73: p6-11-03-p6-11-03. [DOI: 10.1158/0008-5472.sabcs13-p6-11-03](https://doi.org/10.1158/0008-5472.sabcs13-p6-11-03). [Abstract S6-02: Long-term burden (RCB) classification following neoadjuvant chemotherapy](https://doi.org/10.1158/0008-5472.sabcs13-s6-02)Symmans W, Wei C, Gould R, Zhang Y, Hunt K, Buchholz T, Valero V, Hortobagyi G, Pusztai L, Hatzis C. Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy Cancer Research 2013, G, D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States Cancer Research 2013, 73: p3-14-02-p3-14-02. [DOI: use in the United States](https://doi.org/10.1158/0008-5472.sabcs13-p5-13-05)Hofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, M, AbuKhalaf M, Mougalian S, Chagpar P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United 73: p5-13-05-p5-13-05. [DOI: 10.1158/0008-5472.sabcs13-p5-13-05](https://doi.org/10.1158/0008-5472.sabcs13-p5-13-05). [Abstract P1-08-09: EGFR response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-09)Rimm D, Holmes E, Schalper K, Bradbury I, Zarrella Ellis C, Baselga J, Eidtmann H, Piccart M, Harbeck N, Pusztai L, Perez E. Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the [DOI: 10.1158/0008-5472.sabcs13-p1-08-09](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-09). High HER2 expression to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42)Scaltriti C, H, J, Piccart M, Baselga J. Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial Cancer 2013, 73: p1-08-42-p1-08-42. [DOI: 10.1158/0008-5472.sabcs13-p1-08-42](https://doi.org/10.1158/0008-5472.sabcs13-p1-08-42). - Wimberly Pusztai L, Rimm D. Abstract P2-10-02: PD-L1 protein expression is a prognostic biomarker in Research 2013, 73: p2-10-02-p2-10-02. [DOI: 10.1158/0008-5472.sabcs13-p2-10-02](https://doi.org/10.1158/0008-5472.sabcs13-p2-10-02). [Abstract P2-11-04: Expression of immune checkpoint related genes are prognostic in untreated breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p2-11-04)Bianchini G, Rossi C, Iwamoto T, Karn T, Callari M, Kelly C, Pusztai L, Gianni L. Abstract P2-11-04: Expression of immune checkpoint related genes are prognostic in untreated breast cancer Cancer Research 2013, 73: p2-11-04-p2-11-04. [DOI: 10.1158/0008-5472.sabcs13-p2-11-04](https://doi.org/10.1158/0008-5472.sabcs13-p2-11-04). [Abstract P3-01-04: Obesity of estrogen receptor-positive breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p3-01-04)Fuentes-Mattei E, Phan L, Velazquez-Torres G, Zhang F, Chou P, Shin J, Choi H, Chen J, Chen J, Gully C, Carlock C, Zhao R, Qi Y, Zhang Y, Wu Y, Esteva F, Lou Y, McKeehan W, Ensor J, Hortobagyi G, Pusztai L, Symmans W, Lee M, Yeung S. Abstract P3-01-04: Obesity induces functional transcriptomic changes enhancing the cancer hallmarks of estrogen receptor-positive P3-05-05: Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p3-05-05)Gy\u00f6rffy B, Karn T, Sztupinszki Z, Weltz B, M\u00fcller V, Pusztai L. Abstract P3-05-05: Classification using dynamic re-discovery of the strongest prognostic features in each analysis outperforms static gene expression signatures for prognostic prediction in breast cancer Cancer Research 2013, 73: p3-05-05-p3-05-05. [DOI: 10.1158/0008-5472.sabcs13-p3-05-05](https://doi.org/10.1158/0008-5472.sabcs13-p3-05-05). [Abstract P4-04-06: Systematic analysis of molecular subgroups and age in patients with breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-p4-04-06)Liedtke C, Karn T, Gluz O, Becker S, Pusztai L, Holtrich U, Rody A. Abstract P4-04-06: Systematic analysis of molecular subgroups and age in patients with breast cancer Cancer Research 2013, 73: p4-04-06-p4-04-06. [DOI: 10.1158/0008-5472.sabcs13-p4-04-06](https://doi.org/10.1158/0008-5472.sabcs13-p4-04-06). molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by immunohistochemistory](https://doi.org/10.1158/0008-5472.sabcs13-p4-05-09)Iwamoto T, Matsuoka L. P4-05-09: Estrogen receptor (ER) mRNA expression and molecular subtype distribution in breast cancers that are ER-negative but progesterone receptor-positive by [DOI: 10.1158/0008-5472.sabcs13-p4-05-09](https://doi.org/10.1158/0008-5472.sabcs13-p4-05-09). PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers](https://doi.org/10.1158/0008-5472.sabcs13-pd4-6)Shi W, Balazs B, Qi Y, Gy\u00f6rffy B, Wang B, Liu C, Shiang C, Valero V, Moulder-Thompson S, Avritscher R, Powis G, Hortobagyi G, Natowicz R, V, Weinstein J, Symmans W, Pusztai L. Abstract PD4-6: Combined analysis of gene expression, DNA copy number and mutation profiling data to display biological process anomalies in individual cancers Cancer Research 2013, 73: pd4-6-pd4-6. [DOI: 10.1158/0008-5472.sabcs13-pd4-6](https://doi.org/10.1158/0008-5472.sabcs13-pd4-6). [Abstract S3-06: in advanced estrogen receptor positive breast cancer](https://doi.org/10.1158/0008-5472.sabcs13-s3-06)Jeselsohn R, Yelensky R, Buchwalter G, Meric-Bernstam M, Arteaga C, Balko J, Gilmore L, Schnitt S, Come S, Pusztai L, Stephens P, Miller V, Brown M. Abstract S3-06: Emergence of constitutively active estrogen receptor mutations in advanced estrogen receptor positive breast cancer Cancer Research 2013, 73: s3-06-s3-06. [DOI: 10.1158/0008-5472.sabcs13-s3-06](https://doi.org/10.1158/0008-5472.sabcs13-s3-06). [Comparison of non-inflammatory breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24274653)Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, JM, Laere SJ, subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers Predict Taxane Chemosensitivity in Breast Gohda Assay for by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient Journal Of clinical cancer genomic profiling test based on massively parallel DNA sequencing](http://www.ncbi.nlm.nih.gov/pubmed/24142049)Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, Sun J, Juhn F, Brennan K, Iwanik K, Maillet A, Buell J, White E, Zhao M, Balasubramanian S, Terzic S, Richards T, Banning V, Garcia L, Mahoney K, Zwirko Z, Donahue A, Beltran H, Mosquera JM, Rubin Lechner M, Boshoff C, Jarosz M, Vietz C, Parker A, Miller VA, Ross JS, Curran J, Cronin MT, Stephens PJ, Lipson D, Yelensky R. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase](http://www.ncbi.nlm.nih.gov/pubmed/24014597)Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase F. Reproducibility of research and preclinical validation: problems and solutions Nature [PMID: 24080600](https://pubmed.ncbi.nlm.nih.gov/24080600), [DOI: resistance to anthracyclines in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/26484051)Haibe-Kains B, Desmedt C, Di Leo A, Azambuja E, Larsimont Selleslags Delaloge V, Piccart-Gebhart M, Sotiriou C. Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients Data In Brief 21-Gene Recurrence Score (RS) in Early-Stage, Hormone Receptor-Positive, HER2-Normal, Lymph Node-Negative Breast Cancers](https://doi.org/10.1016/j.ijrobp.2013.06.260)Thaker N, Pusztai L, Buchholz T, Woodward W. Complementing Ipsilateral Breast Tumor Recurrence (IBTR!) Estimates With the 21-Gene Recurrence Score (RS) in Early-Stage, Hormone Receptor-Positive, HER2-Normal, Lymph Node-Negative Breast Cancers International Journal Radiation Biology Physics 2013, 87: s100-s101. [DOI: 10.1016/j.ijrobp.2013.06.260](https://doi.org/10.1016/j.ijrobp.2013.06.260). - Hayashi N, Bottai GN, L, Bianchini G. DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/24060333)Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, M\u00fcller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Fasolo A, Del Conte Zambetti M, Sotiriou Haibe-Kains B, Symmans WF, Gianni L. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers Breast in combination with capecitabine in a biweekly schedule in advanced breast cancer.](https://doi.org/10.1200/jco.2013.31.26_suppl.154)James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. [DOI: 10.1200/jco.2013.31.26_suppl.154](https://doi.org/10.1200/jco.2013.31.26_suppl.154). Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA Journal Of of genomics on adjuvant treatments for pre-invasive and invasive breast cancer Breast 2013, 22: s83-s87. [PMID: 24074799](https://pubmed.ncbi.nlm.nih.gov/24074799), [DOI: 10.1016/j.breast.2013.07.015](https://doi.org/10.1016/j.breast.2013.07.015). [Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression Data](http://www.ncbi.nlm.nih.gov/pubmed/23874497)Trentini F, Ji Y, Iwamoto T, Qi Y, Pusztai L, M\u00fcller P. Bayesian Mixture Models for Assessment of Gene Differential Behaviour and Prediction of pCR through the Integration of Copy Number and Gene Expression in Early Stage Breast Cancer and Evaluation of IIITubulin Expression as a Predictive Marker](http://www.ncbi.nlm.nih.gov/pubmed/23853246)Saura C, Tseng L, Chan S, Chacko RT, Campone A, Horak L. Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of IIITubulin Expression as a Predictive Marker KS, P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials Clinical Cancer in combination with capecitabine in a biweekly schedule in advanced breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.2587)James E, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Sowers N, Clark M, Lilian R, Chmael S, Cappiello M, Abraham G, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 2587-2587. E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. [DOI: 10.1200/jco.2013.31.15_suppl.1565](https://doi.org/10.1200/jco.2013.31.15_suppl.1565). [Correlation of heterogeneity with chemotherapy sensitivity in breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.1013)Natowicz R, Jiang T, Shi W, Qi Y, Delpech Y, Symmans W, Pusztai L. Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer. Journal Of Clinical Oncology 2013, 31: 1013-1013. [DOI: 10.1200/jco.2013.31.15_suppl.1013](https://doi.org/10.1200/jco.2013.31.15_suppl.1013). Y, Kulka J, Pusztai L. Genomic alterations in matching primary tumors and metastasis in breast cancer. Journal Of Clinical Oncology 2013, 31: 1549-1549. [DOI: 10.1200/jco.2013.31.15_suppl.1549](https://doi.org/10.1200/jco.2013.31.15_suppl.1549). [Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.](https://doi.org/10.1200/jco.2013.31.15_suppl.532)Pusztai L, Mattair D, Ueno N, Valero V, Moulder S, Murray J, Alvarez R, Chavez-Mac Gregor M, Santiago L, Avritscher R, Sahin A, Hortobagyi G, Symmans W, Meric-Bernstam F, Burton E, Gonzalez-Angulo A. Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection. Journal Of Clinical Oncology 2013, 31: 532-532. [DOI: 10.1200/jco.2013.31.15_suppl.532](https://doi.org/10.1200/jco.2013.31.15_suppl.532). [A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.](https://doi.org/10.1200/jco.2013.31.15_suppl.598)Kelly C, Beamish R, McCaffrey J, SMITH M, Crown J, O'Connor M, McGee S, O'Reilly S, Moylan E, Gonzalez-Angulo A, Litton J, Pusztai L, Kelly C. A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer. Journal 10.1200/jco.2013.31.15_suppl.598](https://doi.org/10.1200/jco.2013.31.15_suppl.598). [Abstract 1899: Metabolic vulnerability of breast on shifts in the expression of metabolic enzyme isoforms.](https://doi.org/10.1158/1538-7445.am2013-1899)Shi W, Gong A, Jiang T, Natowicz R, Pusztai L. Abstract 1899: Metabolic vulnerability of breast cancer based on shifts in the expression of metabolic enzyme breast cancer through receptor tyrosine kinase Axl.](https://doi.org/10.1158/1538-7445.am2013-3032)Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward W, Reuben J, Hortobagyi G, Hung M, Ueno N. Abstract 3032: Tazarotene-induced gene 1 promotes tumorigenicity and invasiveness of inflammatory breast cancer through receptor Wnt signaling as chemotherapy marker of triple negative breast cancer (TNBC).](https://doi.org/10.1158/1538-7445.am2013-5580)Huelsewig C, Bernemann C, Ruckert C, Kiesel L, Pusztai L, Liedtke C. Abstract 5580: Wnt signaling as chemotherapy sensitivity marker of triple negative breast cancer (TNBC). Cancer Research 2013, 73: high-risk categories](http://www.ncbi.nlm.nih.gov/pubmed/23504136)Szekely B, Iwamoto T, Szasz can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories Breast Cancer Research And Treatment 2013, LM, Chan S, Welcher R, D. Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Gonzalez-Angulo AM. The prognostic impact of age in patients with triple-negative breast cancer Breast Cancer Research And Treatment cancer containing tumorigenic CD49f quiescent cells](http://www.ncbi.nlm.nih.gov/pubmed/23376849)Kai K, Iwamoto Kobayashi mammary cells into triple-negative breast cancer containing in oestrogen receptor-positive invasive ductal and C. Cancer heterogeneity: implications for targeted therapeutics Factor Following Neoadjuvant Therapy in Women With Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/23337751)Bayraktar S, Barrera A, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer The Cancer E, Liedtke C, Ahr A, Heinrich TM, S\u00e4nger N, Becker S, Karn T. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes Breast Cancer survival in early-stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/23242617)Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim Pusztai L, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer Breast Cancer Research response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study.](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-17)Karn T, Hatzis C, Symmans F, Pusztai L, Ruckhaberle Schmidt M, Muller V, Hanker L, Heinrich T, Holtrich U, Kaufmann M, Rody A. Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. Cancer Research 2012, 72: p2-10-17-p2-10-17. [DOI: 10.1158/0008-5472.sabcs12-p2-10-17](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-17). HER2-negative breast cancer](https://doi.org/10.1158/0008-5472.sabcs12-p2-10-10)Bianchini Callari M, Symmans W, Gianni L. Abstract P2-10-10: implications of molecular heterogeneity in highly proliferative, ER-positive, tumour infiltrating immune cell programs in distinct molecular breast cancer subtypes](https://doi.org/10.1158/0008-5472.sabcs12-p5-10-01)Paladini L, Truglia M, Arcangeli A, De Mattos Iwamoto T, Bottai G, Pusztai L, G, Di Leo A, Santarpia L. Abstract P5-10-01: MicroRNAs 181 and 135a modulate tumour infiltrating immune cell programs in distinct molecular breast cancer subtypes Cancer Research 2012, 72: p5-10-01-p5-10-01. [DOI: 10.1158/0008-5472.sabcs12-p5-10-01](https://doi.org/10.1158/0008-5472.sabcs12-p5-10-01). [Abstract S6-7: Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study](https://doi.org/10.1158/0008-5472.sabcs12-s6-7)Gianni L, Bianchini G, Valagussa P, Belousov A, Thomas M, Ross G, Pusztai L. Abstract S6-7: Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere [DOI: 10.1158/0008-5472.sabcs12-s6-7](https://doi.org/10.1158/0008-5472.sabcs12-s6-7). [High stearoyl-CoA desaturase 1 expression is with shorter survival in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/23208590)Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients Breast Cancer Research And Treatment the Pathological Response of Breast Cancer Patients to Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/23185353)Shen K, Song N, Kim Y, Tian C, Rice SD, Gabrin MJ, Symmans WF, Pusztai L, Lee JK. A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients Setting: A Model to Safely Tailor Care While Accelerating Drug Development](http://www.ncbi.nlm.nih.gov/pubmed/23169510)Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Veer L, Berry DA, Esserman L. Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development Journal Of Clinical Oncology 2012, to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/23158478)Shen K, Qi Y, Song N, Tian Rice SD, Gabrin MJ, Brower SL, Symmans WF, O'Shaughnessy J, Pusztai L. Cell Line Derived Multi-Gene Predictor of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer: A Validation Study on US Oncology 02-103 Clinical Dean-Colomb Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 10-10. [DOI: 10.1200/jco.2012.30.30_suppl.10](https://doi.org/10.1200/jco.2012.30.30_suppl.10). - Cheng J, Greshock J, Shi L, Painter J, Lin X, Lee K, Zheng S, Wooster R, Pusztai L, Menius A. An Adaptive Feature Selection Method for Microarray Data Analysis 2012, 1-6. [DOI: 10.1109/bibm.2012.6392686](https://doi.org/10.1109/bibm.2012.6392686). - Dumay Bertheau P, Espi\u00e9 M, Plassa L, Cottu P, M, Andr\u00e9 F, Sotiriou C, Pusztai L, de Th\u00e9 H. Distinct tumor protein p53 mutants in breast cancer subgroups International Journal Of Cancer 2012, 1227-1231. [PMID: 22886769](https://pubmed.ncbi.nlm.nih.gov/22886769), [DOI: 10.1002/ijc.27767](https://doi.org/10.1002/ijc.27767). - Pusztai L. Molecular Triage Help to Identify Highly Sensitive Disease? Annals Of Oncology 2012, + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups](https://doi.org/10.1016/s0923-7534(20)32783-6)Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly C, Qi Y, Motoki T, Taira N, Santarpia L, Doihara H, G. 172O ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups Annals Of Oncology 2012, 23: ix74-ix75. [DOI: 10.1016/s0923-7534(20)32783-6](https://doi.org/10.1016/s0923-7534(20)32783-6). [Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22890751)Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer [PMID: 22890751](https://pubmed.ncbi.nlm.nih.gov/22890751), Oncology 2012, 30: 2931-2931. [DOI: 10.1200/jco.2012.43.5990](https://doi.org/10.1200/jco.2012.43.5990). [Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping](http://www.ncbi.nlm.nih.gov/pubmed/22759093)Schwartz H, Burstein HJ, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, ReisFilho Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping E, Booser D, Hatzis C, Wallace M, Zhang Y, Gong Y, Ignatiadis M, Sotiriou C, Andre F, Peintinger F, Regitnig P, Marth C, Desmedt C, Loi S, Moulder S, Hortobagyi G, Pusztai L, Valero V. Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance [DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes.](https://doi.org/10.1200/jco.2012.30.15_suppl.1012)Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer Guarducci C, Symmans W, Hortobagyi G, Pusztai L, Giampaolo B. DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. Journal Of Clinical Oncology 2012, 30: 1012-1012. [DOI: comparison and human triple-negative noninflammatory breast cancer (TN-non-IBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.1047)Masuda H, Baggerly K, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Woodward W, Reuben J, Van Laere S, Bertucci F, Hortobagyi G, Ueno N. Molecular comparison of human triple-negative inflammatory breast cancer (TN-IBC) and human triple-negative noninflammatory breast to high frequency of targetable alterations in primary and metastatic breast cancer (MBC).](https://doi.org/10.1200/jco.2012.30.15_suppl.10559)Pusztai L, Yelensky R, Wang B, Avritscher R, Symmans W, Lipson D, Palmer G, Moulder S, Stephens P, Wu Y, Cronin M. Use of next-generation sequencing (NGS) to detect high frequency of targetable alterations in primary and metastatic breast cancer (MBC). Journal Clinical Oncology 2012, 30: 10559-10559. [DOI: 10.1200/jco.2012.30.15_suppl.10559](https://doi.org/10.1200/jco.2012.30.15_suppl.10559). - Dean-Colomb W, Hess K, Young E, Gornet T, Handy B, Moulder S, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi G, Esteva F. Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer. Journal 10613-10613. 10.1200/jco.2012.30.15_suppl.10613](https://doi.org/10.1200/jco.2012.30.15_suppl.10613). - Giampaolo T, Kelly C, Zambetti M, Symmans W, Gianni L. A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. Journal Of Clinical Oncology 2012, 30: 545-545. [DOI: 10.1200/jco.2012.30.15_suppl.545](https://doi.org/10.1200/jco.2012.30.15_suppl.545). - Kelly C, Parker I, McCaffrey J, Crown J, O'Connor M, McGee S, Pusztai L, Kelly C. Assessment of method of breast cancer detection and Onco type DX recurrence score. Journal Of Clinical Oncology 2012, 30: 581-581. [DOI: 10.1200/jco.2012.30.15_suppl.581](https://doi.org/10.1200/jco.2012.30.15_suppl.581). L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. for relapse in estrogen protein-A, prognostic marker for relapse in estrogen receptor-positive breast Sensitivity to Endocrine Therapy (Set)](https://doi.org/10.1016/s0923-7534(19)65684-x)Karn T, Hatzis C, Symmans W, Pusztai V, U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set) Annals Of Oncology 2012, 23: ii18. [DOI: 10.1016/s0923-7534(19)65684-x](https://doi.org/10.1016/s0923-7534(19)65684-x). - Chen W, Yousef Gallas Hsu E, Lababidi S, Tang R, Pennello G, Symmans W, Pusztai L. Uncertainty estimation with a finite dataset in the assessment of classification models Computational Statistics & Data Analysis 2012, 56: 1016-1027. [DOI: 10.1016/j.csda.2011.05.024](https://doi.org/10.1016/j.csda.2011.05.024). [Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/22538770)Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen V, GN, WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers Breast Cancer Research And and \"TCF7L2\" as novel potential biomarkers of triple negative breast cancer](https://doi.org/10.1158/1538-7445.am2012-3024)Huelsewig C, Goette M, Bernemann C, Ruckert C, Liedtke of WNT signaling pathway players \"sFRP-1\" and \"TCF7L2\" as novel potential biomarkers of triple negative breast cancer Cancer Research [DOI: 10.1158/1538-7445.am2012-3024](https://doi.org/10.1158/1538-7445.am2012-3024). [Abstract 682: Increased stearoyl-CoA desaturase 1 is associated with shorter survival in breast cancer patients](https://doi.org/10.1158/1538-7445.am2012-682)Holder A, Gonzalez-Angulo A, Chen H, Akcakanat A, Anh-Do K, Symmans F, Pusztai L, Hortobagyi G, Meric-Bernstam F. Abstract 682: Increased stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients Cancer Research 2012, 72: 682-682. [DOI: 10.1158/1538-7445.am2012-682](https://doi.org/10.1158/1538-7445.am2012-682). Swanton C. Intratumor Heterogeneity: Seeing the Wood for the Trees 2012, 4: 127ps10. clinical outcome for human HER2+:ER breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/22460789)Liu JC, Voisin V, Bader GD, Deng WF, Esteva FJ, signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America Score Assay (Oncotype DX\u00ae) and EarlyStage Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22418568)Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L. Agreement in Risk Prediction Between the 21Gene Recurrence Score Assay (Oncotype DX\u00ae) and Rutgers EJ, Solin LJ, Palazzo J, Committee A. Adjuvant therapy in stage I carcinoma of the breast Cancer pathways that drive breast cancer clinical subtypes](http://www.ncbi.nlm.nih.gov/pubmed/22343619)Dutta B, Pusztai L, Qi Y, Andr\u00e9 F, Lazar V, Bianchini G, N, Agarwal WF, Bal\u00e1zsi network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes British Journal Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22235097)Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer Clinical Cancer in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry](http://www.ncbi.nlm.nih.gov/pubmed/22291085)Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by trial](http://www.ncbi.nlm.nih.gov/pubmed/22257673)Baselga Eidtmann Di Cosimo S, de Azambuja E, Aura C, G\u00f3mez H, Dinh P, Fauria K, Van Dooren V, Aktan Goldhirsch A, Chang Horv\u00e1th Z, M, Team O. Lapatinib with early breast cancer (NeoALTTO): a randomised, open-label, Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures](http://www.ncbi.nlm.nih.gov/pubmed/22220191)Karn T, Pusztai L, Holtrich U, Iwamoto Shiang M, M\u00fcller V, Solbach C, Gaetje R, Hanker L, Ahr E, Kaufmann M, Rody A. Homogeneous Datasets of Triple Negative Breast Cancers Enable the Identification of Novel Prognostic and Predictive Signatures the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile](http://www.ncbi.nlm.nih.gov/pubmed/22369035)Zhao C, Shi L, Tong W, Shaughnessy JD, Oberthuer A, Pusztai L, Deng Y, Symmans WF, Shi T. Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22193884)Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer Annals Of Surgical Oncology 2011, 19: 1508-1516. [PMID: 22193884](https://pubmed.ncbi.nlm.nih.gov/22193884), [DOI: 10.1245/s10434-011-2108-2](https://doi.org/10.1245/s10434-011-2108-2). - Chang C, Wang J, Zhao C, Fostel J, Tong W, Bushel PR, Deng Y, Pusztai L, Symmans WF, Shi T. Maximizing biomarker discovery in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry.](https://doi.org/10.1158/0008-5472.sabcs11-p1-07-09)Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, Ueno N, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi G, Hatzis C, Symmans Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive Immunohistochemistry. Cancer Research 2011, A Inflammatory Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness Kinase Axl.](https://doi.org/10.1158/0008-5472.sabcs11-p2-02-01)Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward W, Reuben J, Hortobagyi G, Ueno N. P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through Lehmann-Che J, Bertheau P, Espie M, de C, Andre F, Sotiriou C, Pusztai L, de T. P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups. Cancer Research 2011, 71: p2-02-09-p2-02-09. [DOI: 10.1158/0008-5472.sabcs11-p2-02-09](https://doi.org/10.1158/0008-5472.sabcs11-p2-02-09). [P2-12-06: Nomogram To Predict with Non Metastatic Breast Carcinomas.](https://doi.org/10.1158/0008-5472.sabcs11-p2-12-06)Lousquy R, Delpech Y, Rouzier R, Gligorov E, Pusztai L, S, Hortobagyi G, Coutant C, Ibrahim N. P2-12-06: Nomogram To Predict Subsequent Bone Metastasis in Patients with Non Metastatic Breast Carcinomas. Cancer Delord M, Soulier J, Hamy A, Espie M, Andre F, Marty M, Sotiriou C, Piccart-Gebhart M, Pusztai L, Bertheau P, de T. P3-05-01: Gene Profiling of Histopathologically Characterized Apocrine Breast 2011, ApoE and Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target.](https://doi.org/10.1158/0008-5472.sabcs11-p3-17-01)Shiang C, Qi Y, Wang B, Broom B, Pusztai L. P3-17-01: ApoE and Its Receptors (LRP8, VLDLR) Function as Growth Signals for Triple-Negative Breast Cancer and Represent a Novel Therapeutic Target. Cancer Research 2011, 71: p3-17-01-p3-17-01. [DOI: 10.1158/0008-5472.sabcs11-p3-17-01](https://doi.org/10.1158/0008-5472.sabcs11-p3-17-01). [P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model.](https://doi.org/10.1158/0008-5472.sabcs11-p4-03-04)Kai K, Iwamoto T, Pusztai L, Hortobagyi G, Saya H, Ueno N. P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model. Cancer Research 2011, 71: p4-03-04-p4-03-04. [DOI: 10.1158/0008-5472.sabcs11-p4-03-04](https://doi.org/10.1158/0008-5472.sabcs11-p4-03-04). [P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers.](https://doi.org/10.1158/0008-5472.sabcs11-p4-16-02)Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Nakamura S, Hortobagyi G, Pusztai L, Symmans F, Ueno N. P4-16-02: Problems with Identifying Bone Metastasis-Specific Genes without Considering Biological Differences between ER-Positive and ER-Negative Breast Cancers. Cancer Research 2011, Karn Schmidt M, Muller V, Gatje R, Hanker L, A, Holtrich A, Kaufmann M. PD03-02: Prognostic and Predictive Predictors for Triple Negative Breast Cancer. Cancer Research 2011, 71: pd03-02-pd03-02. [DOI: 10.1158/0008-5472.sabcs11-pd03-02](https://doi.org/10.1158/0008-5472.sabcs11-pd03-02). - Bianchini C, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans W, Gianni L. S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. Cancer Research 2011, 71: s1-7-s1-7. [DOI: 10.1158/0008-5472.sabcs11-s1-7](https://doi.org/10.1158/0008-5472.sabcs11-s1-7). - Pusztai L, Qi Y, Shi W, Liu C, Wang B, Liu X, Booser D, Esteva F, Symmans F, Hortobagyi G. S6-4: Protein Kinase Mutation Patterns in Human Breast Cancer. Cancer Research 2011, 71: s6-4-s6-4. [DOI: 10.1158/0008-5472.sabcs11-s6-4](https://doi.org/10.1158/0008-5472.sabcs11-s6-4). [Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems](http://www.ncbi.nlm.nih.gov/pubmed/22132775)Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems chemotherapy sensitivity in different molecular subtypes of breast cancer](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247034)Pusztai L. Gene pathways associated with prognosis and chemotherapy sensitivity in different molecular subtypes of breast cancer Breast Cancer Research profiling in breast cancer: classification, prognostication, and prediction neoadjuvant breast cancer clinical trials: timing and specimen types](http://www.ncbi.nlm.nih.gov/pubmed/21684810)Loi S, Symmans WF, Bartlett J, Fumagalli D, Veer LJ, BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen [PMID: 21684810](https://pubmed.ncbi.nlm.nih.gov/21684810), [DOI: Integrity and Microarray Measurements From Resected Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/22034635)Hatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers Journal Of The National Biology: Two Complementary Sides of Breast Cancer Prognostication Journal L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, M\u00fcller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer Breast Cancer to trastuzumab and tumor presence in breast cancer patients](http://www.ncbi.nlm.nih.gov/pubmed/22370716)Jung E, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le X, Bast RC, Park S, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients The Value of Genomic Analysis of Breast Cancer in Drug differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes.](https://doi.org/10.1200/jco.2011.29.27_suppl.157)Chavez-MacGregor M, Liu S, Chen H, Do K, Pusztai L, Symmans W, Hortobagyi G, Mills G, Meric-Bernstam F, Gonzalez-Angulo A. Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. Journal Of Clinical Oncology 2011, 29: 157-157. [DOI: 10.1200/jco.2011.29.27_suppl.157](https://doi.org/10.1200/jco.2011.29.27_suppl.157). [Capecitabine in operable breast A subgroup analysis of a randomized phase III trial.](https://doi.org/10.1200/jco.2011.29.27_suppl.292)Kelly C, Green M, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim N, Gonzalez-Angulo A, Booser D, Hunt K, Hortobagyi G, Buzdar A. Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial. Journal Of Clinical Oncology 2011, 29: 292-292. [DOI: 10.1200/jco.2011.29.27_suppl.292](https://doi.org/10.1200/jco.2011.29.27_suppl.292). [Response to Neoadjuvant Systemic for in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience](http://www.ncbi.nlm.nih.gov/pubmed/21900106)Arun B, Bayraktar S, Liu DD, Barrera A, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience INVITED Role of Gene Expression Profiling for Biomarker Discovery European Journal Of Cancer 2011, 47: s78. Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic Nature Reviews Clinical Oncology gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations](http://www.ncbi.nlm.nih.gov/pubmed/21833625)Iwamoto T, Lee JS, Bianchini G, Hubbard RE, WF, Hortobagyi GN, Pusztai L. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations Breast Cancer Research And Treatment 2011, 130: 155. [PMID: 21833625](https://pubmed.ncbi.nlm.nih.gov/21833625), Nikoloff DM, Hillman Fontecha M, Li R, Michaud L, Hortobagyi G, GonzalezAngulo A. Effect of CYP2D6 polymorphisms on breast 21823108](https://pubmed.ncbi.nlm.nih.gov/21823108), of chemotherapy response](http://www.ncbi.nlm.nih.gov/pubmed/21798043)Li Q, Eklund S, Richardson AL, Szallasi Z. Consistent metagenes from cancer expression profiles yield agent specific predictors of predict pathologic complete response in patients with breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21906370)Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer Clinical by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation](http://www.ncbi.nlm.nih.gov/pubmed/21741824)Karn T, Pusztai L, Ruckh\u00e4berle E, Liedtke C, M\u00fcller J, Coombes KR, G\u00e4tje R, Hanker U, Rody A, Kaufmann M. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation European Journal Of Cancer 2011, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients Breast Cancer Research And Treatment 2011, 129: 451-458. [PMID: 21710134](https://pubmed.ncbi.nlm.nih.gov/21710134), [DOI: 10.1007/s10549-011-1645-5](https://doi.org/10.1007/s10549-011-1645-5). a pre-operative, window-of-opportunity, Iwamoto G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial 21655990](https://pubmed.ncbi.nlm.nih.gov/21655990), chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).](https://doi.org/10.1200/jco.2011.29.15_suppl.1016)Gonzalez-Angulo A, Green M, Murray J, Palla S, Koenig K, Brewster A, Valero V, Ibrahim N, Moulder S, Litton J, Crawford D, Flores P, Dryden M, Symmans W, Giordano S, Pusztai L, Buzdar A, Mills G, Hortobagyi G, Meric-Bernstam F. Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer the to assess risk in ER+ breast cancers: A direct comparison to Onco type DX.](https://doi.org/10.1200/jco.2011.29.15_suppl.503)Bastien R, Ebbert M, Boucher K, Kelly C, Wang B, Iwamoto T, Krishnamurthy S, Pusztai L, Bernard P. Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to Onco type DX. Of Clinical Oncology 2011, 29: 503-503. neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer.](https://doi.org/10.1200/jco.2011.29.15_suppl.534)Thompson A, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Hardie G, Pusztai L, Moulder S, Dewar J, Hadad S. Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. Journal Of Clinical Oncology 2011, 29: 534-534. [DOI: 10.1200/jco.2011.29.15_suppl.534](https://doi.org/10.1200/jco.2011.29.15_suppl.534). [A Genomic Predictor of and Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/21558518)Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chac\u00f3n JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, J, Hortobagyi GN, Symmans Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast L, Liedtke M\u00fcller V, Schmidt M, Metzler D, Wang J, Coombs K, S\u00e4nger N, G\u00e4tje R, Hanker L, Ahr U, Rody A, M. Mogushi K, Tanaka H, Iwamoto T, Pusztai L, Hortobagyi G, Saya H, Ueno N. Abstract 2376: Mouse mammary tumor model relevant to human triple negative breast cancer Cancer Research 2011, 71: as growth signals for triple-negative breast cancer and represents novel therapeutic targets](https://doi.org/10.1158/1538-7445.am2011-lb-219)Shiang C, Qi Y, Wang B, Broom B, Pusztai L. Abstract LB-219: ApoE and its' receptors (LRP8, VLDLR) function as growth signals for triple-negative breast cancer and represents novel therapeutic targets Cancer Research 2011, 71: lb-219-lb-219. [DOI: 10.1158/1538-7445.am2011-lb-219](https://doi.org/10.1158/1538-7445.am2011-lb-219). [Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/21248301)Coutant C, Rouzier R, F, de Th\u00e9 H, Pusztai L. Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers Clinical [DOI: profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure](https://doi.org/10.1002/prca.201190010)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andr\u00e9 F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure Proteomics Clinical Applications 2011, 5: 193-193. [DOI: 10.1002/prca.201190010](https://doi.org/10.1002/prca.201190010). - Desmedt C, Di Leo A, Larsimont D, Haibe-Kains B, Selleslags V, Piccart-Gebhart M, Sotiriou C. Multifactorial Approach to Predicting Resistance to 2011, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a Oncology 2011, a call for a comprehensive biomarker study registry Clinical 21364690](https://pubmed.ncbi.nlm.nih.gov/21364690), [DOI: 10.1038/nrclinonc.2011.4](https://doi.org/10.1038/nrclinonc.2011.4). - Pusztai L, Kelly C. Systemic Adjuvant Therapy for Stage I Breast Cancer 2011, 269-281. [DOI: 10.1007/978-94-007-0489-3_11](https://doi.org/10.1007/978-94-007-0489-3_11). [Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/21191116)Iwamoto T, Bianchini G, Booser D, Qi B, J, Andre F, Simon R, Pusztai L. Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer Journal Of The National Cancer Institute 2010, 103: 264-272. [PMID: 21191116](https://pubmed.ncbi.nlm.nih.gov/21191116), [DOI: and immonohistochemistry to breast cancer diagnostics](http://www.ncbi.nlm.nih.gov/pubmed/21172090)Shiang C, Pusztai L. Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics Breast Animal Model of Human Triple-Negative Breast Cancer by Retroviral Oncogene Transduction of Mouse Mammary Cells](https://doi.org/10.1158/0008-5472.sabcs10-p1-03-02)Kai Pusztai L, Hortobagyi G, Ueno N. Abstract P1-03-02: Development of a Novel Animal Model of Human Triple-Negative Breast Cancer by Retroviral Oncogene Transduction of Mouse Mammary P2-09-39: Multi-Gene Predictors Developed Cell Lines To Predict Response to Chemotherapy: A Validation Study on US Oncology Study 02-103](https://doi.org/10.1158/0008-5472.sabcs10-p2-09-39)Shen K, Pusztai L, Qi Y, Symmans W, Song N, Rice S, Gabrin M, O'Shaughnessy J, Holmes F. Abstract P2-09-39: Multi-Gene Predictors Developed from Breast Cancer Cell Lines To Predict Response to Chemotherapy: A Validation Study on US Oncology Study Leo Calin G, Symmans Esteva F, Hortobagyi G, Pusztai L. Abstract P3-09-03: microRNAs and Target Gene Networks in Breast Cancer Cell Lines Cancer Research 2010, 70: p3-09-03-p3-09-03. [DOI: Inflammatory Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p5-05-05)Wang X, Saso H, Iwamoto Pusztai P5-05-05: Tazarotene-Induced Gene 1(TIG1) Is a Novel Tumorigenic Gene of Inflammatory Breast Cancer Cancer Research 2010, 70: p5-05-05-p5-05-05. [DOI: 10.1158/0008-5472.sabcs10-p5-05-05](https://doi.org/10.1158/0008-5472.sabcs10-p5-05-05). [Abstract P5-10-02: Clinical of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC)](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-02)Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. Abstract P5-10-02: Clinical Outcome of Two Sequences of Administering Paclitaxel (P) and Anthracyclines (A) as Primary Systemic Therapy (PST) and Adjuvant Chemotherapy (ACT) in Breast Cancer (BC) Patients: A Retrospective Analysis from the M. D. Anderson Cancer Center (MDACC) Cancer Research 2010, 70: p5-10-02-p5-10-02. [DOI: 10.1158/0008-5472.sabcs10-p5-10-02](https://doi.org/10.1158/0008-5472.sabcs10-p5-10-02). [Abstract P6-14-06: Prospective Testing of Three Gene-Signatures for Patient Selection for Dasatinib Therapy in Metastatic Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-p6-14-06)Pusztai L, Moulder S, Litton J, Valero V, Ueno N, Melhem-Bertrandt A, Morrow P, Dotter K, Mattair D, Strauss L, Hortobagyi G, Qi Y, Symmans W. Abstract P6-14-06: Prospective Testing of Three Different Gene-Signatures for Patient Selection for Dasatinib Therapy in Metastatic Breast Cancer Research 2010, 70: [DOI: Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis](https://doi.org/10.1158/0008-5472.sabcs10-pd07-01)Saura C, Tseng L, Chan S, Chacko R, Campone M, Liu D, Mukhopadhyay J, Mudenda B, Horak C, Xing G, Pusztai L. Abstract PD07-01: Phase 2 Study of Ixabepilone Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis Cancer Research 2010, 70: in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to Paclitaxel (pac)](https://doi.org/10.1158/0008-5472.sabcs10-pd07-02)Horak C, Pusztai L, Mudenda B, Xing G, Trifan O, Saura C, Tseng L, Chan S, Welcher R, Liu D. Abstract PD07-02: III Tubulin Expression by Immunohistochemistry (IHC) and mRNA in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to [DOI: 10.1158/0008-5472.sabcs10-pd07-02](https://doi.org/10.1158/0008-5472.sabcs10-pd07-02). [Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer](https://doi.org/10.1158/0008-5472.sabcs10-s5-5)Rody A, Karn T, Liedtke L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M. Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer Cancer Research 2010, 70: s5-5-s5-5. [DOI: 10.1158/0008-5472.sabcs10-s5-5](https://doi.org/10.1158/0008-5472.sabcs10-s5-5). [Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/21153052)Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer Breast Cancer Research And L, Members T. Use of standard markers and incorporation of molecular markers into breast cancer therapy Cancer 2010, 117: 1575-1582. [PMID: 21472705](https://pubmed.ncbi.nlm.nih.gov/21472705), [DOI: 10.1002/cncr.25660](https://doi.org/10.1002/cncr.25660). - Iwamoto T, Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome 2010, GN, Meric-Bernstam F. Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer Annals Of CA. Estrogen and HER2 Receptor Discordance Between Primary Kinase Expression Patterns in Different Subtypes of Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20959472)Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, WF, Gianni L. Prognostic and Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer 2010, Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20829329)Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, LJ, Souchon E, Paclitaxel, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer Clinical [PMID: M, Pusztai L, Sneige N. Stability of estrogen receptor status in 2010, 117: 20939012](https://pubmed.ncbi.nlm.nih.gov/20939012), [DOI: profiles during neoadjuvant chemotherapy in HER2positive breast cancer using an LCMALDITOF/MS procedure](http://www.ncbi.nlm.nih.gov/pubmed/20827732)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andr\u00e9 F, Buzdar AU, Martin P, Kobayashi R, Pusztai L. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2positive breast cancer Vannucci Do K, Broom B, Kim S, Sha N, Tadesse M, Yan K, Pusztai L. Gene Selection for the Identification of Biomarkers in High- Throughput Data 2010, 259-280. [DOI: 10.1201/ebk1420070170-14](https://doi.org/10.1201/ebk1420070170-14). [Molecular Anatomy of Breast Cancer Value in Estrogen Receptor-Positive and G, Alvarez T, Coutant Ibrahim NK, Valero WF, Pusztai L. Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor-Positive and [DOI: 10.1200/jco.2009.27.2419](https://doi.org/10.1200/jco.2009.27.2419). [The role tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches](http://www.ncbi.nlm.nih.gov/pubmed/20739212)Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches Drug Resistance Updates C, Domont DJ, GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer Journal Of common practices for the development and validation of microarray-based predictive models.](http://www.ncbi.nlm.nih.gov/pubmed/20676074)Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. in clinically intermediate risk hormone receptorpositive, HER2normal, grade II, lymph nodenegative breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/20665886)Kelly CM, Krishnamurthy Bianchini G, Litton JK, GonzalezAngulo A, Hortobagyi GN, Pusztai L. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptorpositive, HER2normal, grade II, lymph nodenegative F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. [PMID: 20665494](https://pubmed.ncbi.nlm.nih.gov/20665494), [DOI: of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers.](https://doi.org/10.1200/jco.2010.28.15_suppl.1039)Santarpia L, Gonzalez-Angulo A, Qi Y, Stemke-Hale K, Wang B, Booser D, Hortobagyi G, Symmans W, Di Leo A, Pusztai L. Use of mutation profiling of breast cancer using sequenom technology to detect distinct mutation patterns in triple-negative compared to receptor-positive cancers. Journal Of Clinical Oncology 2010, 28: 1039-1039. [DOI: 10.1200/jco.2010.28.15_suppl.1039](https://doi.org/10.1200/jco.2010.28.15_suppl.1039). [Do experts agree on to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research.](https://doi.org/10.1200/jco.2010.28.15_suppl.1084)Saad E, Katz A, Pusztai L, Hoff P, Buyse M. Do experts agree on how to assess disease progression (DP) and progression-free survival (PFS) in phase III trials? A survey with experts in breast cancer research. Journal Of Clinical Oncology 2010, 28: 1084-1084. L, Mueller V, Schmidt M, Holtrich U, Kaufmann M. Clinically relevant gene signatures in triple-negative and basal-like breast cancer. Journal Of Clinical Oncology 2010, 28: 521-521. [DOI: 10.1200/jco.2010.28.15_suppl.521](https://doi.org/10.1200/jco.2010.28.15_suppl.521). [Correlation of in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy.](https://doi.org/10.1200/jco.2010.28.15_suppl.522)Loi S, Haibe-Kains B, Brown D, Metallo J, Huan Desmedt C, Pusztai L, Piccart M, Esteva F, Sotiriou C. Correlation of molecular and clinically distinct phenotypes in HER2-overexpressing breast cancer (HER2+ BC) with estrogen receptor status (ER) status: Implications for anti-HER2 therapy. Clinical Oncology and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.](https://doi.org/10.1200/jco.2010.28.15_suppl.548)Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. Journal Of Clinical Oncology 2010, 28: 548-548. [DOI: 10.1200/jco.2010.28.15_suppl.548](https://doi.org/10.1200/jco.2010.28.15_suppl.548). [Use of efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and Goubar A, Lacroix Desmedt V, Sotiriou C, Mathieu M, Delaloge S, Pusztai L. Use of myxovirus resistance 1 (MX1) expression to predict efficacy of anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant and adjuvant Oncology 2010, 28: [DOI: ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer.](https://doi.org/10.1200/jco.2010.28.15_suppl.569)Swanton C, Juul N, Larkin J, Eklund A, Li Q, Desmedt C, Sotiriou C, Pusztai L, Szallasi Z. Use of an RNA interference screen-derived mitotic and ceramide pathway metagene to predict response to paclitaxel combination chemotherapy in primary breast cancer. Journal Of Clinical Oncology 2010, 28: 569-569. Pusztai L, Gonzalez-Angulo A. The prognostic impact of age in patients with triple-negative breast cancer. Journal Of Clinical Oncology 2010, 28: 597-597. [DOI: 10.1200/jco.2010.28.15_suppl.597](https://doi.org/10.1200/jco.2010.28.15_suppl.597). - Pusztai L, Moulder Litton Valero V, Ueno N, Morrow P, Dotter K, Mattair D, Strauss L, Symmans W. Gene-signature-based patient selection for dasatinib therapy in metastatic breast cancer 2010, 28: tps130-tps130. [DOI: 10.1200/jco.2010.28.15_suppl.tps130](https://doi.org/10.1200/jco.2010.28.15_suppl.tps130). [PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/20479250)Loi Haibe-Kains P, Tutt AN, CE, Mills GB, Phillips MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, cancer prognostic markers in the post-genomic era Breast Cancer Research And 2010, 125: 647-650. [PMID: 20464478](https://pubmed.ncbi.nlm.nih.gov/20464478), [DOI: 10.1007/s10549-010-0932-x](https://doi.org/10.1007/s10549-010-0932-x). F, Hatzis C, Pusztai L. Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy Cancer Breast Cancer 2010, 297-323. [DOI: 10.1201/b11127-15](https://doi.org/10.1201/b11127-15). [Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials](http://www.ncbi.nlm.nih.gov/pubmed/20421265)Andre Pusztai GN. Receptor and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four an effective therapeutic approach for triple-negative breast cancer](https://doi.org/10.1158/1538-7445.am10-lb-107)Pelicano H, Zhang W, Hammoudi N, Pusztai L, Dai J, Huang P. Abstract LB-107: Targeting the glycolytic pathway as an effective therapeutic approach for triple-negative breast cancer Cancer Research 2010, 70: lb-107-lb-107. [DOI: 10.1158/1538-7445.am10-lb-107](https://doi.org/10.1158/1538-7445.am10-lb-107). Graesslin O, Abdulkarim Gabos Z, Hsu L, NK. to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer Journal Tumor Progression During Neoadjuvant Chemotherapy in Breast Cancer Journal Of of p53 Mutant Breast Cancers](http://www.ncbi.nlm.nih.gov/pubmed/20228131)LehmannChe J, Andr\u00e9 F, Desmedt C, Mazouni C, Giacchetti WF, H. Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials](http://www.ncbi.nlm.nih.gov/pubmed/20189874)Juul N, Szallasi Z, Eklund AC, Li Q, Burrell RA, C, Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials 2010, 11: 358-365. Response to Neoadjuvant Chemotherapy in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/20068086)Lee JK, Coutant C, Kim WF, Baggerly K, Rouzier Comparison Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya Symmans WF, Pusztai L. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors Breast breast cancer and the effects of brivanib alaninate](http://www.ncbi.nlm.nih.gov/pubmed/20024612)Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate Breast Cancer Research And 20024612](https://pubmed.ncbi.nlm.nih.gov/20024612), [DOI: 10.1007/s10549-009-0677-6](https://doi.org/10.1007/s10549-009-0677-6). - Pusztai L. Gene expression profiling of breast cancer Breast Cancer 2009, 11: 315-343. [PMID: Role in ER-Positive and ER-Negative Cancers.](https://doi.org/10.1158/0008-5472.sabcs-09-105)Bianchini G, Bianchini G, Alvarez R, Qi Hatzis Iwamoto T, Shiang C, Coutant C, Hortobagyi G, Symmans W, Pusztai L. The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and 2009, [From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Samples from the 150007/150012, Das D, Lenburg Paquette Spellman P, Gray J, Gray J, Pusztai L, Symmans F, Hatzis C, Esserman L, van 't Veer L, I-SPY Investigators .. From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Samples from the [Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-101)Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. 2009, 69: 101-101. [DOI: of Axillary 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-1086)Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf Pusztai Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. [DOI: 10.1158/0008-5472.sabcs-09-1086](https://doi.org/10.1158/0008-5472.sabcs-09-1086). - Caudle L, Kau S, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. Cancer Research 2009, 69: 1090-1090. [DOI: 10.1158/0008-5472.sabcs-09-1090](https://doi.org/10.1158/0008-5472.sabcs-09-1090). [Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure.](https://doi.org/10.1158/0008-5472.sabcs-09-2037)Mazouni C, Baggerly K, Hawke D, Tsavachidis S, Andre F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. Cancer Research 2009, 69: 2037-2037. [DOI: 10.1158/0008-5472.sabcs-09-2037](https://doi.org/10.1158/0008-5472.sabcs-09-2037). [Genomic Profiling of Breast Comparative Genomic Hybridization Marty V, Scott V, Pusztai L, Berrada N, Lazar V, Job B, Viehl P, Bernaudin J, Andre F. Genomic Profiling of Breast Cancer (BC) in Mali by Oligonucleotide Comparative Genomic Hybridization [DOI: 10.1158/0008-5472.sabcs-09-3059](https://doi.org/10.1158/0008-5472.sabcs-09-3059). [Consistent Principal Components from Triple Negative Breast Cancer Expression Profiles Yields Agent Specific Predictors of Chemotherapy Response.](https://doi.org/10.1158/0008-5472.sabcs-09-3163)Li Q, Eklund W, Pusztai L, Richardson A, Szallasi Z, Szallasi Z. Consistent Principal Components from Triple Negative Breast Cancer Expression Profiles Yields Agent Specific Predictors of Chemotherapy Response. Cancer Research 2009, [DOI: 10.1158/0008-5472.sabcs-09-3163](https://doi.org/10.1158/0008-5472.sabcs-09-3163). [Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy.](https://doi.org/10.1158/0008-5472.sabcs-09-4047)Liedtke C, C, Pusztai L. Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant 2009, 69: 4047-4047. [DOI: 10.1158/0008-5472.sabcs-09-4047](https://doi.org/10.1158/0008-5472.sabcs-09-4047). [Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers.](https://doi.org/10.1158/0008-5472.sabcs-09-6122)Pusztai L, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, Symmans W, Andre F, de The H, Coutant C, Coutant C. Clinical Subtype-Derived p53 Gene Signature Is Predictive of Prognosis and Response to Chemotherapy in ER-Positive but Not in ER-Negative Breast Cancers. Cancer Research 2009, 69: 6122-6122. [DOI: 10.1158/0008-5472.sabcs-09-6122](https://doi.org/10.1158/0008-5472.sabcs-09-6122). [Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer.](https://doi.org/10.1158/0008-5472.sabcs-09-6124)Iwamoto T, Iwamoto T, Bianchini Shiang J, Symmans W, Hortobagyi G, Simon R, Pusztai L. Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer. Cancer Research 2009, 69: 6124-6124. [DOI: 10.1158/0008-5472.sabcs-09-6124](https://doi.org/10.1158/0008-5472.sabcs-09-6124). - Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada S, Michiels S, Cristofanilli M. CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence The Oncologist 2009, 14: 1182-1188. [PMID: 19939894](https://pubmed.ncbi.nlm.nih.gov/19939894), [DOI: 10.1634/theoncologist.2009-0161](https://doi.org/10.1634/theoncologist.2009-0161). - Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu U, Harbeck N. Triple-negative breast cancer\u2014current status 169 Genomics in early clinical trials European Journal Of Cancer Supplements 2009, 7: 43. [DOI: 10.1016/s1359-6349(09)70149-1](https://doi.org/10.1016/s1359-6349(09)70149-1). [Evaluation of Microtubule-Associated Protein-Tau Expression As Prognostic Predictive Marker in the NSABP-B 28 Randomized Clinical Trial](http://www.ncbi.nlm.nih.gov/pubmed/19667268)Pusztai L, Jeong JH, Gong Y, Ross JS, Andre of Microtubule-Associated Protein-Tau As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial Journal Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines Breast Cancer Research And Treatment 2009, 121: 301-309. primary and recurrent breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19596702)Liedtke C, Broglio K, Moulder S, Hsu L, Kau of discordance between triple-receptor measurements in primary and recurrent breast cancer of breast cancer: implications for treatment and clinical trial design Breast Cancer Research 2009, 11: s4. [PMCID: genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.1044)Andreopoulou E, Hatzis C, Booser D, Valero V, Wallace M, Sotiriou C, Hortobagyi G, Pusztai L, Symmans W. Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer Journal Of 27: 1044-1044. 10.1200/jco.2009.27.15_suppl.1044](https://doi.org/10.1200/jco.2009.27.15_suppl.1044). triple-negative breast cancer patients](https://doi.org/10.1200/jco.2009.27.15_suppl.1028)Pusztai L, Rouzier R, Pusztai L, Ibrahim N. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients 1028-1028. [DOI: 10.1200/jco.2009.27.15_suppl.1028](https://doi.org/10.1200/jco.2009.27.15_suppl.1028). [Estrogen receptor efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials](https://doi.org/10.1200/jco.2009.27.15_suppl.1046)Mazouni Andr\u00e9 F, Broglio K, Pusztai L, Hortobagyi G. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials Of (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers](https://doi.org/10.1200/jco.2009.27.15_suppl.533)Loi S, Haibe-Kains B, Lallemand F, Pusztai L, Bardelli A, Gillett C, Ellis P, Piccart-Gebhart M, Phillips W, McArthur G, Sotiriou C. Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers Journal [DOI: 10.1200/jco.2009.27.15_suppl.533](https://doi.org/10.1200/jco.2009.27.15_suppl.533). [Functional pathways targets in triple-negative breast cancer](https://doi.org/10.1200/jco.2009.27.15_suppl.569)Andre F, Dessen P, Job B, Delaloge S, Pusztai L, Lazar V. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer Journal Of Clinical Oncology 2009, 27: 569-569. [DOI: 10.1200/jco.2009.27.15_suppl.569](https://doi.org/10.1200/jco.2009.27.15_suppl.569). - Caudle Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer Journal Of Clinical Oncology 2009, 27: 603-603. [DOI: 10.1200/jco.2009.27.15_suppl.603](https://doi.org/10.1200/jco.2009.27.15_suppl.603). [Evaluation of serum breast cancer using MALDI-TOF/MS procedure](https://doi.org/10.1200/jco.2009.27.15_suppl.e22072)Hawke D, Mazouni Andr\u00e9 F, Baggerly K, Baggerly Tsavachidis S, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure Journal Of Clinical Oncology 2009, 27: e22072-e22072. [DOI: 10.1200/jco.2009.27.15_suppl.e22072](https://doi.org/10.1200/jco.2009.27.15_suppl.e22072). [Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/19381845)Tordai A, Liedtke C, Pusztai L. Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer Clinical & Experimental Metastasis 2009, M, Sotiriou C, Pusztai L. Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer Journal Of Clinical and Breast Cancer: Ten Years of Targeted Anti-HER2 Therapy and Personalized cancers](http://www.ncbi.nlm.nih.gov/pubmed/19272155)Rody E, Solbach C, Hanker L, Ahr A, D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers Gene-Expression Signatures in Breast Cancer New England Journal Medicine 2009, 360: 790-800. [PMID: 19228622](https://pubmed.ncbi.nlm.nih.gov/19228622), [DOI: 10.1056/nejmra0801289](https://doi.org/10.1056/nejmra0801289). [Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables](http://www.ncbi.nlm.nih.gov/pubmed/19152025)Rouzier R, Coutant C, Lesieur B, Mazouni C, Incitti R, Natowicz R, Pusztai L. Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables Breast Cancer Research And Treatment 2009, 117: 325-331. [PMID: 19152025](https://pubmed.ncbi.nlm.nih.gov/19152025), Array](http://www.ncbi.nlm.nih.gov/pubmed/19147748)Andre A, Michiels S, Liedtke C, Richon C, GN, Symmans WF, Lazar Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization 10.1158/1078-0432.ccr-08-1791](https://doi.org/10.1158/1078-0432.ccr-08-1791). [Targeting of breast cancer non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer.](https://doi.org/10.1158/0008-5472.sabcs-2119)Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs - possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. [DOI: 10.1158/0008-5472.sabcs-2119](https://doi.org/10.1158/0008-5472.sabcs-2119). - Li C, Pusztai L, Cohen E, Symmans F, Wang B, Lee B, Hortobagyi G, Cristofanilli M, Reuben J. Epstein-Barr virus (EBV) in fine needle aspirates containing inflammatory breast cancer cells. Cancer Research 2009, 69: 3084. [DOI: 10.1158/0008-5472.sabcs-3084](https://doi.org/10.1158/0008-5472.sabcs-3084). [Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.](https://doi.org/10.1158/0008-5472.sabcs-54)Pusztai L, Jeong J, Gong Y, Ross J, Kim C, Hortobagyi G, Paik S, Symmans W. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Cancer Research 2009, 69: 54. [DOI: 10.1158/0008-5472.sabcs-54](https://doi.org/10.1158/0008-5472.sabcs-54). [p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical trials.](https://doi.org/10.1158/0008-5472.sabcs-6064)Lehmann-Che J, Andre F, Desmedt C, Giacchetti S, Sotiriou C, Turpin E, Espie M, Marty M, Piccart M, Pusztai L, De The H. p53 mutations to predict efficacy of alkylating-containing regimen: a metaanalysis of four different clinical 69: 6064. [DOI: 10.1158/0008-5472.sabcs-6064](https://doi.org/10.1158/0008-5472.sabcs-6064). [The Bimodality Index: A criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data](http://www.ncbi.nlm.nih.gov/pubmed/19718451)Wang J, Wen Symmans WF, Pusztai L, Coombes KR. Bimodality Index: A criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer 2009, 101-110. 10.1007/978-0-387-87366-4_10](https://doi.org/10.1007/978-0-387-87366-4_10). - Sotiriou C, Pusztai L. Advances in translational research in breast cancer; a bridge to future therapies European Journal Of Cancer 2008, 44: 2705-2706. W. Molecular Pathology and Transcriptional Profiling in Early Drug Development 2008, 47-84. [DOI: 10.1002/9780470475959.ch3](https://doi.org/10.1002/9780470475959.ch3). - Pusztai L. Individualized therapy of breast cancer: are we there yet? Personalized Medicine 2008, R. Are short-term or long-term recurrence rates more important in breast cancer screening? Annals Of Internal Medicine 2008, 149: Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin Symmans WF, de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast 6084-6091. L, Hortob\u00e1gyi G. Commercialized Multigene Predictors of Clinical Outcome Breast The 13: 921-921. [DOI: 10.1634/theoncologist.2007-0248erratum](https://doi.org/10.1634/theoncologist.2007-0248erratum). - Pusztai Promises and caveats of in silico biomarker discovery British Journal HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab](http://www.ncbi.nlm.nih.gov/pubmed/18667396)Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, GN, WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18662965)Pusztai GN. of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer L. Paclitaxel-induced sickle cell 1333-6. L. Lost translation\u2014prognostic signatures for breast cancer Nature Reviews Clinical Oncology 2008, 363-363. [PMID: 18583992](https://pubmed.ncbi.nlm.nih.gov/18583992), [DOI: 10.1038/ncponc1177](https://doi.org/10.1038/ncponc1177). - Oncology 2008, 26: 3288-3288. [DOI: 10.1200/jco.2008.17.2502](https://doi.org/10.1200/jco.2008.17.2502). [Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers](http://www.ncbi.nlm.nih.gov/pubmed/18560403)Mazouni C, Arun B, Andr\u00e9 F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers British Journal Of Cancer 2008, and Pathologic Assessment of Response [PMID: Expression Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis](http://www.ncbi.nlm.nih.gov/pubmed/18509176)Andre F, Broglio K, Roche H, Martin M, Mackey JR, Penault-Llorca F, Hortobagyi GN, Pusztai L. Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis Journal clinical activity and biological correlations](http://www.ncbi.nlm.nih.gov/pubmed/18515258)Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee B, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez R, Valero GN. mesylate (Gleevec\u00ae) in advanced chemotherapy in phenotypic subsets of Liedtke Kuerer A, Hortobagyi G, Pusztai L, Symmans W. Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast 544-544. [DOI: 10.1200/jco.2008.26.15_suppl.544](https://doi.org/10.1200/jco.2008.26.15_suppl.544). [Use of (GGI) predict pathologic response to preoperative chemotherapy in breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.541)Symmans W, Hatzis C, Liedtke C, C, G, Gebhart M, Pusztai L, Sotiriou C. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer Journal Of Clinical Oncology 2008, 541-541. M, Hortobagyi G, Veer L, Symmans W. Combined use of genomic prognostic and treatment response predictors in breast cancer and ER-positive/HER2-negative breast cancers](https://doi.org/10.1200/jco.2008.26.15_suppl.571)Hatzis C, Symmans W, Lin F, Zheng B, Yan K, Booser D, Gong Y, Valero V, Hortobagyi G, Pusztai L. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast Oncology 2008, 26: 571-571. [DOI: 10.1200/jco.2008.26.15_suppl.571](https://doi.org/10.1200/jco.2008.26.15_suppl.571). [Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy](https://doi.org/10.1200/jco.2008.26.15_suppl.576)Peintinger F, Hatzis C, Morkowski J, Hubbard Qureshi G, Pusztai L, Symmans W. Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy Journal Of Clinical Oncology chemotherapy with paclitaxel/FAC-FEC in breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.11078)Gonzalez-Angulo A, Hennessy B, Ju Z, Meric-Bernstam F, Lajos P, Symmans W, Coombes K, Hortobagyi G, Mills G. Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer Journal Of Clinical Oncology 2008, 26: 11078-11078. [DOI: 10.1200/jco.2008.26.15_suppl.11078](https://doi.org/10.1200/jco.2008.26.15_suppl.11078). [Cross-platform performance of response to doxorubicin-paclitaxel containing regimens](https://doi.org/10.1200/jco.2008.26.15_suppl.11061)Bianchini G, Zhao Y, Zambetti Pusztai L, Mariani G, Carcangiu M, Valagussa P, Gianni L, Simon R. Cross-platform performance of genes predictive of pathologic response to doxorubicin-paclitaxel containing regimens Journal Symmans W, Levy A, Delaloge S, Dessens P, Michiels S, Pusztai L. High resolution oligonucleotide array-CGH to identify therapeutic targets in breast cancer Journal Clinical Oncology by tissue microarrays](https://doi.org/10.1200/jco.2008.26.15_suppl.560)Zoubir M, Mathieu M, Liedtke Bidard biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue Of Clinical (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)](https://doi.org/10.1200/jco.2008.26.15_suppl.504)Gianni L, Eiermann W, Pusztai L, Semiglazov V, Hoegel G, M, P, Baselga J. Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) Journal Of Clinical 26: 504-504. Arun Pusztai L, Valero V, Hortobagyi G, Albarracin C. Response to neoadjuvant chemotherapy in BRCA1- and BRCA2-related breast cancers Oncology 10.1200/jco.2008.26.15_suppl.618](https://doi.org/10.1200/jco.2008.26.15_suppl.618). [Transcriptional profiles Are Caucasian, Hispanic, and African-American women different?](https://doi.org/10.1200/jco.2008.26.15_suppl.22014)Dean-Colomb W, Yan K, Liedtke C, Symmans W, Holmes F, O'Shaughnessy J, Asmar G, Pusztai L, Gonzalez-Angulo A. Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women Of Clinical Oncology 2008, 26: 22014-22014. 10.1200/jco.2008.26.15_suppl.22014](https://doi.org/10.1200/jco.2008.26.15_suppl.22014). - Ibrahim N, Abdulkarim Huguet Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom E, Hortobagyi G, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients [Prognostic impact triple-receptor between primary tumor and metastasis in patients with metastatic breast cancer](https://doi.org/10.1200/jco.2008.26.15_suppl.1001)Broglio K, Moulder S, Hsu L, Kau W, G, C. Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer Journal Of Clinical 2008, 477-493. [PMID: 18515733](https://pubmed.ncbi.nlm.nih.gov/18515733), K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer Breast Cancer 2008, and chemotherapy sensitivity in stage II-III breast cancer Breast Cancer of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses](http://www.ncbi.nlm.nih.gov/pubmed/18366635)Natowicz R, Incitti R, Horta EG, Charles B, Guinot P, Yan K, Coutant C, Andre F, Pusztai L, Rouzier R. Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses BMC Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer Journal Of in Patients With Triple-Negative Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/18250347)Liedtke C, Mazouni C, Hess GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer Journal Of Clinical Histopathologic and Molecular Markers of Prognosis and Response to Therapy 2008, 323-343. [DOI: 10.1007/978-0-387-34952-7_11](https://doi.org/10.1007/978-0-387-34952-7_11). - Peintinger F, L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer British Journal 2007, 95: 433-437. [PMID: by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/18086299)Esteva FJ, Wang J, Lin F, Mejia JA, Yan K, Altundag K, Valero V, Buzdar AU, Hortobagyi GN, paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing predicting clinical benefit in breast cancer from microtubule-targeting agents Annals Of Hess KR. Pharmacogenomic Predictor Discovery in Phase II Clinical Trials for Breast Cancer Clinical Cancer Research 2007, 13: 6080-6086. [PMID: 17947471](https://pubmed.ncbi.nlm.nih.gov/17947471), [DOI: 10.1158/1078-0432.ccr-07-0809](https://doi.org/10.1158/1078-0432.ccr-07-0809). - Pusztai L. Limitations pharmacogenomic predictor discovery in Phase II trials Pharmacogenomics 2007, microarrays provide new prognostic 2007, Boulet T, Aziz M, Yuan LX, S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy Journal Of Clinical DCIS of the Breast: A Look towards Discovery and Advancements in the Field Annals Of Surgical Cancer Burden after Preoperative Chemotherapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17634532)Peintinger F, Anderson K, Mazouni C, L. Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer Clinical Cancer [PMID: 17634532](https://pubmed.ncbi.nlm.nih.gov/17634532), [DOI: 10.1158/1078-0432.ccr-06-2600](https://doi.org/10.1158/1078-0432.ccr-06-2600). [Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome](http://www.ncbi.nlm.nih.gov/pubmed/17602071)Mazouni C, Peintinger F, Wan-Kau S, Andre F, V, Hortobagyi GN, Pusztai L. Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome Journal Of Oncology 2007, 25: 2650-2655. [PMID: 17602071](https://pubmed.ncbi.nlm.nih.gov/17602071), status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab](https://doi.org/10.1200/jco.2007.25.18_suppl.533)Peintinger F, Buzdar A, Kuerer H, Gonzalez-Angulo A, Hatzis L, Esteva F, Green M, Hortobagyi G, Symmans W. The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab Journal Of Clinical Oncology 2007, 25: 533-533. [DOI: 10.1200/jco.2007.25.18_suppl.533](https://doi.org/10.1200/jco.2007.25.18_suppl.533). [Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer](https://doi.org/10.1200/jco.2007.25.18_suppl.10519)Liedtke C, Mazouni C, Hess K, Tordai A, Andr\u00e9 F, Symmans W, Gonzalez-Angulo A, Green M, Hortobagyi G, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer Journal Of Clinical Oncology 2007, 25: 10519-10519. [DOI: 10.1200/jco.2007.25.18_suppl.10519](https://doi.org/10.1200/jco.2007.25.18_suppl.10519). [Gene response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients](https://doi.org/10.1200/jco.2007.25.18_suppl.10564)Desmedt C, Andr\u00e9 F, Azambuja E, Haibe-Kains B, Larsimont D, V, Di Leo A, Piccart M, Pusztai L, Sotiriou C. Gene expression profiling can predict pathological complete response (pCR) to anthracycline-based therapy in estrogen- receptor (ER) negative breast cancer (BC) patients Journal Of Clinical Oncology 2007, 25: 10564-10564. [DOI: 10.1200/jco.2007.25.18_suppl.10564](https://doi.org/10.1200/jco.2007.25.18_suppl.10564). [Identification of paclitaxel activity in ER-negative breast cancer patients](https://doi.org/10.1200/jco.2007.25.18_suppl.2525)Wu S, Chasalow S, Lee H, Xu L, Paul B, Mokliatchouk O, Symmans W, Zerba K, Pusztai L, Clark E. Identification of predictive markers to differentiate ixabepilone from paclitaxel activity in ER-negative breast cancer patients Clinical Oncology 2007, 25: 2525-2525. [DOI: 10.1200/jco.2007.25.18_suppl.2525](https://doi.org/10.1200/jco.2007.25.18_suppl.2525). [Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy](https://doi.org/10.1200/jco.2007.25.18_suppl.530)Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo Symmans F, Meric-Bernstam F, Valero V, Hortobagyi G, Pusztai L. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy Journal Of Clinical Oncology 2007, 25: 530-530. [DOI: 10.1200/jco.2007.25.18_suppl.530](https://doi.org/10.1200/jco.2007.25.18_suppl.530). [Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials](https://doi.org/10.1200/jco.2007.25.18_suppl.537)Andre F, Broglio K, Roche H, Martin M, Penault-Lorca F, Hortobagyi G, Berry D, Pusztai L. Estrogen receptor expression and efficacy of docetaxel in early breast cancer: A pooled analysis of 3,490 patients included in two randomized trials Journal Of Clinical Oncology 2007, 25: doxorubicin chemotherapy in F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in 25: 548-548. [DOI: chemotherapy-induced neutropenic fever in breast cancer patients](https://doi.org/10.1200/jco.2007.25.18_suppl.574)Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer Clinical Oncology 2007, 25: 574-574. [DOI: 10.1200/jco.2007.25.18_suppl.574](https://doi.org/10.1200/jco.2007.25.18_suppl.574). [Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes](https://doi.org/10.1200/jco.2007.25.18_suppl.586)Ueno N, Kim S, Symmans W, Detry M, Pusztai L, Sanchez L, Ishihara H, Hortobagyi G, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes Journal Of Cancer: Hormone Receptors, HER2, and Sentinel Lymph Nodes Clinical Cancer Research 2007, 13: 2831-2835. [PMID: 17504980](https://pubmed.ncbi.nlm.nih.gov/17504980), efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Research 108: Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/17404087)Andre F, Hatzis C, Anderson K, Sotiriou Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer Cancer S. New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer Seminars In 34: s10-s16. [PMID: The use of microarray technology in the management of breast cancer. Clinical Advances In Hematology And Oncology 2007, 5: 193-4, 197. [PMID: 17519880](https://pubmed.ncbi.nlm.nih.gov/17519880). of breast carcinoma: a gene-expression profiling study](http://www.ncbi.nlm.nih.gov/pubmed/17329190)Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, ERBB2 status of breast carcinoma: a gene-expression [PMID: 17329190](https://pubmed.ncbi.nlm.nih.gov/17329190), [DOI: 10.1016/s1470-2045(07)70042-6](https://doi.org/10.1016/s1470-2045(07)70042-6). Saad E, Porter P, Pusztai L. P135 Primary systemic therapy of invasive lobular cancer: Is there a role for chemotherapy? s51-s52. pathologic complete response rate in estrogen receptor-positive breast cancers](http://www.ncbi.nlm.nih.gov/pubmed/17293601)Mazouni C, Kau S, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive patients with HER2positive primary breast cancer after initiation of primary chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/17149760)Mazouni C, Hall A, Broglio K, Fritsche H, Andre HER2/neu changes in patients with HER2positive primary breast cancer after initiation of primary chemotherapy Cancer 2007, 109: 496-501. [PMID: 17149760](https://pubmed.ncbi.nlm.nih.gov/17149760), expression-based predictors of response to preoperative chemotherapy Breast Cancer Research 2007, 9: s5. [DOI: 10.1186/bcr1688](https://doi.org/10.1186/bcr1688). - Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast The Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen](http://www.ncbi.nlm.nih.gov/pubmed/17200359)Buzdar AU, Valero V, Ibrahim NK, Francis Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen Clinical Cancer Research 2007, 13: 228-233. [PMID: 17200359](https://pubmed.ncbi.nlm.nih.gov/17200359), [DOI: 10.1158/1078-0432.ccr-06-1345](https://doi.org/10.1158/1078-0432.ccr-06-1345). - Ross Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer 2007, 269-278. [DOI: 10.1007/978-0-387-33227-7_24](https://doi.org/10.1007/978-0-387-33227-7_24). - Symmans W, Pusztai L. Chapter 1 Selection of patients for endocrine therapies 2007 [DOI: 10.1093/med/9780199218141.003.0001](https://doi.org/10.1093/med/9780199218141.003.0001). - Pusztai L. Chips to Bedside: Incorporation of Microarray Data into Clinical Practice Clinical Cancer Research 2006, [PMID: Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy Nature Reviews Clinical Oncology 2006, 3: Personalized medicine for breast cancer: moving forward and going back Personalized Medicine 2006, 3: [PMID: 29788594](https://pubmed.ncbi.nlm.nih.gov/29788594), [DOI: 10.2217/17410541.3.4.363](https://doi.org/10.2217/17410541.3.4.363). [Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16948128)Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer Cancer 2006, [DOI: 10.1002/cncr.22177](https://doi.org/10.1002/cncr.22177). Wu Y, Symmans WF. Molecular Classification of Breast Cancer: Limitations intraplatform reproducibility of gene expression measurements.](http://www.ncbi.nlm.nih.gov/pubmed/16964229)Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies TS, G, Deng Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y, Slikker W. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16926572)Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt I, Lucci Kuerer HM. Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer Annals Of Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/16906452)Andre F, Pusztai L. Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy Pharmaceutical Research 2006, adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design](http://www.ncbi.nlm.nih.gov/pubmed/16962247)Andre F, Mazouni C, Hortobagyi GN, Pusztai L. DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16896004)Hess KR, Anderson K, Symmans WF, Valero Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer Valero V, Hennessy B, Green M, Singletary E, Hortobagyi G, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy Journal Of Clinical Oncology 2006, 24: 536-536. 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.10000)Pusztai L, Hess K, Anderson K, Valero V, Ibrahim N, Mejia J, Vidaurre T, Gomez H, Hortobagyi G, Symmans W. Pharmacogenomic predictor complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in Clinical Oncology 2006, 24: 10000-10000. [DOI: 10.1200/jco.2006.24.18_suppl.10000](https://doi.org/10.1200/jco.2006.24.18_suppl.10000). - Katz A, Saad E, Pusztai L. Is histology (His) relevant in adjuvant (Adj)/neoadjuvant (NA) therapy of breast cancer (BC)? Journal Of Clinical Oncology 2006, 24: 10541-10541. [DOI: 10.1200/jco.2006.24.18_suppl.10541](https://doi.org/10.1200/jco.2006.24.18_suppl.10541). [Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)](https://doi.org/10.1200/jco.2006.24.18_suppl.10576)Green M, Pusztai L, Theriault M, Mita A, Bindra N, Hortobagyi G. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC) Journal Of Clinical Oncology 2006, 24: 10576-10576. [DOI: (TX/FEC) chemotherapy for breast cancer](https://doi.org/10.1200/jco.2006.24.18_suppl.10595)Holmes J, Vukelja E, Lin F, Symmans W, Pusztai L. Pharmacogenomic analysis of needle biopsies obtained before preoperative docetaxel/capecitabine/FEC (TX/FEC) chemotherapy for breast cancer 24: 10595-10595. [DOI: 10.1200/jco.2006.24.18_suppl.10595](https://doi.org/10.1200/jco.2006.24.18_suppl.10595). [Pharmacogenomic Mejia J, Altundag K, Buzdar A, Hortobagyi G, Symmans W, Pusztai L. Pharmacogenomic analysis of HER2 and [RefSeq Refinements of UniGene-Based Gene Matching the Correlation of Expression Measurements Between Two Microarray Platforms](http://www.ncbi.nlm.nih.gov/pubmed/16722773)Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq Refinements of UniGene-Based Gene Matching Improve the Correlation of Expression Measurements Between Two Microarray Platforms Applied Bioinformatics 2006, 5: 89-98. M, Tirrell S, Courtemanche J, Wang Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of Gene Expression Signature-Based Predictions in Replicate Experiments Clinical new staging classification: is it useful for S CH, Gonzalez-Angulo AM, Reuben JM, Booser breast cancer: pharmacodynamics, biological effects, and prediction of clinical 2006, 17: 813-817. Therapy in HER-2-Positive Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16619408)Pusztai L, Esteva FJ. Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in TA, Sahin A, Hunt KK, MericBernstam F, Ross MI, Ames FC, Kuerer HM. Impact of concurrent proliferative highrisk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breastconserving with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human M, Sahin AA. The Nuclear Transcription Factor B/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer Clinical Cancer Research and Clinical Biomarkers in Drug Discovery and Development American Journal Of Clinical cancers associated with immature cell type and short duration of prior breastfeeding](http://www.ncbi.nlm.nih.gov/pubmed/16322343)Symmans W, Fiterman D, Anderson S, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross J, Wagner P, Theriault R, Arun B, Kuerer H, Hess K, Zhang W, Hortobagyi G, Pusztai L. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding Endocrine Survival After Preoperative Chemotherapy for Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16293864)Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre M, Mathieu MC, Symmans D, V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer Journal HER2-positive breast cancer: the molecular rationale. Oncology 2005, 19: 4. [PMID: 19364050](https://pubmed.ncbi.nlm.nih.gov/19364050). - Esteva FJ, Pusztai L. Optimizing outcomes in Oncology Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/16145055)Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer Journal Of Clinical Oncology 2005, 23: 7265-7277. [PMID: 16145055](https://pubmed.ncbi.nlm.nih.gov/16145055), [DOI: 10.1200/jco.2005.02.0818](https://doi.org/10.1200/jco.2005.02.0818). [Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicinbased neoadjuvant chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/15981280)Buchholz TA, Tu X, Ang KK, Esteva GN, Sahin AA. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicinbased neoadjuvant inhibitor, in patients with chemotherapyresistant, advanced breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15986399)Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective Pglycoprotein inhibitor, in patients with chemotherapyresistant, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Clinical in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks](http://www.ncbi.nlm.nih.gov/pubmed/16087943)Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks Journal Of 5983-5992. [PMID: 16087943](https://pubmed.ncbi.nlm.nih.gov/16087943), cDNA Arrays and J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross G, Hortobagyi GN, Symmans W, Pusztai of Array-Based Multigene Classifiers across cDNA Arrays Mediator of Paclitaxel Sensitivity In Vitro and In Vivo](http://www.ncbi.nlm.nih.gov/pubmed/16103753)Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo Cell Cycle 2005, 1149-1152. [PMID: 16103753](https://pubmed.ncbi.nlm.nih.gov/16103753), [DOI: 10.4161/cc.4.9.2038](https://doi.org/10.4161/cc.4.9.2038). - Hennessy B, Pusztai L. Adjuvant therapy for breast cancer. Minerva Obstetrics And Gynecology 2005, 57: 305-26. [PMID: 16166938](https://pubmed.ncbi.nlm.nih.gov/16166938). [Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial](https://doi.org/10.1200/jco.2005.23.16_suppl.623)Rouzier R, Andre F, Arriagada Pusztai M, Marsiglia H, Dunant A, Hortobagyi G, Delaloge S. Individual benefits from adjuvant anthracycline-based chemotherapy can be predicted from a predictive nomogram created from primary chemotherapy (PC) data: Results of a randomized trial Journal Of Clinical Garbay J, Spielmann M, Mathieu M, Valero V, Hortobagyi G. Predictive and prognostic nomograms for breast cancer treated with primary chemotherapy (PC) Journal Of Clinical Oncology 2005, 23: 599-599. [DOI: 10.1200/jco.2005.23.16_suppl.599](https://doi.org/10.1200/jco.2005.23.16_suppl.599). - Symmans W, Sotiriou C, Anderson K, Valero V, Booser D, Hess K, Ross J, Piccart M, Hortobagyi G, Pusztai L. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer Journal Of Clinical Oncology 2005, 23: 546-546. [DOI: 10.1200/jco.2005.23.16_suppl.546](https://doi.org/10.1200/jco.2005.23.16_suppl.546). - Pusztai L. Gene expression profile-based predictors of response to chemotherapy Cancer [PMCID: PMC4231888](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231888), [DOI: P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, A marker of paclitaxel sensitivity in breast cancer Proceedings Of The National Academy Of Sciences Of The United States Of America 2005, Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer Breast Cancer 2005, 12: 73-85. [DOI: 10.1007/bf02966817](https://doi.org/10.1007/bf02966817). - Pusztai L. The Role of Receptor in Breast Cancer 2005 [DOI: 10.21236/ada436919](https://doi.org/10.21236/ada436919). [Oncogenomics 2005--Dissecting Cancer through Genome Research. Diego, CA, USA.](http://www.ncbi.nlm.nih.gov/pubmed/15772892)Pusztai L. Oncogenomics 2005--Dissecting Cancer through Genome Research. 2-6 February 8: 215-8. [PMID: 15772892](https://pubmed.ncbi.nlm.nih.gov/15772892). [Significantly Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15738535)Buzdar AU, Ibrahim NK, Francis D, Booser Thomas KK, Singletary SE, AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer Journal Morandi P, Pusztai L. Gene expression profiling of primary breast cancer Current Oncology Reports 2005, of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. 2005, 12: 15858436](https://pubmed.ncbi.nlm.nih.gov/15858436), [DOI: 10.1007/bf02966817](https://doi.org/10.1007/bf02966817). [Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry](http://www.ncbi.nlm.nih.gov/pubmed/15692757)Pawlik TM, Fritsche H, Coombes KR, Xiao L, Krishnamurthy S, Hunt KK, Pusztai L, Chen JN, Clarke CH, Arun B, Hung MC, Kuerer HM. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry Breast Cancer Research And Treatment Albarracin C, Sahin A, Wagner P, Yang Y, Smith T, Meric-Bernstam F, Aldaz C, Hortobagyi G, Pusztai L. Expression of sigma 1 receptor in human breast cancer Breast Cancer Research And Treatment 2005, 89: 95-95. [DOI: 10.1007/s10549-004-8255-4](https://doi.org/10.1007/s10549-004-8255-4). - Pusztai L, Rouzier R, Symmans WF. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Clinical trial design for microarray predictive marker discovery and assessment Annals to preoperative chemotherapy in breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/16264799)Pusztai L, Gianni L. Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer Nature Reviews Clinical Oncology 2004, L, Hortobagyi GN. Targeted Therapies for Cancer 2004 American Journal Of Clinical Pathology 2004, 122: 598-609. [PMID: 15487459](https://pubmed.ncbi.nlm.nih.gov/15487459), van De Vijver M. Improving patient care through molecular diagnostics Seminars In Oncology 2004, 31: 14-20. Albarracin C, Sahin A, Wagner P, Yang Y, Smith T, Bernstam F, Marcelo A, Hortobagyi G, Pusztai L. Expression of sigma 1 receptor in human breast cancer Breast Cancer Research And Treatment 2004, 87: 205-214. [PMID: 15528963](https://pubmed.ncbi.nlm.nih.gov/15528963), [DOI: 10.1007/s10549-004-6590-0](https://doi.org/10.1007/s10549-004-6590-0). [Her2/neu-positive disease does not of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy](http://www.ncbi.nlm.nih.gov/pubmed/15275718)Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy International Journal Of response to preoperative taxanes in patients with breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15241821)GonzalezAngulo A, Krishnamurthy between amplification of her2 and response to preoperative taxanes in patients samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer](https://doi.org/10.1200/jco.2004.22.14_suppl.2109)Pusztai L, Gregory B, Baggerly K, Esteva F, Laronga C, Gabriel H, Semmes O, Wright G, Richard D, Vlahou A. Pharmacoproteomic analysis of pre-and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer Journal Of Clinical Oncology 2004, 22: 2109-2109. Pusztai L, Walters R, Hortobagyi G, Reuben J, Esseltine D, Wright J. A phase II trial of PS-341 in metastatic breast cancer (MBC) response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips](https://doi.org/10.1200/jco.2004.22.14_suppl.503)Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer](https://doi.org/10.1200/jco.2004.22.90140.2109)Pusztai L, Gregory B, Baggerly K, Esteva F, Laronga C, Gabriel H, Semmes O, Wright G, Richard D, Vlahou A. Pharmacoproteomic analysis of pre-and post-chemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast cancer Journal Of Clinical Oncology 2004, 22: 2109-2109. Pusztai L, Walters R, Hortobagyi G, Reuben J, Esseltine D, Wright J. A phase II trial of PS-341 in metastatic breast cancer (MBC) response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips](https://doi.org/10.1200/jco.2004.22.90140.503)Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays [DOI: - Pusztai L. Perspectives and challenges cancer Pharmacogenomics 2004, 10.1097/01.pap.0000131825.77317.ee](https://doi.org/10.1097/01.pap.0000131825.77317.ee). - Whitman G, Iyer R, Reeve C, Patel P, Phelps M, Pusztai L. Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer: Imaging Considerations Seminars In Breast Disease 2004, 7: 61-74. [DOI: 10.1053/j.sembd.2005.01.005](https://doi.org/10.1053/j.sembd.2005.01.005). [Gene Expression Profiles Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15136595)Ayers M, Symmans W, Stec J, Damokosh A, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi G, Pusztai L. Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/15112261)Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma Cancer 2004, [PMID: 15112261](https://pubmed.ncbi.nlm.nih.gov/15112261), [DOI: breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response](http://www.ncbi.nlm.nih.gov/pubmed/15042669)Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, GalGombos E, Whitman G, H, AU, Hortobagyi GN, Symmans WF. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response Cancer 2004, 100: 1365-1373. [PMID: 15042669](https://pubmed.ncbi.nlm.nih.gov/15042669), [DOI: 10.1002/cncr.20134](https://doi.org/10.1002/cncr.20134). - Pusztai L. The of Sigma Receptor in Breast Cancer 2004 [DOI: 10.21236/ada425685](https://doi.org/10.21236/ada425685). - Ross JS, Linette GP, Stec WF, GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II Expert Review Of Molecular Diagnostics 2004, 4: 169-188. [PMID: 14995904](https://pubmed.ncbi.nlm.nih.gov/14995904), [DOI: 10.1586/14737159.4.2.169](https://doi.org/10.1586/14737159.4.2.169). agent taxanes and HER-2 gene amplification in patients with breast carcinoma](https://doi.org/10.1016/s1359-6349(04)90651-9)Gonzalez-Angulo A, Krishnamurthy S, Yamamura Y, Pusztai L, Buzdar A, Hortobagyi G, Esteva F. Correlation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma European Journal Of Cancer Supplements 2004, 2: 70. [DOI: 10.1016/s1359-6349(04)90651-9](https://doi.org/10.1016/s1359-6349(04)90651-9). - Ross JS, Fletcher Pusztai Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein Molecular & Cellular Proteomics 2004, [PMID: J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/14745865)Esteva FJ, Sahin AA, Smith TL, Yang and HER2 and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/15199607)Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva M, Breitenfelder P, RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer Cancer Investigation 2004, 22: 248-256. [PMID: 15199607](https://pubmed.ncbi.nlm.nih.gov/15199607), Stec J, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of 2003, 120 Suppl: s53-71. [PMID: 15298144](https://pubmed.ncbi.nlm.nih.gov/15298144), [DOI: 10.1309/949fpq1aq3p0rlc0](https://doi.org/10.1309/949fpq1aq3p0rlc0). [Jun activation domain binding 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/14654548)Esteva FJ, Sahin M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. [PMID: 14654548](https://pubmed.ncbi.nlm.nih.gov/14654548). [Her2-Neu overexpression does not increase the of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation](https://doi.org/10.1016/s0360-3016(03)01004-6)Buchholz T, Huang E, Berry D, Strom E, McNeese M, Pusztai L, Kuerer H, Buzdar A, Hortobagyi G, Valero V, Perkins G, Sahin A. Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation International Journal Of Radiation Oncology Biology Physics 2003, 57: s201. [DOI: 10.1016/s0360-3016(03)01004-6](https://doi.org/10.1016/s0360-3016(03)01004-6). [Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12972520)Pusztai L, Zhen JH, Arun B, Rivera E, A, Symmans WF, V, Smith TL, Hortobagyi GN. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. Journal WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine Expert Review Of Molecular Diagnostics 2003, 3: 573-585. [PMID: with gemcitabine in patients with metastatic breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12947059)Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Journal J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of obtained fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.](http://www.ncbi.nlm.nih.gov/pubmed/12855612)Pusztai L, Ayers M, Stec J, Clark E, Hess K, Stivers D, Damokosh A, Sneige N, Buchholz TA, Esteva FJ, Arun B, Cristofanilli M, Booser D, M, Valero V, Adams C, Hortobagyi GN, Symmans WF. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical Cancer Research 2003, 9: 2406-15. Pusztai L, from fineneedle aspiration biopsy and coreneedle biopsy samples of breast Stec J, Hess Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fineneedle aspiration biopsy and coreneedle biopsy samples chemotherapy with 5fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/12655533)Zhang F, Yang Y, Smith T, Kau response to neoadjuvant chemotherapy with 5fluorouracil, doxorubicin, and cyclophosphamide in patients profiles of invasive mucinous and ductal carcinomas of the breast a molecular case Cancer Genetics 2003, 141: 148-153. Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse Breast Cancer Research And Chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/12602766)Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy The Cancer Journal 2003, 9: 33-41. J, Ayers M, Clark E, Meric F, Stivers D, Hess K. Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer 2003, 257-275. [DOI: 10.1007/0-306-47825-0_15](https://doi.org/10.1007/0-306-47825-0_15). - Buchholz TA, Stivers DN, Stec A, Sahin AA, Symmans WF, Hess KR, Kuerer HM, Valero V, GN, Pusztai L. Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer The Cancer Journal 2002, 461-468. J, Ayers M, Brown J, Pusztai L. Global Gene Expression Changes during Neoadjuvant Chemotherapy of Human Breast Cancer The Cancer Journal 2002, 8: 488. [DOI: 10.1097/00130404-200211000-00026](https://doi.org/10.1097/00130404-200211000-00026). [Phase II Study of Weekly Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer](http://www.ncbi.nlm.nih.gov/pubmed/11919237)Esteva Valero Booser N, TL, GN. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast L, Hortobagyi G. Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance Breast 2001, 10: 492-500. [PMID: 14965629](https://pubmed.ncbi.nlm.nih.gov/14965629), [DOI: 10.1054/brst.2001.0310](https://doi.org/10.1054/brst.2001.0310). [Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11839324)Kuerer H, Singletary S, Buzdar A, Ames F, Valero V, Buchholz T, Ross M, Pusztai L, Hortobagyi G, Hunt K. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma The American Journal Of Surgery 2001, 182: breast cancer using quantitative immunohistochemistry](http://www.ncbi.nlm.nih.gov/pubmed/11692142)Esteva F, Hortobagyi G, Sahin A, Smith T, Chin D, Liang S, Pusztai L, Buzdar A, Bacus S. Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry breast cancer (IBC)](https://doi.org/10.1016/s0959-8049(01)81123-0)Cristofanilli M, Fratarcangeli T, Esteva F, Rosales M, Booser D, Ibrahim N, Pusztai L, Bast R, Rivera E, Hortobagyi G. Weekly high-dose paclitaxel(HD-P) has significant antitumor activity in inflammatory breast cancer (IBC) European Journal Of Cancer 2001, 37: s173. [DOI: 10.1016/s0959-8049(01)81123-0](https://doi.org/10.1016/s0959-8049(01)81123-0). - Esteva Buzdar A, Hortobagyi G. Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and 6: 133-146. cancer (MBC)](https://doi.org/10.1016/s0959-8049(01)81198-9)Esteva F, Valero Guerra L, Murray J, Pusztai L, Cristofanilli M, Sneige N, Smith T, Hortobagyi G. Phase II study of weekly docetaxel (Taxotere; txt) (HER2+) metastatic 37: s193. [DOI: 10.1016/s0959-8049(01)81198-9](https://doi.org/10.1016/s0959-8049(01)81198-9). [Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.](http://www.ncbi.nlm.nih.gov/pubmed/11693900)Buchholz T, Hill B, Tucker S, Frye Kuerer Buzdar A, McNeese M, Singletary S, Ueno N, Pusztai L, Valero V, Hortobagyi G. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. The pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.](http://www.ncbi.nlm.nih.gov/pubmed/10778954)Madden T, Tran H, Beck D, Huie R, Newman R, Pusztai L, Wright J, Abbruzzese J. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clinical Cancer Research 2000, 6: 1293-301. [PMID: 10778954](https://pubmed.ncbi.nlm.nih.gov/10778954). - Pusztai Hung M, Hortobagyi G. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer Cancer Treatment Reviews 1999, 25: extracellular domain of cerbB2 (HER2/neu) gene product p185](http://www.ncbi.nlm.nih.gov/pubmed/10404066)Boyer C, Pusztai L, Wiener J, Xu F, Dean G, Bast B, O'Briant K, Greenwald M, DeSombre K, Bast R. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the cerbB2 (HER2/neu) gene product p185 10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j](https://doi.org/10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j). chemotherapy in metastatic breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/10472774)Pusztai L, Asmar L, Smith T, Hortobagyi G. Relapse after complete response to anthracyclinebased combination chemotherapy in metastatic breast cancer Breast Cancer Research Treatment 1999, 55: [PMID: infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy](http://www.ncbi.nlm.nih.gov/pubmed/9923546)Pusztai L, Holmes F, Fraschini G, Hortobagyi G. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy Cancer Chemotherapy And 1999, breast cancer The Lancet 1998, 352: 1552. [DOI: 10.1016/s0140-6736(05)60360-1](https://doi.org/10.1016/s0140-6736(05)60360-1). - Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer American susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/9796989)Dean G, Pusztai L, Xu F, O'Briant K, DeSombre K, Conaway M, Boyer C, Mendelsohn J, Bast R. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clinical Cancer Research 1998, 4: 2545-50. [PMID: 9796989](https://pubmed.ncbi.nlm.nih.gov/9796989). - Pusztai L, Hortobagyi G. Discouraging news for high-dose chemotherapy in high-risk breast cancer The Lancet 1998, [PMID: and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues](http://www.ncbi.nlm.nih.gov/pubmed/9790065)Bast R, Pusztai L, Kerns B, MacDonald J, Jordan P, Daly L, Boyer C, Mendelsohn J, Berchuck A. Coexpression of the HER-2 Gene Product, pl85HER-2, and Epidermal Growth Factor Receptor, pl70EGF-R, on Epithelial Ovarian Cancers and Normal Tissues Monoclonal Antibodies how resistant is breast 1: 62-72. [PMID: [COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE](http://www.ncbi.nlm.nih.gov/pubmed/9474132)ANDERSON C, PUSZTAI L, PALMER J, CABANILLAS F, ELLERHORST J. COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE Investigative Urology 1998, 159: 714-717. [PMID: 9474132](https://pubmed.ncbi.nlm.nih.gov/9474132), PALMER J, CABANILLAS F, ELLERHORST J. COINCIDENT RENAL CELL CARCINOMA Drug in Carcinoma: A Hypothesis Based on a Clonal Progression Model](http://www.ncbi.nlm.nih.gov/pubmed/10050979)Pusztai L, Siddik Z, Mills G, Bast R. Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Breast Cancer Hospital at Yale New Haven35 Park Street, Fl 1st, suite ANew Haven, CT 06511 - Center for Breast CancerSmilow Cancer Hospital at Yale New Haven35 Park Street, Fl "}